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Abstract 
 
Polyketide natural products are secondary metabolites produced in fungi, plants and 
bacteria. Since their discovery, these versatile small molecules have served as 
pharmaceuticals in many fields of medicine. From use as antibiotics to anti-cancer agents 
to immunosuppresants, polyketides remain staple components in the pharmacopeia. 
Nature biosynthesizes members of this natural product class through use of a complex 
network of enzymes known as polyketide synthases.  
 
There is an interest in studying enzymatic pathways that install chemical functional 
groups and unique three-dimensional form in hopes of rationally modifying them to 
create new drug molecules. This is an attractive prospect as enzyme catalysis can be 
predicted by genetic examination of the pathway. In theory, swapping, deleting or 
inserting a catalytic domain in the pathway would offer a means of controlled alteration 
of the natural product. While initial efforts have led to limited success, recently the focus 
has been shifted to understanding the mechanistic and structural details of these pathways 
with the aim of improving rational pathway diversification.  
 
Three aspects of polyketide synthesis: cryptic domains, distal stereochemistry and non-
canonical domain architecture; remain relatively unexplored in the polyketide literature. 
Cryptic domains involve the configuration of polyketide intermediates obscured by later 
domain action. Stereochemistry distal to the site of manipulation on the polyketide may 
be a factor in pathway alteration, as the new catalytic site may not accept subtle changes 
made by prior enzymes. Modern genetics has revealed many pathways don’t follow the 
rules pertaining to the presence and order of catalytic domains. Bizarre exceptions to 
canonical domain architecture are difficult to reproduce and predict in modified 
pathways. Additionally, discovering how the product is ultimately produced may offer 
insight and new strategies for the coupling of polyketide synthase modules to create new 
products. We hypothesized that all three aspects of polyketide synthases (cryptic 
domains, distal stereochemistry and non-canonical domain architecture) could be studied 
	 iv	
through interrogation of individual catalytic domains with synthetic, diffusible substrates. 
 
In our studies we revealed several key elements of polyketide synthases that were 
previously unknown in the literature. We biochemically verified that cryptic 
stereochemistry and geometry can be accurately predicted based on genetic patterns in a 
polyketide synthase. A novel, mass spectrometry-based method of quantifying enzyme 
turnover in polyketide synthases was developed. This new technique allowed for the 
direct comparison of substrates with changes in distal stereochemistry in a dehydratase 
domain. Single inversions in configuration in substrates were found to result in a 14- to 
45-fold loss in enzyme activity. Additionally, we were able to elucidate a unique 
mechanism for vinylogous dehydration in the curacin A pathway. This discovery explains 
why the polyketide synthase is missing domains and provides a clear exception to the 
notion of enzyme-product co-linearity. The combined work suggests that many potential 
pitfalls in the rational design of polyketide synthases can be anticipated and avoided 
through increased knowledge of pathway mechanisms and limitations. 
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Chapter 1: Introduction to the Polyketides 
 
1.1 Polyketide natural products: Occurrence and value 
 
Polyketide natural products represent a chemically broad, multifaceted family of 
secondary metabolites. Members of this class are commonly isolates from fungal, 
bacterial and botanical organisms, ranging from simple  (5-methyl-1-napthoic acid, 1.1) 
to complex (rifamycin B, 1.2) molecules (Figure 1.1). A consequence of the wide 
structural diversity of polyketides is their extensive use in many therapeutic areas. 
Erythromycin (1.3) was isolated and marketed by Eli Lilly as a broad-spectrum antibiotic 
in 1955, paving the way for a host of other natural and semi-synthetic macrolides.1 The 
natural product analogs of erythromycin range from subtle transformations (O-
methylation, clarithromycin, 1.4) to a series of intricate functional group manipulations 
(telithromycin, 1.5) each bestowing favorable pharmacokinetic, drug-stabilizing, efficacy 
and reduced drug resistance properties to the original scaffold (Figure 1.2). The field of 
cholesterol regulation was greatly advanced by polyketide antihypolipodemic agents. The 
discovery of lovastatin (1.6), compactin (1.7) and related pharmaceuticals (simvastatin 
(1.8), and pravastatin (1.9)) provided clinicians safe and reliable therapeutic medications 
(Figure 1.3). Highlights of polyketide usage in other therapeutic areas include: 
immunosuppressants tacrolimus (1.10) and rapamycin (1.11), antineoplastic agents 
ixabepilone (1.12, an epothilone B analog) and the antibody-drug conjugate Kadcyla 
(1.13, derived from maytansine and the monoclonal antibody trastuzumab), as well as the 
antifungal drug amphotericin B (1.14) (Figure 1.4)  
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Figure 1.1. Simple and complex polyketide natural products. 
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Figure 1.2. Natural and semi-synthetic macrolide antibiotics. Erythromycin analogs 
clarithromycin and telithromycin are shown with modifications highlighted in red. 
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Figure 1.3. Lovastatin, compactin and derived antihypolipodemic agents. The semi-
synthetic manipulations are shown in red for simvastatin and pravastatin. 
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Figure 1.4. A representative collection of polyketide and polyketide-derived 
pharmaceutical agents. 
 
Prior to the first use of the term, polyketides were defined as “multiple keten” by John 
Norman Collie as early as 1907.2 This descriptor was used to define the hypothetical 
biosynthetic intermediates responsible for many early natural products. As evidence 
towards his proposal, Collie highlighted the total synthesis of the natural product orcinol 
(1.15) from diacetylacetone (1.16) after heating under strong alkaline conditions (Figure 
1.5).3 The biosynthetic theory lay unproven until 1955 when A. J. Birch and coworkers 
developed a clever isotope labeling experiment that would lay the groundwork for more 
than a half-century of fruitful research.4 Birch had hypothesized that acetate could serve 
as the fundamental building block based on common substitution patterns in polyphenolic 
natural metabolites. In his key experiment, 14C-labeled sodium acetate (1.17) was fed to 
Penicillium griseofulvum, a common mold known for producing 2-hydroxy-6-
methylbenzoic acid (1.18) (Figure 1.6). Analysis revealed an isotope incorporation rate 
	 4 
and pattern consistent with a polyketone intermediate (1.19), strikingly similar to 
diacetylacetone (1.16). Isotope feeding experiments, based on Birch’s insightful work, 
would later stitch together the polyketide class of natural products based on their 
biosynthetic building blocks.  
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O O
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-O O
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conditions
 
Figure 1.5. The total synthesis of the polyketide orcinol. Diacetylacetone (1.16) served as 
the inspiration for Collie’s biosynthetic building blocks. 
O
Me ONa
Penicillium
griseofulvum
OH
O
Me OH1.17
1.18O
O
OHO
Me
O
1.19
=14C
 
Figure 1.6. Birch’s isotopic labeling of 2-hydroxy-6-methylbenzoic acid. The 
incorporated 14C-labeled carbons are shown in blue. 
 
The next major hurdle in the study of polyketide biosynthesis was proving how 
producing organisms catalyzed Claisen reactions and controlled cyclization or reduction 
reactions in vitro.  
 
1.2 Polyketide synthases: Natural product assembly lines 
 
The advent of molecular genetics and parallel discoveries in the field of fatty acid 
biosynthesis led to the isolation and characterization of polyketide-producing enzymes, or 
polyketide synthases (PKSs). Polyketide synthases are a broad enzyme family ranging 
from huge megaenzymes to small monofunctional proteins. The synthase enzymes are 
now subdivided into three distinct types based on their size, function and substrate 
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preference. Type I polyketide synthases are large multifunctional proteins that are chiefly 
characterized by their distinct catalytic domains (Figure 1.7). Each catalytic domain is 
responsible for one transformation in the polyketide synthase, instilling a co-linear 
architecture in the PKS. In contrast, a cluster of individual proteins, each catalyzing a 
defined step towards polyketide biosynthesis, typifies type II polyketide synthases. 
Iterative and non-iterative sub-families of type I exist, differing in single use or multiple 
uses of megaenzyme catalytic domains. Both type I and type II PKSs act upon substrates 
bound to an acyl-carrier protein (ACP). These are typically derived from acyl-coenzyme 
A intermediates. Type III polyketide synthases differ by their single active site capable of 
catalyzing several reactions and their preference for acyl-CoA substrates instead of ACP-
bound substrates. For simplicity, the remaining sections will depict all steps as they occur 
in in type I, bacterial (non-iterative) PKS.  
 
ACP ACP 
S
O
CoAS
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Polyketide
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S
or
type III PKS type II PKS
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Figure 1.7. Type I, II and III polyketide synthases.  
 
Chain elongation occurs via a ketosynthase catalyzed Claisen reaction that is chemically 
identical across all three types of polyketide synthases. Enzymatically, the process varies 
in the substrate identity (ACP-bound in type I and II, CoA-thioester in type III) and 
intermolecular or intramolecular substrate-protein interaction (type I vs. type II and III). 
The process begins via intermediate transfer from an ACP domain from a previous 
module (or loading module ACP if n = 1) to the current module’s ketosynthase domain 
(KS) (Figure 1.8). The acyltransferase domain (AT) catalyzes a transesterfication of the 
	 6 
coenzyme A-thioester extender unit (usually malonyl- or methylmalonyl-CoA) onto 
itself, forming a new, transient ester. The AT-bound ester is attacked intramolecularly by 
the current module’s ACP domain, transferring the carboxyester building block and 
priming the module for the key Claisen reaction. The KS domain catalyzes the 
decarboxylation of the ACP-bound malonate (or methylmalonate) extender unit and 
guides the resulting enolate in its attack on the KS-bound polyketide intermediate. The 
formed β-ketone intermediate may be directly passed to the KS domain of the next 
module (n+1) or it may undergo processing by additional domains in the same module 
(n). 
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Figure 1.8. Polyketide chain extension via enzyme-catalyzed Claisen reactions. The 
generic module number is represented as n or n-1. 
 
The optional processing of β-ketothioesters by additional domains in the module instills 
functional group and stereogenic diversity in the final polyketide product. Traditionally 
known as β-processing, this process can actually modify both the α- and β-carbon centers 
proximal to the thioester on an extended, ACP-bound thioester intermediate.  
 
The first possible modification is α-methylation catalyzed by a carbon-methyltransferase 
(CMT) domain. This domain takes advantage of the acidic nature of the α-proton in the 
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β-carbonyl-intermediate, deprotonating it to form a resonance-stabilized enolate. The 
enolate’s attack on S-adenosylmethionine (SAM) fixes a methyl group in the α-position 
and leaves S-adenosylhomocysteine (SAH) as the sole byproduct (Figure 1.9). The 
limited studies on this rare PKS module thus far have focused on the origin of dimethyl 
units in polyketides. Preliminary work has revealed two possible routes: 1) The action of 
CMT on a malonyl-CoA prior to condensation by the KS domain (R = OH), 2) The 
dimethylation of an unmethylated intermediate of a polyketide by a CMT (R = growing 
polyketide).5 There is currently a lack of information on the catalytic mechanism, 
stereoselectivity and structure in CMT domains leaving these unknown aspects attractive 
subjects of future research. 
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Figure 1.9. Proposed mechanisms of polyketide C-methyltransferase domains. Two 
hypotheses are in effect, one acting on the malonate building blocks prior to (R = OH) 
and following (R = growing chain) KS-catalyzed Claisen reaction. 
 
A ketoreductase (KR) domain catalyzes the reduction of the β-ketone moiety in 
polyketide chain intermediates. This process utilizes nicotinamide adenine dinucleotide 
phosphate (NADPH) and stereoselectively forms a β-hydroxythioester intermediate 
(Figure 1.10). In addition to setting the hydroxyl-bearing stereogenic center, the domain 
also serves to fix the α-stereocenter in appropriately substituted substrates. The native 2S-
configuration resulting from the KS-catalyzed condensation may be epimerized by 
ketoreductase employing the same catalytic residues used for catalyzing stereoselective 
reduction.6,7 KR domains have been classified as types A and B for production of L- and 
D-alcohols, respectively (Figure 1.11). 8 Type C ketoreductases fail to catalyze reduction. 
	 8 
Further sub-types 1 and 2 denote the ketoreductases’ ability or inability to catalyze 
epimerization of the α-stereocenter to 2R-configuration.  
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Figure 1.10. The fundamental mechanism for the KR-catalyzed ketone reduction. The 
essential serine and tyrosine residues of the KR domain are shown with their 
hypothesized roles in catalysis. The delivery of the pro-S hydride from NADPH is 
invariant. Polyketide substrate orientation determines stereoselectivity. 
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Figure 1.11. Ketoreductase classification by stereoselectivity.  
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Once the β-hydroxythioester intermediate is formed, water can be eliminated by a 
dehydratase (DH) domain to form an olefin product. Although their study has lagged 
behind that of the ketoreductase domain, there has been resurgence in interest in DH 
domains. The polyketide dehydration is stereospecific in respect to both α- and β-
stereogenic centers.9 The net reaction is a syn-dehydration, similar to elimination in fatty 
acid biosynthesis and utilizes a catalytic histidine-aspartic acid dyad (Figure 1.12). Both 
cis- and trans-alkenes are present in polyketides, though little is known about cis-alkene 
formation as it has yet to be observed in vitro. 
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Figure 1.12. Elimination catalyzed by polyketide dehydratase domain. The proposed 
mechanism for syn-elimination with DH catalytic residues is displayed in brackets. In the 
example a trans-olefin product is formed after elimination of water. 
 
The final reductive processing event is the enoyl reductase (ER) domain. As its name 
suggests, the ER domain catalyzes the reduction of thioenoates, formed by dehydratase 
domains, yielding saturated alkanes in the process. This reduction utilizes NADPH in a 
similar to ketoreduction catalyzed by KR domains. The α-stereoselectivity appears to rely 
heavily on the presence or absence of a tyrosine residue, conferring 2S- or 2R-selectivity, 
respectively.10,11 This residue is not essential for catalysis and was determined to be 
necessary but not sufficient in dictating stereoselectivity. Recently, it has been revealed 
that the mechanism invokes an ene reaction with a transient, observable adduct (Figure 
1.13).12-14  
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Figure 1.13. The proposed ene-mechanism of reduction by enoyl reductase domains. The 
stereo-identity of the transient ene-adduct has yet to be deciphered. 
 
The final module of the polyketide synthase usually contains a thioesterase (TE) domain 
responsible for cleaving the mature chain elongation intermediate. The reaction typically 
results in macrocyclization or hydrolysis, affording a macrolactone or carboxylic acid 
product, respectively (Figure 1.14). The enzymatic mechanism involves a serine-
histidine-aspartic acid triad that loads the module’s ACP-bound thioester onto the serine 
residue via a transesterification. In addition to terminating thioesterases there have also 
been reports of editing TE (also known as type II or TE II) domains responsible for 
releasing stalled intermediates in the biosynthetic pathway.15,16 
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Figure 1.14. Polyketide chain termination by a thioesterase domain. The thioesterase can 
catalyze macrolactonization (blue arrow) or hydrolysis (red arrow) to release the ester 
intermediate from the polyketide synthase. 
 
A number of tailoring enzymes can alter the polyketide once it has been released from the 
PKS (Figure 1.15). These enzymes vary widely in their identity and catalytic role in 
biosynthesis. P450 enzymes are often recruited for C-H oxidation of the polyketide 
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backbone. Glycosylation is another a common means of modification. Other enzymes 
catalyze alkene isomerization, epoxidation, cyclopropanation and halogenation. 
Examining the natural product for deviation from the normal, alternating substitution 
pattern seen in polyketides can give insight into the post-PKS alterations occurring. 
Additionally, one can use the genetic sequence of the pathway to tease out functionality 
that may be the result of a tailoring event, unaccounted for by the central PKS (i.e. 
reduction, oxidation, elimination or methylation chemistry in the absence of KR, ER, DH 
or MT domains). The complete biosynthetic pathway to erythromycin (1.3) is the 
archetypal example of polyketide formation in nature (Figure 1.16). 
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Figure 1.15. Polyketide tailoring by post-PKS enzymes. The modifications made after 
the polyketide synthase are shown in blue. 
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Figure 1.16. PKS and post-PKS biosynthesis of the antibiotic erythromycin. One loading 
module and 6 extension modules, each incorporating a unit of methylmalonyl-CoA, yield 
the aglycone, 6-deoxyerythronolide B (1.23). P450 enzyme oxidation and glycosylation 
furnish the final natural product. 
 
Chapter 2: Tylosin Module 3 Cryptic Ketoreductase and Dehydratase Domains 
 
This chapter is based on previously published work appearing in: Fiers, W.D., Dodge, G. 
J., Li, Y., Smith, J. L., Fecik, R. A., Aldrich, C. C. Chem. Sci. 2015, 6, 5027-5033. 
 
2.1 Cryptic β-processing in polyketide synthase domains 
 
The stereochemical outcome of β-processing domains is often concealed or obscured 
through subsequent, downstream catalytic events. These instances of hidden domain 
action can fall into two broad categories: cryptic ketoreductase stereochemistry and 
cryptic dehydratase geometry (Figure 2.1). Cryptic KR reductions arise from presence of 
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a subsequent DH domain, catalytically eliminating water and, in so doing, removing both 
α- and β-stereogenic centers. Trans-olefin configuration arises from the elimination of D-
alcohols while cis-olefins emanate from enzyme-mediated isomerization events.17,18 
Despite recent, compelling evidence suggesting that, in phoslactomycin biosynthesis, 
PKS DH domain-catalyzed generation of Z-olefins occurs from L-alcohols, in vitro 
validation has yet to be obtained.19,20 Olefin geometry may be rendered cryptic through 
successive reduction by an ER domain, potentially yielding a new α-stereogenic center in 
the process. Cryptic reductions have received a significant amount of attention over the 
last decade resulting in several novel approaches to their study.21,22  Bioinformatic 
analysis has shown promise in predicting stereogenic centers based on amino acid 
sequence of the KR domain in question.17,23,8 
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Figure 2.1. Cryptic stereochemistry in a polyketide synthase. Depicted is the obscured 
stereochemistry placed by the KR domain and the hidden geometry of the dehydratase 
domain. Pikromycin is shown as an example with cryptic KR activity in blue (Δ10,11) and 
doubly cryptic KR and DH activity shown in purple (C-6,7). 
2.2 Chemical strategy and rationale 
Tylosin (2.1), a 16-membered macrolactone product of Streptomyces fradiae, was chosen 
as a model system for our initial cryptic domain studies. The tylosin polyketide synthase 
includes one loading module and seven extension modules terminating in a thioesterase 
(TE) domain affording the aglycone tylactone (2.2) (Figure 2.2).24 By virtue of their DH 
domains, modules 2, 3, and 5 have cryptic KR stereochemistry. Additionally, module 5, 
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housing an ER domain constitutes a complete reductive sequence further obscuring the 
geometry of the precursor olefin. Prior methods to study cryptic KRs and DHs using 
synthetic substrates have generally been limited to diketides. Truncated substrates, while 
synthetically more accessible, are often poorly tolerated resulting in low conversion and 
exhibit loose stereochemical discrimination.25,26 As a result, the inferred substrate 
specificity obtained using truncated substrates remains dubious given their significant 
deviation from the native chain intermediates. Cane and coworkers overcame this 
limitation through the in situ chemoenzymatic synthesis of a triketide from a diketide 
substrate using a KS-AT didomain and excised ACP domain from 6-deoxyerythronolide 
B synthase (DEBS).27 However, we anticipated this strategy would be difficult to 
implement for tetraketides as this would require the use of two complete modules in 
tandem.  
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Figure 2.2. The modular PKS of tylactone (2.1). The module 3 β-processing domains and 
their postulated product are highlighted in red. 
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As part of ongoing studies in our laboratories, we are interested in the development and 
use of small molecule tools for exploring innate reactivity within polyketide synthase 
modules. In the present study we sought to probe the enzyme catalyzed turnover of full-
length tetraketide substrates 2.4, 2.6 and 2.7 by TylKR3 and TylDH3 via LC-MS/MS 
detection (Figure 2.3). One virtue of our chosen tetraketides is that they uniformly lack a 
δ-hydroxyl moiety which has been shown to spontaneously lactonize with the 
thioester25,27,28. Our previous strategy utilized stable full-length polyketide intermediate 
mimics that are resistant to spontaneous intramolecular lactonization through replacement 
of the labile thioester linkage with a stable thioether moiety. 22,29 In light of these results, 
we sought to validate the use of thioether analogs 2.5, 2.8 and 2.9 for direct comparison 
with the aforementioned thioester substrates. This would constitute the first steady-state 
analysis of a polyketide dehydratase domain using native substrates, uncover the cryptic 
stereochemistry of TylKR3, and would offer a unique, more native context to discover 
innate substrate biases. The use of a natural full-length tetraketide chain intermediates 
and epimers at each stereogenic center would also allow us to evaluate the impact of 
vicinal and distal stereochemistry on KR and DH substrate processing.  
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Figure 2.3. Native and synthetic TylKR3 substrates with their possible β-processing 
products. The truncated region of the native substrate (2.3) serving as the basis of 
substrates 2.4 and 2.5 is highlighted in blue. 
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2.3 Synthesis of substrate and product compounds 
2.3.1 Chemical synthesis of two carbon homologate thioethers 
The synthesis of tetraketide substrate mimic 2.9 for TylDH3 began with known 
vinylketene silyl N,O-acetal 2.13, obtained in two steps from commercially available 
trans-2-methyl-2-pentenoic acid 2.12 (Scheme 2.1).30 The vinylogous Mukaiyama aldol 
reaction of 2.13 with propionaldehyde set the two distal stereogenic centers with 
excellent yield and diastereoselectivity (92%, >98:2 dr), illustrating the power of 
Kobayashi’s methodology for synthesis of this triketide building block.30 The relative and 
absolute stereochemistry was confirmed by comparison of its NMR spectral data and 
optical rotation value to the reported enantiomer.31 The vinylogous aldol adduct 2.14 was 
subsequently protected as the TIPS ether 2.15 in quantitative yield and reductive removal 
of the oxazolidinone auxiliary with DIBAL-H provided aldehyde 2.16.  
Scheme 2.1. Synthesis of thioether 2.9. 
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With the enal 2.16 in hand, we were poised to set the unknown stereochemistry of the 
TylKR3 reduction product. Utilization of Nagao’s N-acetylthiazolidinethione 2.17 under 
titanium-catalyzed conditions developed by Vilarrasa, Urpí and coworkers furnished the 
D-alcohol as the only detectable diastereomer in 81% yield.32,33 The thiazolidinethione 
chiral auxiliary of 2.18 was displaced with HN(OMe)Me to afford the corresponding 
Weinreb amide 2.19.34 The newly formed β-hydroxyl group was protected as TES ether 
2.20. Due to susceptibility to α,β-elimination, the strength of base was crucial, as tertiary 
amines (TEA, DIPEA) yielded exclusively the conjugated dienamide, whereas 2,6-
lutidine afforded the desired TES ether. The precise order of this two-step sequence 
(2.18→2.20) was critical as reversal led to a sterically encumbered, hydroxyl-protected 
thiazolidine resistant to displacement. Grignard addition of vinylmagnesium bromide to 
Weinreb amide 2.20 provided 2.21 that was globally deprotected with HF to afford 2.22. 
Regioselective Michael addition of N-acetylcysteamine (NAC) to the terminal enone of 
2.23 produced TYLDH3 substrate mimic 2.9 containing a two-carbon spacer. The L-
alcohol diastereomer 2.8 was prepared in an analogous fashion from 2.16 employing the 
antipode of 2.17 (2.23) (Scheme 2.2).  
Scheme 2.2. Synthesis of enantiomeric thioether 2.8. 
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At the onset of the project we had planned to prepare the TylKR3 substrate mimic 2.5 
from the corresponding TylDH3 substrate 2.9 through regioselective oxidation of the 
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allylic alcohol in preference to the distal secondary alcohol. Unfortunately 2.9 and its 
precursor 2.22 proved recalcitrant to a variety of oxidants (MnO2, BaMnO4, 
Pd(OAc)2/O2, etc.), returning starting material or dehydration products under more 
forcing conditions.35-37 In light of these results, we decided to chemoselectively remove 
the TES protecting group in 2.21 to provide mono-protected 2.29 (Scheme 2.3). A 
variety of common oxidants were then screened to affect the transformation of alcohol 
2.29 to the desired β-diketone 2.30 including the Dess-Martin periodinane, TPAP/NMO, 
and SO3•pyr. Surprisingly, most common reagents led to quick decomposition of the 
starting material or unwanted hetero-Michael additions. A recently described β-
hydroxyketone oxidation employing iodoxybenzoic acid (IBX) as the oxidant was 
employed as a mild, neutral method.38 This procedure afforded β-diketone 2.30 in near 
quantitative yields after simple filtration of the sparingly soluble oxidant from the 
products. Facile TIPS deprotection with aqueous HF provided 2.31, which was reacted 
with NAC to afford TylKR3 substrate 2.5. 
Scheme 2.3. Synthetic route to ketoreductase substrate 2.5. 
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Scheme 2.4. Synthesis of thioester TylKR3 product 2.7. 
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Scheme 2.5. Synthesis of thioester TylKR3 substrate 2.4. 
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2.3.2 Synthesis of thioester substrates 
The NAC thioester TylKR3 and TylDH3 substrates 2.4 and 2.7 were synthesized in a 
straightforward approach from intermediates 2.32 and 2.18, respectively, prepared in 
Scheme 1. The thiazolidinethione in 2.18 was directly displaced with N-acetylcysteamine 
(NAC) yielding the β-hydroxythioester 2.32 (Scheme 2.4). TIPS deprotection with 
aqueous HF furnished the TylDH3 NAC thioester substrate mimic 2.7. As anticipated, 
this compound displayed reasonable stability at room temperature and was stable for up 
to three months at 4 °C (determined by repeated 1H-NMR). Oxidation of β-
hydroxythioester 2.32 would provide the required β-ketothioester. Several reaction 
conditions were studied to affect this transformation and it was found, once again, that 
IBX afforded near quantitative yield of 2.33 (Scheme 2.5). TIPS deprotection promoted 
by aqueous HF yielded TylKR3 NAC thioester substrate mimic 2.4. β-Hydroxy thioester 
2.6, the C-2 epimer of compound 2.7, could be synthesized in a similar manner to 2.7 
(Scheme 2.6).  
Scheme 2.6. Synthesis of thioester substrate 2.6. 
2.24
NACSH, imid.
OH
Me Me Me
OTIPSO
NACS
2.34
OH
Me Me Me
OHO
NACS
2.6
HF
97% 80%
 
2.3.3 Unsuccessful synthesis of one-carbon homologs of the TylKR3 substrate. 
We had initially planned to make one-carbon extended thioether substrate analogs for the 
tylosin module 3 ketoreductase. This would allow us to assess the intermediary change 
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between the two-carbon analog (2.5) and the thioester (2.4) to determine if an optimal 
length could be obtained. The synthetic route, utilizing common Weinreb (2.2) amide, 
closely parallels that of 2.5 (Scheme 2.7). Careful addition of MeLi to a cooled solution 
of the Weinreb amide and ClCH2I furnished chloromethyl ketone 2.35 in variable yields 
(30-78%). Selective TES deprotection and oxidation were carried out in a similar fashion 
as previous syntheses. Reaction of the fully deprotected product 2.38 with HSNAC 
yielded one product in moderate conversion by TLC.  Surprisingly, upon isolation of the 
product it was discovered that the product was devoid of the characteristic N-
acetylcysteamine peaks predicted for thioether 2.39. Careful 1H-NMR analysis of the 
product revealed formation of a new alkene-singlet peak. We rationalized that a 
cyclization of the keto-enol tautomer occurred during the course of the reaction forming 
enone 2.40. In retrospect, this result is not unexpected, as several instances of this 
transformation have been reported to date in the literature.39,40 Attempts to slow the 
cyclization by reducing the temperature (-20, 0 °C) or the equivalents of base (0.5, 0.1 
equiv) either only slowed the formation of the undesired product or led to an increase in 
recovered starting material. Although the thiol (pKa 7) is expected to act as a better acid 
than the diketone (pKa 9) the undesired product is the result of an intramolecular 
reaction, outpacing the desired intermolecular reaction. Attempts to preform the thiol 
anion (nBuLi or Na2CO3) also resulted in the sole formation of the undesired furanone 
product. In light of these results, we decided to forgo the synthesis of TylKR3 substrate, 
one-carbon homologs. 
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Scheme 2.7. Unsuccessful synthesis of one-carbon thioether substrate. 
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2.4 Expression of Tylosin Module 3 β-Processing Domains.  
With TylKR3 substrate mimics 2.4 and 2.5 in hand, we sought to express and purify the 
KR and DH domains of Tyl module 3. By sequence alignment to structurally 
characterized domains8,41-43, the sequence boundaries of the KR and DH were 
determined.  Initial efforts to recombinantly express the mono-domain TylKR3 were 
hampered by poor expression levels and protein aggregation. Strategies to alleviate these 
issues included an increase of rare tRNA codons (Rosetta cell line), optimization of 
codon selection (synthetic TylKR3 gene), toxic protein-compatible expression hosts 
(pLysS cell line), appending a fusion protein (attempted with SUMO, mOCR, and GST), 
chaperone coexpression (GroEL-GroES) and truncations of both N- and C-termini. 
Disappointingly, these techniques failed to improve expression of soluble non-aggregated 
TylKR3 and forced us to abandon the expression of the mono-domain construct. As the 
TylKR3 was recalcitrant to purification, our collaborators at the University of Michigan 
(Greg Dodge, Dr. Janet L. Smith) constructed a plasmid encoding the TylDH3-KR3 di-
domain including a portion of linker between the KR and ACP domains (residues 957-
1682 of tylosin PKS module 3). The didomain was stable upon purification, and used in 
further analysis.  The molecular weight of the recombinant proteins determined by SDS-
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PAGE was 76 kDa and found to be 76,265 by mass spectrometry, both consistent with 
the calculated value (76,511 Da).  
2.5 Enzymatic Analysis of TylDH3-KR3.  
2.5.1 Analysis of ketoreductase activity 
We initially attempted to characterize the activity of the TylKR3 domain with substrates 
2.4 and 2.5 in the presence of NADPH using LC-MS/MS analysis with an internal 
standard for rigorous quantitation and synthetic standards for product identification. 
Overnight incubation of the TylDH3-KR3 di-domain with 2.4 and 2.5 afforded the D-
configured reduction products 2.7 and 2.9 in relatively minor amounts, consistent with 
the B-type KR domain, along with the dehydration products 2.10 and 2.11 as the major 
species. NAC thioester 2.4 provided 2.7:2.10 in ratio of 1:22 while NAC thioether 2.5 
furnished 2.9:2.11 in a ratio of 1:102 (Figure 2.4, panels A and B). However, the KR 
acted very slowly, as the total conversion in each case was less than 2% of input 
substrate. The combination of slow KR conversion and low KR:DH product ratio 
suggests that the ketoreductase product can efficiently shuttle to the dehydratase in 
absence of ACP tethering.  It further suggests that the chemically reversible dehydration 
reaction is unidirectional with TylDH3 since an unexpectedly high amount of 
dehydration product was formed from a freely diffusible reduction product. 
Unfortunately, we were unable to kinetically characterize TylKR3 due to the slow 
substrate turnover.  
2.5.2 Analysis of dehydratase activity 
We next examined the ability of TylDH3-KR3 to process DH substrates 2.6, 2.7, 2.8, and 
2.9. Each substrate (1 mM) was individually incubated overnight with 10 µM TylDH3-
KR3 and the reactions were analyzed by LC-MS/MS as before.  The D-alcohols 2.7 and 
2.9 led to nearly quantitative formation of trans-olefin products 2.10 and 2.11, 
respectively (Figure 2.4, panels C and D) whereas L-alcohols 2.6 and 2.8 were not turned 
over by the enzyme. This further corroborates the bioinformatic prediction that the 
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preceding B-type TylKR3 should produce D-alcohols and is consistent with empirical 
observations that D-alcohols yield trans-olefins.44,45 Based on the enhanced activity of 
TylDH3 relative to TylKR3 we performed a large-scale incubation of 2.7 and 2.9, and 
isolated 2.10 and 2.11 in 67 and 98% yield, respectively after column chromatography. 
The product identities were unequivocally confirmed by 1H and 13C-NMR spectroscopy 
and exhibited nearly identical diagnostic 13C chemical shifts of ~147 and ~133 ppm and a 
3JHH coupling constant of ~ 16 Hz.  
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Figure 2.4. LC-MS/MS traces of in vitro ketoreduction and dehydration reactions. 
Overnight incubation conducted with KR substrates 2.4 (panel A) and 2.5 (panel B) and 
TylDH3-KR3 in the presence of NADPH. The identity of the β-hydroxy products (shown 
in blue) was confirmed by co-injection with authentic standards. Incubation with 
synthetic 2.7 (panel C) and 2.9 (panel D) resulted in sole formation of dehydration 
products 2.10 and 2.11 (trace shown in red), respectively. Panels A and C blue trace 
represents MRM (m/z 340→184) and red trace represents MRM (m/z 300→181). Panels 
B and D blue trace represents MRM (m/z 368→212) red trace represents MRM (m/z 
328→151).) 
 
The enhanced activity of TylDH3 domain enabled characterization by steady-state kinetic 
analysis.  The velocity remained linear up to 10 minutes reaction time and was also linear 
with respect to TylDH3-KR3 concentration from 0.25 to 1 µM. The initial rates, v0 at a 
given [S] were thus determined by single-time point stopped-time incubations at 8 
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minutes with 0.5 µM TylDH3-KR3. Due to the limited solubility of substrates 6b and 7b 
we were unable to reach saturation, consequently the plots of initial velocity versus [S] 
were fit by linear regression analysis to determine the specificity constants (kcat/KM). 
Thioester 2.7 and thioether 2.9 displayed specificity constants of 908 ± 30 and 410 ± 20 
min-1 M-1, respectively (Table 2.1 and Figure 2.5 (panels A and B)). The modest 2.5-fold 
difference in kcat/KM indicates thioethers are well tolerated, validating their use as 
stabilized forms of substrates otherwise prone to nonproductive, intramolecular 
cyclization.  
Table 2.1. Steady-state kinetic analysis of TylDH3 substrates.  
cmpd# DH Substrate  kcat/KM, min-1 M-1 
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Me Me
OH
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O
NACS
2.6  
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2.7 
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Me Me
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2.42  
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(±) 2.54 
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(±) 2.54  
<10a 
abelow the limit of detection (LOD) of products in LC-
MS/MS.
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R2 = 0.991 R2 = 0.976 
kcat/KM = 980 ± 30 min-1M-1 kcat/KM = 410 ± 20 min-1M-1 
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Figure 2.5. Linear regression analysis of TylDH3KR3 kinetic data with substrates 2.7, 
2.9, 2.41, and 2.42. The kinetic plots of thioester 2.7, thioether 2.9, thioester 2.41 and 
thioester 2.42 are shown in panels A, B, C and D, respectively. Represented data is the 
result of duplicate LC-MS/MS data normalized with controls lacking enzyme. Specificity 
constants (kcat/KM) for each substrate are displayed below the corresponding plot. 
 
2.6 Synthesis and Activity of Epimeric DH Substrates 
To explore the impact of remote stereocenters on processing by TylDH3 we synthesized 
full-length tetraketide NAC thioesters 2.41 and 2.42, epimeric at the ε- and ζ-
stereocenters, respectively (Schemes 2.8 and 2.9).  The syntheses closely followed that of 
previous TylDH3 substrates except in regards to the use of use Hosokawa’s modified 
vinylogous aldol conditions for obtaining syn-aldol products.46 The serendipitous 
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formation of dehydration product 2.48 during the extended aldol reaction served to 
provide a route to the dehydration product (2.53) for an authentic LC-MS/MS standard 
(Scheme 2.10).  
With the epimers in hand, we kinetically evaluated the TylDH3 in a similar manner as we 
had done with 2.7 and 2.9. The specificity constant for 2.41 was 22 ± 2 min-1 M-1, which 
is 45-fold less than 2.7 (Table 1, Figure 2.5 (panel C)). Although 2.41 only differs from 
2.7 via inversion of the ε-methyl group, we expect the trisubstituted olefin may enhance 
the 1,3-allylic (A1,3) strain and more severely impact the side chain conformation, 
potentially contributing to the drastic attenuation in kcat/KM.  Boddy and co-workers also 
invoked A1,3 strain to rationalize substrate tolerance in their work on PKS  thioesterases.47 
We next evaluated the ζ-epimer 2.42, whose specificity constant was 72 ± 6 min-1M-1, 
approximately 14-fold less than 2.7 (Figure 2.5 (panel D)).  Since inversion of the ζ-
stereocenter is not expected to significantly alter the substrate conformation, we speculate 
that the ζ-hydroxyl group may be important for substrate recognition that is otherwise 
dominated by hydrophobic interactions of this nonpolar substrate. To complete our 
substrate specificity studies, we also evaluated diketide (±)-2.54, but it was not processed, 
highlighting the significance of using full-length substrates.29 
Scheme 2.8. Synthetic route towards dehydratase substrate 2.41. 
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Scheme 2.9. Synthesis of substrate 2.42. 
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Scheme 2.10. Synthetic route towards authentic product standard 2.53. 
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2.7. Tylosin Module 3 Summary 
The use of full-length, diffusible tetraketide probes allowed for systematic analysis of the 
module 3 processing domains of tylosin: TylKR3 and TylDH3. The TylKR3 domain was 
weakly active and produced D-alcohols stereoselectively, further confirming the accuracy 
of existing bioinformatic approaches.17,23 In contrast, the TylDH3 domain proved robust 
in its production of trans-olefins allowing for the chemoenzymatic synthesis of 
dehydration products. Dehydratase substrate specificity in relation to each stereocenter 
was independently determined through steady-state kinetic analysis via LC-MS/MS 
detection revealing unpredicted biases for the native substrate. TylDH3 did not tolerate β-
stereochemistry inversion, and epimerization of distal stereocenters attenuated the 
activity by 14-45 fold when compared to the native substrate. This finding was 
rationalized through recognition of allylic A1,3 strain within the molecule and the 
potential electrostatic and/or hydrogen bonding interactions of the distal hydroxyl moiety. 
The distant elements of the substrate were necessary for activity as truncated substrate 
(±)-2.54 was not dehydrated by TylDH3. Additionally, thioethers proved to be stable 
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thioester surrogates. 
This work highlights the in vitro use of di-domains in the study of cryptic processes as 
potential solutions for insoluble and/or unreactive domains. The ACP domain has been 
largely assumed to control the flow of intermediates throughout the reductive progression 
of domains towards the ultimate module product.48-50 Unexpectedly, we discovered that 
tylosin module 3 funnels diffusible substrates from ketoreductase to dehydratase 
independent of ACP tethering. The exact mechanism of this observed phenomenon 
remains to be determined and could involve the proximity of the KR product exit and DH 
substrate entrance, thereby increasing the local concentration of DH substrate. 
Alternatively, a conformational change prior to or upon substrate release from the 
ketoreductase may draw the two catalytic sites together, leading to the observed shuttling 
process.  Our results are consistent with structures of the pikromycin module 5 in which 
the ACP localization was determined by the tethered acyl group.51,52 
 
The finding that the distal stereochemical fidelity of preceding modules can be closely 
regulated by dehydratase activity via a stringently stereospecific process may have far-
reaching implications in the fields of natural product isolation and synthetic biology. 
Specifically, this research directly supports the hypothesis that tightly controlled relative 
and absolute polyketide stereochemistry may not necessitate the action of exquisitely 
stereoselective domains but, instead, be the consequence of iterative, stereospecific 
checkpoints or gatekeeper domains. Stalled chain intermediates have been previously 
shown to be hydrolyzed by downstream TE domains, freeing a non-productive, immature 
polyketide acid and phosphopantetheine-ACP arm for productive product formation.53-55 
Interestingly, our work suggests that the dehydratase domain, which removes 
stereochemical information via elimination of water, can additionally enrich the final 
product optical purity. As the dehydratase-catalyzed syn-elimination of water is the only 
β-processing domain to require a specific, two-centered tetrahedral substrate 
conformation, it may be naturally sensitive to the local stereochemical features of the 
substrate. 
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2.8 Chemistry experimental section 
 
General Chemistry Procedures. All chemical reagents were used as provided unless 
explicitly indicated otherwise. Tetrahydrofuran (THF) and dichloromethane (CH2Cl2) 
were purified via passage through alumina columns. All reactions were performed under 
anhydrous argon atmosphere using oven-dried (150 °C) glassware. Reaction mixtures 
were stirred magnetically using oven-dried magnetic stir bars. Compound purification via 
flash chromatography utilized silica gel (300–400 mesh) in the indicated solvent system. 
TLC was performed using 250 µm, F254 silica gel plates and visualized UV and para-
anisaldehyde stain. A Rudolph Autopol III polarimeter at the indicated temperature using 
the sodium D line (λ = 589 nm) unless otherwise specified and reported as follows: 
[α] D
temp= rotation (c g/100 mL, solvent). 1H and 13C NMR spectra were recorded on a 
Bruker 400 spectrometer at 400 Hz for 1H NMR and at 100 Hz for 13C NMR. Chemical 
shifts are reported in ppm based on an internal standard of residual CHCl3 (7.26 ppm in 
1H NMR and 77.16 in 13C NMR). Proton chemical data are reported in the following 
format: chemical shift (ppm) (multiplicity (s = singlet, d= doublet, t = triplet, q = quartet, 
quin = quintet, sextet = sextet, sept = septet, m = multiplet, br = broad peak), J = coupling 
constant (Hz), integration). High-resolution mass spectra (HRMS) were obtained on a 
Bruker BioTOF II ESI-TOF/MS using either PEG or PPG standards as high-resolution 
calibrants.  
O
N
Me Me
O
O
iPr
Me
OH
 
(S)-3-((4S,5R,E)-5-Hydroxy-2,4-dimethylhept-2-enoyl)-4-isopropyloxazolidin-2-one 
(2.14). Freshly distilled propionaldehyde56 (4.93 mL, 68.3 mmol, 2.00 equiv) in 
anhydrous CH2Cl2 (120 mL) was placed in dry ice-acetone bath (-78 °C) and allowed to 
equilibrate.  To the cooled solution was added TiCl4 (3.77 mL, 34.2 mmol, 1 equiv).  To 
the resulting yellow reaction mixture was slowly added the vinylketene silyl N,O-acetal 
2.1331 (11.6 g, 34.2 mmol, 1.00 equiv) as a solution in CH2Cl2 (45 mL).  The reaction 
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quickly adopted a dark red hue.  Following completion of addition, the reaction mixture 
was transferred to a dry ice-MeCN bath (-40 °C) and stirred for 21 h.  The reaction 
mixture was quenched upon treatment with saturated aqueous Rochelle’s salt, followed 
by saturated aqueous sodium bicarbonate solutions at -40 °C.  The cloudy, white mixture 
was allowed to warm to room temperature and stirred for 1 h.  The resulting biphasic 
solution was separated and the aqueous layer was extracted with CH2Cl2 (3 × 75.0 mL) 
and EtOAc (3 × 75.0 mL).  The combined organic solutions were dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  The resulting crude oil was dry-loaded 
onto silica column and purified by flash chromatography (30% EtOAc/hexanes) to afford 
the title compound (8.76 g, 30.9 mmol, 90%) as a viscous, slightly yellow oil. TLC: Rf = 
0.20 (20% EtOAc/hexanes); [α] D
23 = 28.3 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 
5.82 (d, J = 10.4 Hz, 1H), 4.58 (dt, J = 8.8, 4.8 Hz, 1H), 4.34 (t, J = 8.8 Hz, 1H), 4.18 
(dd, J  = 7.2, 7.6 Hz, 1H), 3.32–3.25 (m, 1H), 3.08 (br s, 1H), 2.63–2.52 (m, 1H), 2.38–
2.28 (m, 1H), 1.94 (s, 3H), 1.76–1.64 (m, 1H), 1.44 (app. sept, J = 7.6 Hz, 1H), 1.01 (t, J 
= 7.2 Hz, 3H), 0.98 (d, J = 7.2 Hz, 3H), 0.95–0.89 (m, 6H); 13C NMR (CDCl3, 100 MHz) 
δ 171.7, 154.7, 142.5, 131.2, 76.7, 63.6, 58.3, 39.9, 28.6, 26.8, 18.0, 16.3, 15.4, 14.1, 
10.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H24NO4Na 306.1676, found 
306.1673. 
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(S)-3-((4S,5R,E)-2,4-Dimethyl-5-((triisopropylsilyl)oxy)-hept-2-enoyl)-4-isopropylox-
azolidin-2-one (2.15). A solution containing the aldol adduct 2.14 (0.889 g, 3.14 mmol, 
1.00 equiv) in CH2Cl2 (24.0 mL) was cooled in an ice-water bath. To the chilled, 
colorless solution was added i-Pr2NEt (0.655 mL, 3.76 mmol, 1.20 equiv) followed by 
TIPSOTf (1.01 mL, 3.76 mmol, 1.20 equiv). The resulting solution was stirred at 0° C for 
1 h and transferred to a refrigerator (3-5° C) for 24 h. The clear yellow solution was 
quenched upon addition of saturated aqueous NaHCO3 solution (12.0 mL) at 0° C, and 
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allowed to warm to room temperature over 20 min. The biphasic mixture was separated, 
and the aqueous layer was extracted with CH2Cl2 (4 × 20.0 mL). The combined organic 
layers were dried (Na2SO4), filtered, and concentrated under reduced pressure. The 
product residue was purified by flash chromatography (10% EtOAc/hexanes) to afford 
the title compound (1.3805 g, 3.14 mmol, quant.) as a transparent, colorless oil. TLC: Rf = 
0.68 (20% EtOAc/hexanes); [α] D
21  = 29.5 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 
6.19 (dd, J = 9.6, 1.2 Hz, 1H), 4.50 (ddd, J = 9.2, 5.6, 4.4 Hz, 1H), 4.29 (t, J = 8.8 Hz, 
1H), 4.14 (dd, J = 9.2, 6.0 Hz, 1H), 3.73 (ddd, J = 5.2, 2.4, 7.6 Hz, 1H), 2.72 (ddq, 9.6, 
6.8, 2.4 Hz, 1H), 2.42–2.30 (m, 1H), 1.92 (d, J = 1.2 Hz, 3H), 1.63–1.48 (m, 2H), 1.10–
1.04 (m, 24H), 0.90 (t, J = 7.2 Hz, 6H), 0.86 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 172.4, 153.8, 141.1, 130.6, 77.8, 63.4, 58.4, 37.0, 28.3, 18.5, 18.4, 18.0, 16.7, 
15.1, 13.7, 13.2, 10.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H45NO4Na 
462.3010, found 462.3019. 
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(4S,5R,E)-2,4-Dimethyl-5-((triisopropylsilyl)oxy)hept-2-enal (2.16). A solution of 
imide 2.15 (3.185 g, 7.24 mmol, 1.00 equiv) in anhydrous dichloromethane (229 mL) 
was equilibrated in dry ice-acetone bath (-78 °C) under argon atmosphere. To the stirred 
solution was added DIBAL-H (1.49 M in toluene, 9.73 mL, 14.5 mmol, 2.00 equiv) in a 
dropwise fashion over 2 min. The reaction mixture was allowed to stir at -78 °C for 14 
min then quenched upon successive addition of MeOH (15.0 mL) and saturated aqueous 
sodium potassium tartrate (15.0 mL). The resulting mixture was allowed to warm to room 
temperature and stirred vigorously for 14 h. The biphasic solution was separated and the 
aqueous layer was extracted with CH2Cl2 (3 × 100 mL). Combined organic extracts were 
dried over Na2SO4, filtered and concentrated under vacuum. The crude oil was purified 
by flash chromatography (10% EtOAc/hexanes) furnishing the title compound (1.98 g, 
6.34 mmol, 88%) as a clear, colorless oil. TLC: Rf = 0.52 (10% EtOAc/hexanes); [α] D
23 = 
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–4.3 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 9.40 (s, 1H), 6.59 (d, J = 10.0 Hz, 
1H), 3.78 (app. quin, J = 4.0 Hz, 1H), 2.89 (ddq, J = 10.0, 6.8, 3.2 Hz, 1H), 1.76 (s, 3H), 
1.65–1.54 (m, 1H), 1.41 (app. sept, J = 7.6 Hz, 1H), 1.12 (d, J = 7.2 Hz, 3H), 1.08 (s, 
21H), 0.86 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 195.8, 156.8, 139.1, 77.4, 
37.7, 28.6, 18.4, 16.9, 13.1, 9.9, 9.6; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C18H36O2SiNa 335.2377, found 335.2372. 
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(3S,6S,7R,E)-3-Hydroxy-1-((R)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-
7-((triisopropylsilyl)-oxy)non-4-en-1-one (2.18). A CH2Cl2 (19.6 mL) solution of acetyl 
thiazolidinone 2.17 (1.07 g, 5.26 mmol, 1.70 equiv) was cooled to -40 °C (dry ice-
MeCN) under inert, argon atmosphere. To the chilled, yellow solution was added TiCl4 
(0.611 mL, 5.57 mmol, 1.80 equiv) resulting in a sudden color change to bright orange. 
The reaction mixture was stirred for 30 min.  Slow addition of freshly distilled iPrNEt56 
(0.970 mL, 5.57 mmol, 1.80 equiv) over 3 min caused a dramatic color change to blood 
red. The enolate solution was stirred for 2 h 12 min while maintaining an external 
temperature of -40 °C. The reaction was cooled to -78 °C and aldehyde 2.16 (0.967 g, 
3.09 mmol, 1.00 equiv) was slowly added over the course of 1 min as a solution in 
CH2Cl2 (3.87 mL) and stirred for 5 h. The resulting red-orange mixture was quenched via 
addition of saturated aqueous NH4Cl (10.0 mL) at -78 °C. The biphasic solution was 
allowed to warm to room temperature and the layers were separated. The aqueous layer 
was extracted with CH2Cl2 (3 × 15 mL) and the combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The resulting clear, golden oil 
was purified by flash chromatography (20% EtOAc/hexanes) affording the title 
compound (1.29 g, 2.50 mmol, 81%) as a bright yellow, viscous oil. TLC: Rf = 0.29 (20% 
EtOAc/hexanes); [α] D
22 = –219.0 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.51 (d, 
J = 9.6 Hz, 1H), 5.15 (app. t, J = 6.8 Hz, 1H), 4.58 (dd, J = 8.8, 3.2 Hz, 1H), 3.66 (dt, J = 
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6.4, 3.2 Hz, 1H), 3.56–3.44 (m, 3H), 3.03 (d, J = 11.6 Hz, 1H), 2.63–2.55 (m, 1H), 2.38 
(app. sextet, J = 7.2 Hz, 1H), 1.68 (s, 3H), 1.52–1.40 (m, 2H), 1.07 (s, 24H), 0.99 (d, J = 
2.4, 3H), 0.98 (d, J = 2.4, 3H), 0.85 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
203.1, 173.0, 135.2, 129.1, 77.7, 73.4, 71.7, 44.3, 36.6, 31.0, 30.8, 27.6, 19.3, 18.5, 17.9, 
16.9, 13.2, 12.6, 10.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H49NO3S2SiNa 
538.2815, found 538.2815. 
 
OH
Me Me Me
OTIPSO
N
MeO
Me  
 (3S,6S,7R,E)-3-Hydroxy-N-methoxy-N,4,6-trimethyl-7-((triisopropylsilyl)oxy)non-
4-enamide (2.19). To a bright yellow CH2Cl2 (2.00 mL) solution of acyl 
thiazolidinethione 2.18 (0.203 g, 0.390 mmol, 1.00 equiv) was added imidazole (0.133 g, 
1.95 mmol, 5.00 equiv) followed by HN(OMe)Me•HCl (95.0 mg, 0.980 mmol, 2.50 
equiv). A catalytic amount of DMAP (one grain) was added to the final mixture. The 
reaction was stirred 20 h at room temperature and quenched via addition of saturated 
aqueous NH4Cl (2.00 mL). The biphasic mixture was separated and the aqueous layer 
was extracted with CH2Cl2 (4 × 10.0 mL). The combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude residue was purified 
by flash chromatography (30% EtOAc/hexanes) providing the title compound (0.155 g, 
0.372 mmol, 96%) as a slightly yellow, clear, viscous oil. TLC: Rf = 0.34 (40% 
EtOAc/hexanes); [α] D
21 = –35.1 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.49 (d, J 
= 9.6 Hz, 1H), 4.45 (dd, J = 8.0, 4.4 Hz, 1H), 3.69 (s, 3H), 3.68–3.63 (m, 1H), 3.20 (s, 
3H), 2.68–2.56 (m, 3H), 1.69 (s, 1H), 1.47 (dq, J = 7.6, 6.8 Hz, 2H), 1.07 (s, 21H), 0.99 
(d, J = 6.8 Hz, 3H), 0.85 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 173.9, 135.4, 
128.5, 77.8, 73.4, 61.4, 37.2, 36.6, 32.0, 27.4, 18.4, 16.8, 13.1, 12.6, 10.5; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C22H45NO4SiNa 438.3010, found 438.3009. 
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(3S,6S,7R,E)-N-Methoxy-N,4,6-trimethyl-3-((tri-ethylsilyl)oxy)-7-((triisopropylsilyl)-
oxy)non-4-enamide (2.20).  To a reaction flask containing β-hydroxy amide 2.19 (0.345 
g, 0.829 mmol, 1.00 equiv) dissolved in CH2Cl2 (15 mL) in ice-water bath (0 °C) was 
added 2,6-lutidine (0.387 mL, 3.32 mmol, 4.00 equiv). The resulting basic solution was 
supplemented with TESOTF (0.375 mL, 1.66 mmol, 2.00 equiv) and stirred for 1.5 h. 
The reaction was terminated via the sequential addition of MeOH (3 mL) followed by 
saturated aqueous NaHCO3 (5.00 mL) at 0 °C. The biphasic mixture was warmed to 
room temperature, separated, and the aqueous fractions were extracted with CH2Cl2 (4 × 
10.0 mL). The combined organic fractions were dried over anhydrous sodium sulfate, 
filtered and concentrated under reduced pressure. The resulting crude oil was purified by 
flash chromatography (10% EtOAc/hexanes) affording the title compound (0.411 g, 
0.776 mmol, 94%) as a clear, slightly yellow oil. TLC: Rf = 0.61 (20% EtOAc/hexanes); 
[α] D
23 = –20.6 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.45 (d, J = 9.6 Hz, 1H), 4.58 (dd, J 
= 8.8, 4.4 Hz, 1H), 3.70 (s, 3H), 3.65 (dt, J = 6.8, 2.8 Hz, 1H), 3.17 (s, 3H), 2.94–2.80 
(m, 1H), 2.56 (ddq, J = 9.6, 6.8, 2.8 Hz, 1H), 2.31 (dd, J = 14.0, 4.4 Hz, 1H), 1.64 (s, 
3H), 1.52–1.39 (m, 2H), 1.08 (s, 21H), 0.96 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 8.0 Hz, 9H), 
0.85 (t, J = 7.6 Hz, 3H), 0.56 (q, J = 8.0 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 172.3, 
136.8, 128.0, 78.0, 75.5, 61.5, 39.7, 36.6, 32.1, 27.6, 18.4, 16.7, 13.1, 11.7, 10.8, 7.0, 4.9; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C28H59NO4Si2Na 552.3875, found 552.3882. 
 
OTES
Me Me Me
OTIPSO
 
(5S,8S,9R,E)-6,8-Dimethyl-5-((triethylsilyl)oxy)-9-((triiso-propylsilyl)oxy)undeca-
1,6-dien-3-one (2.21). A reaction vessel containing Weinreb amide 2.20 (0.237 g, 0.448 
mmol, 1.00 equiv) in THF (32.0 mL) was placed in ice-water bath (0 °C) and allowed to 
equilibrate. To the chilled, clear solution was added solution of vinylmagnesium bromide 
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(1.0 M in THF, 1.44 mL, 1.44 mmol, 3.20 equiv). The reaction mixture was stirred at 0 
°C for 4 h. An additional aliquot of vinylmagnesium bromide (0.450 mL, 0.450 mmol, 
1.00 equiv) was added and the reaction mixture was stirred for 1 h prior to quenching 
with saturated aqueous NH4Cl (10.0 mL). The biphasic mixture was allowed to warm to 
room temperature, separated and the aqueous layer was extracted with CH2Cl2 (3 × 15.0 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The resulting crude oil was purified by flash chromatography 
(5% EtOAc/hexanes) yielding the title compound (0.192 g, 0.387 mmol, 86%) as a clear, 
colorless oil. TLC: Rf = 0.38 (5% EtOAc/hexanes); [α] D
22 = –20.7 (c 0.978, CHCl3); 1H 
NMR (400 MHz) δ 6.36 (dd, J = 17.6, 10.8 Hz, 1H), 6.20 (d, J = 17.6 Hz, 1H), 5.82 (d, J 
= 10.8 Hz, 1H), 5.43 (d, J = 9.2 Hz, 1H), 4.54 (dd, J = 8.4, 4.4 Hz, 1H), 3.64 (dt, J = 6.9, 
2.6 Hz, 1H), 2.94 (dd, J = 14.0, 8.5 Hz, 1H), 2.63–2.42 (m, 2H), 1.63 (s, 3H), 1.52–1.35 
(m, 2H), 1.08 (s, 21H), 0.95 (d, J = 6.8, 3H), 0.89 (t, J = 8.0 Hz, 9H), 0.85, (t, J = 7.4 Hz, 
3H), 0.54 (q, J = 8.0 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 199.6, 137.6, 136.5, 128.5, 
128.1, 77.9, 75.6, 47.0, 36.6, 27.6, 18.4, 13.1, 11.6, 10.8, 7.0, 6.0, 4.9; HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C28H56O3Si2Na 519.3660, found 519.3647. 
 
OH
Me Me Me
OHO
 
(5S,8S,9R,E)-5,9-Dihydroxy-6,8-dimethylundeca-1,6-dien-3-one (2.22). To a 
polypropylene tube (15 mL, BD FalconTM) containing silylether 2.21 (29.8 mg, 0.0600 
mmol, 1.00 equiv) was added MeCN (3.00 mL) and magnetic stir bar. The mixture was 
stirred in ice-water bath (0 °C) until a homogenous solution was obtained. A solution of 
48% aqueous HF–MeCN (11:89, 8.36 mL) was slowly added to the reaction vessel. The 
resulting clear solution was stirred vigorously for 1 h and placed in a refrigerator (4 °C) 
for 15 h. The reaction was quenched at 0 °C via dropwise addition of a saturated aqueous 
NaHCO3 solution until the pH was 7. The neutralized solution was extracted with EtOAc 
(4 × 15.0 mL). All organic fractions were combined, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified by flash column 
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chromatography (5% MeOH/CH2Cl2) affording the title compound (13.3 mg, 0.586 
mmol, 98%) as a clear, colorless oil. TLC: Rf = 0.30 (5% MeOH/CH2Cl2); [α] D
21 = –37.2 
(c 0.26, CHCl3); 1H NMR (400 MHz) δ 6.37 (dd, J = 17.6, 10.3 Hz, 1H), 6.26 (dd, J = 
17.7, 1.0 Hz, 1H), 5.90 (dd, J = 11.4, 1.0 Hz, 1H), 5.38 (d, J = 9.9 Hz, 1H), 4.52 (dd, J = 
7.3, 4.7 Hz, 1H), 3.32 (ddd, J = 8.4, 6.4, 3.6 Hz, 1H), 2.99 (br s, 1H), 2.86–2.80 (m, 2H), 
2.53–2.41(m, 1H), 1.69 (d, J = 1.2 Hz, 3H), 1.62–1.53 (m, 2H), 1.45–1.33 (m, 1H), 0.97 
(t, J = 7.4 Hz, 3H), 0.96 (d, J = 6.8 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.0, 137.6, 
136.9, 129.5, 128.4, 77.0, 73.0, 44.6, 38.1, 27.1, 17.2, 13.0, 10.2; HRMS (ESI-TOF) m/z: 
[M + Na]+ Calcd for C13H22O3Na 249.1461, found 249.1466. 
 
OH
Me Me Me
OHO
NACS
 
N-(2-(((5S,8S,9R,E)-5,9-Dihydroxy-6,8-dimethyl-3-oxoundec-6-en-1-yl)thio)ethyl)-
acetamide (2.9). A reaction flask containing vinyl ketone 2.22 (3.9 mg) in THF (5.0 mL) 
was supplemented with N-acetylcysteamine (2.0 µL, 0.019 mmol, 1.1 equiv). To the 
resulting clear solution was added a catalytic amount of Cs2CO3 and the resulting 
reaction mixture was stirred for 5 h at ambient temperature under argon atmosphere. The 
reaction was quenched upon addition of a saturated, aqueous NH4Cl solution (5.0 mL). 
The biphasic mixture was separated and the aqueous layer was extracted with EtOAc (8 × 
10 mL). The combined organic fractions were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography with a small CuSO4–impregnated silica gel plug (2.0 cm thick) on top 
(eluent = 10% MeOH/CH2Cl2) furnishing the title compound (5.9 mg, 0.017 mmol, 
quant.) as a colorless, translucent oil. TLC: Rf = 0.13 (5% MeOH/CH2Cl2); [α] D
21  = –24.9 
(c 0.38, CHCl3); 1H NMR (400 MHz) δ 6.11 (s, 1H), 5.36 (d, J = 9.9 Hz, 1H), 4.48 (dd, J 
= 8.5, 3.4 Hz, 1H), 3.43 (app. q, J = 6.1 Hz, 2H), 3.37–3.24 (m, 1H), 2.86–2.58 (m, 8H), 
2.49–2.39 (m, 1H), 1.99 (s, 3H), 1.66 (d, J = 1.0 Hz, 3H), 1.61–1.52 (m, 1H), 1.44–1.32 
(m, 1H), 0.99–0.93 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 209.4, 170.5, 137.5, 128.4, 
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77.1, 73.1, 48.2, 43.8, 38.7, 38.0, 32.2, 27.2, 25.2, 23.4, 17.2, 13.0, 10.2; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C17H31NO4SNa 368.1866, found 368.1872. 
 
OH
Me Me Me
OHO
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S
iPr  
(3R,6S,7R,E)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-
7-((triisopropylsilyl)-oxy)non-4-en-1-one (2.24). A reaction vessel containing 
thiazolidinethione 2.23 (91.9 mg, 0.452 mmol, 1.50 equiv) in CH2Cl2 (3.00 mL) was 
cooled in ice-water bath (0 °C). To the chilled, bright yellow solution was added TiCl4 
(55.0 µL, 0.503 mmol, 1.67 equiv) resulting in a color change to red-orange. The reaction 
was stirred for 5 min, then placed in dry ice–acetone bath (-78 °C) and allowed to 
equilibrate. To the chilled reaction mixture was added freshly distilled iPr2NEt (87.6 µL, 
0.503 mmol, 1.67 equiv) dropwise over 4 min causing a sudden color change to blood 
red. The solution was stirred at -78 °C for 2 h. To the enolate solution was added 
aldehyde 2.16 (94.0 mg, 0.301 mmol, 1.00 equiv) as a solution in anhydrous CH2Cl2 
(11.00 mL) over the course of 6 min. The reaction mixture was stirred at -78 °C for an 
additional 6 h and quenched upon addition of saturated, aqueous NH4Cl (5.00 mL). The 
biphasic solution was warmed to ambient temperature, separated and the aqueous layer 
extracted with dichloromethane (4 × 10.0 mL). The combined, organic fractions were 
dried over Na2SO4, filtered and concentrated under reduced pressure. Purification by 
flash chromatography (20% EtOAc/hexanes) provided the title compound (0.106 mg, 
0.205 mmol, 68%) as a yellow, viscous oil. TLC: Rf = 0.31 (20% EtOAc/hexanes); [α] D
22  
= 217.2 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.51 (d, J = 9.5 Hz, 1H), 5.15 (t, J = 6.5 
Hz, 1H), 4.58 (d, J = 9.3 Hz, 1H), 3.65 (br s, 1H), 3.56–3.38 (m, 3H), 3.03 (d, J = 11.5 
Hz, 1H), 2.58 (br, 1H), 2.45–2.32 (m, 1H), 1.67 (s, 3H), 1.54–1.35 (m, 2H), 1.07 (app. s, 
24H), 0.97 (t, J = 6.0 Hz, 6H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 
203.1, 173.0, 135.1, 129.3, 77.7, 77.4, 73.5, 71.7, 44.2, 36.6, 31.0, 27.7, 19.3, 18.5, 18.0, 
17.0, 13.2, 12.4, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H49NO3S2SiNa 
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538.2815, found 538.2821. 
 
OH
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(3R,6S,7R,E)-3-Hydroxy-N-methoxy-N,4,6-tri-methyl-7-((triisopropylsilyl)oxy)non-
4-enamide (2.25). To a reaction vessel containing acyl thiazolidinethione 2.24 (0.298 g, 
0.578 mmol) in CH2Cl2 (3.00 mL) was sequentially added imidazole (0.197 g, 2.89 
mmol, 5.00 equiv) and HN(OMe)Me•HCl (0.141 g, 1.45 mmol, 2.50 equiv). The reaction 
mixture was stirred at ambient temperature under argon atmosphere for 16 h and 
quenched upon addition of a saturated, aqueous NH4Cl (4.00 mL). The biphasic solution 
was separated and the aqueous layer was extracted with CH2Cl2 (3 × 7.00 mL). Combined 
organic fractions were dried over Na2SO4, filtered, concentrated under reduced pressure 
and purified by flash chromatography (40% EtOAc/hexanes) yielding the title compound 
(0.208 g, 0.501 mmol, 87%) as a slightly yellow, clear oil. TLC: Rf = 0.37 (40% 
EtOAc/hexanes); [α] D
23  = 26.3 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.48 (d, J = 9.6 
Hz, 1H), 4.47–4.41 (m, 1H), 3.67 (s, 3H), 3.66–3.60 (m, 2H), 3.19 (s, 3H), 2.69–2.51 (m, 
3H), 1.67 (s, 3H), 1.52–1.36 (m, 2H), 1.06 (s, 21H), 0.99 (d, J = 6.9 Hz, 3H), 0.84 (t, J = 
7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 173.9, 135.4, 129.8, 77.8, 73.6, 61.4, 37.3, 
36.6, 32.0, 27.6, 18.4, 17.0, 13.1, 12.3, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C22H45NO4SiNa 438.3010, found 438.3010. 
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Me Me Me
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(3R,6S,7R,E)-N-Methoxy-N,4,6-trimethyl-3-((tri-ethylsilyl)oxy)-7-((triisopropyl-
silyl)oxy)non-4-en-amide (2.26). To a flask containing β-hydroxy amide 2.25 (79.0 mg, 
0.190 mmol) under argon atmosphere in an ice-water bath (0 °C) was added CH2Cl2 (3.5 
mL). The resulting clear solution was supplemented with 2,6-lutidine (89.0 µL, 0.761 
	 41 
mmol, 4.00 equiv) and TESOTf (86.0 µL, 0.380 mmol, 2.00 equiv). The reaction mixture 
was stirred at 0 °C for 2.5 h and quenched upon sequential addition of MeOH (2.00 mL) 
and saturated, aqueous NaHCO3 (2.00 mL). The biphasic solution was warmed to 
ambient temperature and the layers were separated. The aqueous layer was extracted with 
CH2Cl2 (3 × 10.0 mL) and the combined organic fractions were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (10-20% EtOAc/hexanes) affording the title compound (89.3 mg, 0.169 
mmol, 89%) as a transparent, clear oil. TLC: Rf = 0.58 (20% EtOAc/hexanes); [α] D
22  = 
9.7 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.45 (d, J = 9.5 Hz, 1H), 4.59 (dd, J = 8.8, 4.5 
Hz, 1H), 3.70 (s, 3H), 3.61 (dt, J = 6.5, 2.8 Hz, 1H), 3.16 (s, 3H), 2.99–2.80 (m, 1H), 
2.60–2.50 (m, 1H), 2.31 (dd, J = 13.9, 4.3 Hz, 1H), 1.64 (d, J = 1.1 Hz, 3H), 1.49–1.34 
(m, 2H), 1.07 (s, 21H), 1.00 (d, J = 6.9 Hz, 3H), 0.91 (t, J = 7.9 Hz, 9H), 0.82 (t, J = 7.4 
Hz, 3H), 0.56 (q, J = 7.9 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 136.7, 128.2, 77.8, 
75.6, 61.4, 39.5, 36.7, 32.1, 27.5, 18.5, 16.5, 13.1. 11.4, 10.7, 6.9, 4.9 (missing amide 
carbonyl carbon); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C28H59NO4Si2Na 
552.3875, found 552.3905. 
 
OTES
Me Me Me
OTIPSO
 
(5R,8S,9R,E)-6,8-Dimethyl-5-((triethylsilyl)oxy)-9-((triiso-propylsilyl)oxy)undeca-
1,6-dien-3-one (2.27). To a reaction vessel containing Weinreb amide 2.26 (37.6 mg, 
0.0710 mmol) under argon atmosphere was added THF (5.00 mL). The resulting clear 
solution was cooled with ice-water bath (0 °C). A solution of vinylmagnesium bromide 
(1.00 M) (0.224 mL, 0.224 mmol, 3.16 equiv) was added to the stirred solution. After 3 h, 
the reaction was quenched at 0 °C via addition of saturated, aqueous NH4Cl (5.00 mL) 
and allowed to warm to ambient temperature. The biphasic solution was separated and 
the aqueous layer was repeatedly extracted with EtOAc (3 × 10 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated under vacuum. 
Purification of the crude residue by flash chromatography (5% EtOAc/hexanes) furnished 
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the title compound (32.7 mg, 0.658 mmol, 93%) as a clear, light yellow oil. TLC: Rf = 
0.45 (5% EtOAc/hexanes); [α] D
22  = 7.6 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 6.35 (dd, 
J = 17.6, 10.5 Hz, 1H), 6.19 (d, J = 17.6 Hz, 1H), 5.81 (d, J = 10.5 Hz, 1H), 5.42 (d, J = 
9.6 Hz, 1H), 4.55 (dd, J = 8.3, 4.7 Hz, 1H), 3.69–3.52 (m, 1H), 2.94 (dd, J = 14.0, 8.4 Hz, 
1H), 2.58–2.47 (m, 2H), 1.62 (s, 3H), 1.50–1.30 (m, 2H), 1.07 (s, 21H), 0.99 (d, J = 6.9 
Hz, 3H), 0.89 (t, J = 7.9 Hz, 9H), 0.81 (t, J = 7.4 Hz, 3H), 0.54 (q, J = 7.9 Hz, 6H); 13C 
NMR (CDCl3, 100 MHz) δ 199.4, 137.6, 136.4, 128.4 (2), 77.8, 75.8, 46.9, 36.6, 27.6, 
18.4, 16.6, 13.2, 11.3, 10.6, 7.0, 4.9; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C28H56NO3Si2Na 519.3660, found 519.3674. 
 
OH
Me Me Me
OHO
 
(5R,8S,9R,E)-5,9-Dihydroxy-6,8-dimethylundeca-1,6-dien-3-one (2.28). Disilylether 
2.27 (10.9 mg, 0.220 mmol) was transferred to a small polypropylene tube (15 mL, BD 
FalconTM) and cooled via ice-water bath (0 °C)  Compound 2.27 was dissolved in MeCN 
(1.00 mL) and to the resulting clear solution was added a solution of 48% HF–MeCN 
(11:89, 3.2 mL). The reaction mixture was placed in a refrigerator (4 °C) for 19 h and 
quenched via addition of an aqueous, saturated NH4Cl until the mixture was neutralized 
(pH = 7). Extraction of the reaction mixture with EtOAc (4 × 15.0 mL), drying over 
Na2SO4, filtration and concentration under reduced pressure gave a crude product 
residue. Purification by flash chromatography (50% EtoAc/hexanes) provided the title 
compound (4.97 mg, 0.220 mmol, quant.) as a cloudy, colorless oil. TLC: Rf = 0.33 (50% 
EtOAc/hexanes); [α] D
21  = 25.6 (c 0.87, CHCl3); 1H NMR (400 MHz) δ 6.37 (dd, J = 17.6, 
10.4 Hz, 1H), 6.26 (d, J = 17.6 Hz, 1H), 5.90 (d, J = 10.4 Hz, 1H), 5.37 (d, J = 10.0 Hz, 
1H), 4.53 (dd, J = 8.4, 4.0 Hz, 1H), 3.34–3.27 (m, 1H), 2.88 (dd, J = 8.4, 16.8 Hz, 1H), 
2.80 (dd, J = 16.8, 4.4 Hz, 1H) 2.52–2.38 (m, 1H), 1.69 (s, 3H), 1.61–1.51 (m, 1H), 1.43– 
1.31 (m, 1H), 0.97 (d, J = 6.8 Hz, 3H), 0.97 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 
MHz) δ 200.8, 137.4, 136.8, 129.5, 129.0, 77.1, 73.2, 44.7, 38.1, 27.2, 17.2, 12.6, 10.2; 
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HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H22O3Na 249.1461, found 249.1463. 
 
OH
Me Me Me
OHO
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N-(2-(((5R,8S,9R,E)-5,9-Dihydroxy-6,8-dimethyl-3-oxoundec-6-en-1-yl)thio)ethyl)-
acetamide (2.8). To a small round bottom flask containing vinyl ketone 2.28 (26.0 mg, 
0.115 mmol) in THF (9.00 mL) under argon atmosphere was added N-acetylcysteamine 
(14.6 µL, 0.138 mmol, 1.20 equiv). A catalytic amount of Cs2CO3 was added to the 
reaction mixture and the solution was stirred at ambient temperature for 11 h. The 
reaction was concentrated under reduced pressure and purified by flash chromatography 
(10% MeOH/CH2Cl2, 1.00 cm plug of CuSO4–silica on top) yielding the title compound 
(21.4 mg, 0.0620 mmol, 54%) as a colorless, cloudy oil. TLC: Rf = 0.46 (10% 
MeOH/CH2Cl2); [α] D
22  = 5.9 (c 0.59, CHCl3); 1H NMR (400 MHz) δ 6.17 (s, 1H), 5.36 
(d, J = 10.0 Hz, 1H), 4.48 (dd, J = 8.1, 3.5 Hz, 1H), 3.43 (q, J = 6.3 Hz, 2H), 3.33–3.26 
(m, 1H), 2.87 (br, 1H), 2.80–2.74 (m, 4H), 2.74–2.58 (m, 4H), 2.49–2.38 (m, 1H), 1.99 
(s, 3H), 1.81 (s, 1H), 1.65 (s, 3H), 1.61–1.50 (m, 1H), 1.36 (dq, J = 14.1, 7.4 Hz, 1H), 
0.96 (d, J = 7.4 Hz, 3H), 0.95 (t, J = 7.7 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 209.1, 
170.5, 137.4, 128.9, 77.4, 73.2, 48.4, 43.6, 38.7, 38.0, 32.2, 27.3, 25.2, 23.4, 17.3, 12.6, 
10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C17H31NO4SNa 368.1866, found 
368.1873. 
 
OH
Me Me Me
OTIPSO
 
(5S,8S,9R,E)-5-Hydroxy-6,8-dimethyl-9-((triisopropylsilyl)-oxy)undeca-1,6-dien-3-
one (2.29). To a reaction vessel containing disilylether 2.21 (39.3 mg, 0.0792 mmol) in a 
mixture of tetrahydrofuran (1.98 mL) and deionized water (0.296 mL) was added TFA 
(15.6 µL, 0.210 mmol, 2.65 equiv). The acidic solution was stirred for 2.5 h at ambient 
temperature and carefully neutralized upon addition of a saturated, aqueous NaHCO3 
	 44 
solution. The biphasic solution was separated and the aqueous layer repeatedly extracted 
with EtOAc (4 × 7.00 mL). The combined organic layers were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography (10% EtOAc/hexanes) producing the title compound (29.5 mg, 
0.0771 mmol, 97%) as a light yellow, clear oil. TLC: Rf = 0.25 (10% EtOAc/hexanes); 
[α] D
24  = –23.0 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 6.37 (dd, J = 17.7, 10.4 Hz, 1H), 
6.25 (d, J = 16.6 Hz, 1H), 5.89 (d, J = 10.4 Hz, 1H), 5.48 (d, J = 9.6 Hz, 1H), 4.52 (dd, J 
= 9.1, 2.8 Hz, 1H), 3.65 (dt, J = 6.2, 3.3 Hz, 1H), 2.87 (dd, J = 16.8, 9.2 Hz, 1H), 2.75 
(dd, J = 16.8, 3.1 Hz, 1H), 2.62–2.54 (m, 1H), 1.68 (d, J = 1.3 Hz, 3H), 1.54–1.40 (m, 
2H), 1.07 (s, 21H), 0.97 (d, J = 6.9 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 
100 MHz) δ 201.1, 136.9, 135.3, 129.2, 128.9, 77.8, 73.3, 44.8, 36.6, 27.6, 18.5, 16.9, 
13.2, 12.5, 10.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C22H42O3SiNa 405.2795, 
found 405.2795. 
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(8S,9R,E)-6,8-Dimethyl-9-((triisopropylsilyl)oxy)undeca-1,6-diene-3,5-dione (2.30). 
To a small flask containing β-hydroxy ketone 2.29 (80.0 mg, 0.209 mmol) in EtOAc 
(10.0 mL) was added IBX (0.390 g, 0.627 mmol, 3.00 equiv, 45% w/w). The white, 
cloudy solution was rapidly stirred and heated at reflux for 2 h. The slightly yellow 
solution was cooled to ambient temperature and concentrated under reduced pressure. 
The resulting concentrated solution was purified by flash chromatography (5% 
EtOAc/hexanes) affording the title compound (72.4 mg, 0.190 mmol, 92%) as a red-
orange oil. TLC: Rf = 0.36 (5% EtOAc/hexanes); [α] D
21  = –47.2 (c 1.00, CHCl3); 1H 
NMR (400 MHz) δ 15.46 (s, 1H), 6.71 (dd, J = 9.9, 1.0 Hz, 1H), 6.25 (dd, J = 17.2, 2.0 
Hz, 1H), 6.17 (dd, J = 9.9, 17.2 Hz, 1H), 5.89 (s, 1H), 5.64 (dd, J = 9.9, 2.0 Hz, 1H), 3.75 
(ddd, J = 7.8, 4.6, 3.6 Hz, 1H), 2.81–2.72 (m, 1H), 1.87 (d, J = 1.1 Hz, 3H), 1.63–1.52 
(m, 1H), 1.49–1.37 (m, J = 14.9, 7.4 Hz, 1H), 1.09–1.07 (m, 24H), 0.86 (t, J = 7.5 Hz, 
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3H); 13C NMR (CDCl3, 100 MHz) δ 193.1, 176.5, 143.0, 134.4, 133.3, 124.5, 96.6, 77.6, 
37.8, 28.4, 18.4, 16.9, 13.2, 11.9, 10.0; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C22H40O3SiNa 403.2639, found 403.2646. 
 
O
Me Me Me
OHO
 
(8S,9R,E)-9-Hydroxy-6,8-dimethylundeca-1,6-diene-3,5-dione (2.31). To a 
polypropylene tube (15 mL, BD FalconTM) containing silylether 22 (72.4 mg, 0.140 
mmol) was added MeCN (1.23 mL). The clear solution was equilibrated in ice-water bath 
(0 °C) for 10 min. A pre-chilled solution of 48% HF–MeCN (11:89, 9.84 mL) was slowly 
added to the rapidly stirred solution. The resulting slightly yellow solution was placed in 
refrigerator (4 °C) for 40 h. The reaction mixture was quenched via slow neutralization 
with aqueous, saturated NaHCO3 solution at 0 °C. The aqueous layer was extracted with 
EtOAc (5 × 20.0 mL) and the combined organic layers were concentrated under reduced 
pressure. The product was placed under high vacuum for 2 h furnishing the title 
compound (42.6 mg, 0.190 mmol, quant.) as a viscous, yellow oil. TLC: Rf = 0.20 (20% 
EtOAc/hexanes); [α] D
22  = –51.2 (c 1.00, CHCl3); (Compound 2.31 was found to exist 
entirely in the enol form (not drawn)) 1H NMR (400 MHz) δ 15.54 (br s, 1H), 6.59 (dd, J 
= 10.0, 0.96 Hz, 1H), 6.28 (dd, J = 17.2, 2.4 Hz, 1H), 6.21 (dd, J = 17.2, 9.5 Hz, 1H) 5.90 
(s, 1H), 5.66 (dd, J = 9.5, 2.4 Hz, 1H), 3.49 (dt, J = 8.8, 4.6 Hz, 1H), 2.73–2.60 (m, 1H), 
1.89 (d, J = 1.0 Hz, 3H), 1.60–1.49 (m, 1H), 1.43 (dq, J = 14.2, 7.5 Hz, 1H), 1.08 (d, J = 
6.7 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 192.1, 177.7, 141.6, 
135.1, 133.3, 125.0, 96.9, 76.9, 39.2, 27.9, 16.8, 12.2, 10.2; HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C13H20O3Na 247.1305, found 247.1310. 
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N-(2-(((8S,9R,E)-9-Hydroxy-6,8-dimethyl-3,5-dioxoundec-6-en-1-yl)thio)ethyl)acet-
amide (2.5). To a round bottom flask containing the vinyl ketone 2.31 (12.3 mg, 0.0550 
mmol) in THF (10.0 mL) was added N-acetylcysteamine (6.40 µL, 0.0600 mmol, 1.10 
equiv) as a solution in anhydrous THF (64.0 µL). The reaction mixture was supplemented 
with a catalytic amount of Cs2CO3 and stirred at ambient temperature for 4.5 h. The 
bright yellow, transparent solution was quenched via addition of aqueous, saturated 
NH4Cl (5.00 mL) and the resulting biphasic solution was separated. The aqueous layer 
was repeatedly extracted with EtOAc (5 × 10.0 mL). Combined organic fractions were 
dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. 
The crude residue was purified by flash chromatography (5% MeOH/CH2Cl2) providing 
the title compound (7.2 mg, 0.021 mmol, 38%) as a viscous, bright orange oil. TLC: Rf = 
0.30 (5% MeOH/CH2Cl2); [α] D
21  = –30.0 (c 0.46, CHCl3); (Compound 2.5 existed in a 
~3:1 mixture of enol (B) and keto (A) tautomers, respectively) 1H NMR (400 MHz) δ 
15.58 (s, 0.75H), 6.66–6.56 (m, 1H), 6.09 (br, 0.25H), 5.96 br, 0.75H), 5.80 (br s, 0.75H), 
3.96 (d, J = 14.7 Hz, 0.25H), 3.79 (d, J = 14.7 Hz, 0.25H), 3.61–3.36 (m, 3H), 2.87–2.80 
(m, 2H), 2.80–2.74 (m, 0.50H), 2.72–2.62 (m, 4.5H), 1.98–2.02 (m, 3H), 1.85 (d, J = 1.2 
Hz, 2.25H), 1.81 (d, J = 1.2 Hz, 0.75H), 1.60–1.48 (m, 1H), 1.47–1.37 (m, 1H), 1.09 (d, J 
= 6.9 Hz, 0.75H), 1.06 (dd, J = 6.8 Hz, 2.25H), 1.00–0.93 (m, 3H); (Only the major 
(enol) tautomer B carbon shifts are recorded) 13C NMR (CDCl3, 100 MHz) δ 194.8, 
183.7, 170.4, 141.2, 132.2, 96.6, 76.9, 39.7, 39.1, 38.6, 32.2, 27.9, 27.2, 23.4, 16.8, 12.4, 
10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C17H29NO4SSi 366.1710, found 
366.1716. 
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S-(2-Acetamidoethyl) (3S,6S,7R,E)-3-hydroxy-4,6-di-methyl-7-((triisopropylsilyl)-
oxy)non-4-enethioate (2.32). A reaction vessel containing thiazoldinethione 2.18 (0.142 
g, 0.276 mmol) in CH2Cl2 (2.00 mL) under argon atmosphere was added imidazole (56.4 
mg, 0.828 mmol, 3.00 equiv). To the clear, yellow solution was added N-
acetylcysteamine (32.3 µL, 0.304 mmol, 1.10 equiv) and the resulting reaction mixture 
was stirred at ambient temperature for 14 h. The crude reaction mixture was purified by 
flash chromatography (5% MeOH/CH2Cl2) affording the title compound (0.119 g, 0.251 
mmol, 91%) as a transparent, slightly yellow oil. TLC: Rf = 0.32 (5% MeOH/CH2Cl2); 
[α] D
22  = –15.0 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.82 (s, 1H), 5.49 (d, J = 9.7 Hz, 
1H), 4.49 (d, J = 8.4 Hz, 1H), 3.65 (br s, 1H), 3.45 (q, J = 5.9 Hz, 2H), 3.05 (t, J = 6.2 
Hz, 2H), 2.85 (dd, J = 15.0, 9.2 Hz, 1H), 2.79–2.64 (m, 1H), 2.63–2.51 (m, 1H), 2.34 (br 
s, 1H), 1.97 (s, 3H), 1.65 (s, 3H), 1.54–1.36 (m, 2H), 1.07 (s, 21H), 0.96 (d, J = 6.9 Hz, 
3H), 0.84 (t, J = 7.3 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.1, 170.5, 134.9, 129.6, 
77.7, 74.4, 49.8, 39.6, 36.6, 29.0, 27.6, 23.4, 18.5, 17.0, 13.2, 12.2, 10.4; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C24H47NO4SSiNa 496.2887, found 494.2896. 
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S-(2-Acetamidoethyl) (3S,6S,7R,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate 
(2.7). A solution of silylether 2.32 (33.4 mg, 0.0706 mmol) in MeCN (3.55 mL) in a 
polypropylene tube (15 mL, BD FalconTM) was cooled in ice-water bath (0 °C). To the 
reaction mixture was added a chilled solution of 48% HF–MeCN (11:89, 10.6 mL) and 
the resulting combined solution was transferred to a refrigerator for 15 h. The reaction 
mixture was neutralized via slow addition of a saturated, aqueous NaHCO3 solution at 0 
°C. The clear solution was extracted with EtOAc (3 × 25.0 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated under vacuum. Flash column 
	 48 
chromatography (10% MeOH/CH2Cl2) of the crude residue produced the title compound 
(14.1 mg, 0.0445 mmol, 63%) as a colorless, clear oil. TLC: Rf = 0.44 (10% 
MeOH/CH2Cl2); [α] D
22  = –6.0 (c 0.51, CHCl3); 1H NMR (400 MHz) δ 6.16 (br s, 1H), 
5.38 (d, J = 9.9 Hz, 1H), 4.46 (br s, 1H), 3.52–3.35 (m, 2H), 3.33–3.22 (m, 1H), 3.11–
2.96 (m, 3H), 2.87 (dd, J = 14.7, 7.5 Hz 1H), 2.79 (dd, J = 14.5, 4.0 Hz 1H), 2.49–2.39 
(m, 1H), 1.96 (s, 3H), 1.67 (s, 3H), 1.62–1.53 (m, 1H), 1.45–1.31 (m, 1H), 1.01–0.88 (m, 
6H); 13C NMR (CDCl3, 100 MHz) δ 199.0, 170.7, 137.2, 128.9, 77.1, 74.0, 49.3, 39.3, 
38.1, 29.3, 27.2, 23.3, 17.2, 13.1, 10.1; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C15H27NO4SNa 340.1553, found 340.1565. 
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S-(2-Acetamidoethyl) (6S,7R,E)-4,6-dimethyl-3-oxo-7-((triisopropylsilyl)oxy)non-4-
enethioate (2.33). To a small round bottom flask was added β-hydroxythioester 2.32 
(20.7 mmol, 0.0437 mmol) in EtOAc (2.00 mL). The colorless solution was diluted with 
additional EtOAc (3.00 mL) and IBX (81.8 mg, 0.131 mmol, 3.00 equiv, 45% w/w) was 
added. The white suspension was refluxed for 1 h. After cooling to ambient temperature, 
the reaction mixture was filtered through a celite pad (3.00 cm) and concentrated under 
reduced pressure affording the crude title compound as a yellow oil which was taken to 
the next step without further purification. TLC: Rf = 0.45 (5% MeOH/CH2Cl2). 
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S-(2-Acetamidoethyl) (6S,7R,E)-7-hydroxy-4,6-dimethyl-3-oxonon-4-enethioate 
(2.4). The crude silylether 2.33 (20.6 mg, 0.0437 mmol) was transferred as an acetonitrile 
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solution (0.200 mL) to a polypropylene tube (15 mL, BD FalconTM) and cooled via ice-
water bath (0 °C)  To the pre-chilled solution was added a 48% HF–MeCN (11:89, 2.50 
mL). The reaction mixture was placed in a refrigerator (4 °C) for 24 h. TLC analysis of 
the reaction mixture indicated incomplete conversion and an additional portion of HF 
solution (freshly prepared and identical to above, 1.00 mL) was added to the reaction 
mixture at 0 °C  After an additional 12 h at 4 °C, the reaction mixture was neutralized at 0 
°C via addition of aqueous, saturated NaHCO3. The reaction mixture was extracted with 
EtOAc (4 × 25.0 mL). The combined organic fractions were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude product was purified by column 
chromatography (5% MeOH/CH2Cl2) yielding the title compound (11.8 mg, 0.0374 
mmol, 86% from 24) as a slightly yellow oil. TLC: Rf = 0.25 (5% MeOH/CH2Cl2); [α] D
21  
= –35.8 (c 0.79, CHCl3); (Compound 26 exists as in equilibrium of A and B (~3:1)) 1H 
NMR (400 MHz) δ 12.71 (br s, 0.25H), 6.65 (d, J = 9.8 Hz, 0.75H), 6.58 (d, J = 10.1 Hz, 
0.25H), 6.24 (s, 0.75H), 6.05 (s, 0.25H), 5.66 (s, 0.25H), 4.08 (d, J = 15.0 Hz, 0.75H), 
3.90 (d, J = 15.0 Hz, 0.75H), 3.59–3.33 (m, 3H), 3.13–3.00 (m, 2H), 2.74–2.59 (m, 1H), 
2.02–1.91 (m, 3H), 1.85–1.78 (s, 3H), 1.58–1.34 (m, 2H), 1.09 (d, J = 6.8 Hz, 2.25H), 
1.04 (d, J = 6.8 Hz, 0.75H), 1.00–0.90 (m, 3H); (Carbon shifts only given for major 
tautomer) 13C NMR (CDCl3, 100 MHz) δ 193.8, 193.5, 170.9, 147.7, 137.3, 76.9, 53.2, 
39.5, 39.2, 29.5, 28.3, 23.2, 16.8, 11.7, 10.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C15H25NO4SSi 338.1397, found 338.1398. 
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S-(2-Acetamidoethyl) (3R,6S,7R,E)-3-hydroxy-4,6-di-methyl-7-((triisopropylsilyl)-
oxy)non-4-enethioate (2.34). To a reaction vessel containing acyl thiazolidinethione 2.24 
(66.0 mg, 0.128 mmol) in CH2Cl2 (2.00 mL) was sequentially added imidazole (26.0 mg, 
0.384 mmol, 3.00 equiv) and N-acetylcysteamine (16.0 µL, 0.154 mmol, 1.20 equiv). The 
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transparent, yellow solution was stirred vigorously under argon atmosphere at ambient 
temperature for 15 h. The reaction was quenched upon addition of aqueous, saturated 
NH4Cl (3.00 mL) and the biphasic solution was separated. The aqueous layer was 
extracted with CH2Cl2 (3 × 10.0 mL). The combined organic layers were dried over 
Na2SO4, filtered, concentrated under reduced pressure and purified by flash 
chromatography (5% MeOH/CH2Cl2) using a small plug of CuSO4–impregnated silica 
gel (1.00 cm) on top furnished the title compound (59.0 mg, 0.125 mmol, 97%) as a 
colorless oil. TLC: Rf = 0.35 (5% MeOH/CH2Cl2); [α] D
22  = –7.4 (c 1.00, CHCl3); 1H 
NMR (400 MHz) δ 5.94 (br s, 1H), 5.48 (d, J = 9.7 Hz, 1H), 4.49 (dd, J = 9.2, 3.4 Hz, 
1H), 3.71–3.56 (m, 1H), 3.44 (q, J = 6.1 Hz, 2H), 3.13–2.94 (m, 2H), 2.85 (dd, J = 15.0, 
9.2 Hz, 1H), 2.71 (dd, J = 14.9, 3.6 Hz, 1H), 2.55 (ddd, J = 9.9, 6.8, 3.2 Hz, 1H), 2.47 
(br, 1H), 1.96 (s, 3H), 1.64 (d, J = 1.1 Hz, 3H), 1.52–1.30 (m, 2H), 1.06 (s, 21H), 0.98 (d, 
J = 6.9 Hz, 3H), 0.82 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.0, 170.6, 
134.9, 129.7, 77.7, 74.5, 49.8, 39.5, 36.5, 28.9, 27.7, 23.3, 18.4, 17.0, 13.1, 12.0, 10.4; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H47NO4SSiNa 496.2887, found 
496.2881. 
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 S-(2-Acetamidoethyl) (3R,6S,7R,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate 
(2.6). The silylether 2.34 (40.0 mg, 0.0845 mmol) was deprotected in a manner analogous 
to the production of diol 6b affording the title compound (21.5 mg, 0.678 mmol, 80%) as 
a clear, colorless oil. TLC: Rf = 0.43 (10% MeOH/CH2Cl2); [α] D
22  = 18.2 (c 1.00, CHCl3); 
1H NMR (400 MHz) δ 6.19 (br s, 1H), 5.34 (d, J = 10.0 Hz, 1H), 4.50 (t, J = 6.6 Hz, 1H), 
3.48 (app. dq, J = 12.4, 6.2 Hz, 1H), 3.42–3.31 (m, 1H), 3.30–3.24 (m, 1H), 3.04 (t, J = 
6.2 Hz, 2H), 2.83 (dd, J = 6.6, 3.1 Hz, 2H), 2.62 (br s, 1H), 2.49–2.39 (m, 1H), 1.96 (s, 
3H), 1.69 (d, J = 1.1 Hz 3H), 1.63–1.52 (m, 1H), 1.43–1.31 (m, 1H), 0.96 (t, J = 7.3 Hz, 
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3H), 0.96 (d, J = 6.7 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 198.6, 170.7, 137.2, 129.9, 
77.1, 74.5, 49.7, 39.4, 38.2, 29.3, 27.2, 23.3, 17.2, 12.2, 10.1; HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C15H27NO4SiNa 340.1553, found 340.1554. 
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(4S,7S,8R,E)-1-Chloro-5,7-dimethyl-4-((triethylsilyl)oxy)-8-
((triisopropylsilyl)oxy)dec-5-en-2-one (2.35). To a flask containing Weinreb amide 2.20 
(0.134 g, 0.252 mmol, 1.00 equiv) in THF (4.00 mL) was added ClCH2I (55.0 µL, 0.756 
mmol, 3.00 equiv). The clear solution was cooled to –78 °C (dry ice–acetone bath). To 
the cold solution was added MeLi (1.4M in Et2O, 0.388 mL, 0.559 mmol, 2.20 equiv) 
over 35 min. The reaction mixture was stirred at –78 °C for 2 h 10 min. The reaction was 
quenched by addition of aqueous saturated NH4Cl (5.00 mL). The biphasic mixture was 
warmed to ambient temperature, separated and the aqueous layer was extracted with Et2O 
(4 × 10 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude material was purified by flash 
chromatography (5% EtOAc/hexanes) affording the title compound (0.102 g, 0.197 
mmol, 78%) as a colorless oil. TLC: Rf = 0.31 (5% EtOAc/hexanes); [α] D
22  = –27.2 (c 
0.35, CHCl3); 1H NMR (400 MHz) δ 5.48 (d, J = 9.6 Hz, 1H), 4.50 (dd, J = 8.4, 3.6 Hz, 
1H), 4.19 (d, J = 16 Hz, 1H), 4.13 (d, J = 16 Hz, 1H), 3.67–3.61 (m, 1H), 2.86 (dd, J = 
13.6, 8.8 Hz, 1H), 2.59–2.51 (m, 1H), 2.47 (dd, J = 14.0, 4.0 Hz, 1H), 1.61 (s, 3H), 1.53–
1.35 (m, 2H), 1.08 (s, 21H), 0.96 (d, J = 6.8 Hz, 3H), 0.91 (t, J = 8.0 Hz, 9H), 0.84 (t, J = 
7.6 Hz, 3H), 0.56 (q, J = 8.0 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 200.9, 135.9, 
128.7, 77.9, 75.6, 50.1, 47.2, 36.5, 27.8, 18.4, 16.9, 13.1, 11.7, 10.8, 6.96, 4.81; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C27H55ClO3Si2Na 541.3270, found 541.3250. 
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(4S,7S,8R,E)-1-Chloro-4-hydroxy-5,7-dimethyl-8-((triisopropylsilyl)oxy)dec-5-en-2-
one (2.36). To a flask containing the silyl ether 2.35 (47.1 mg, 0.0908 mmol, 1.00 equiv) 
in THF–H2O (6.7:1, 4.18 mL) was added dropwise TFA (17.9 µL, 0.241 mmol, 2.65 
equiv). The mixture was vigorously stirred at ambient temperature for 2 h. The reaction 
was quenched upon slow addition of aqueous saturated NaHCO3 until the solution was 
neutral (pH = 7.0). The reaction was diluted with EtOAc–H2O (1:1, 20.0 mL) and the 
biphasic solution was separated. The aqueous layer was extracted with EtOAc (4 × 20.0 
mL). The combined organic layers were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude product residue was purified by flash chromatography 
(20% EtOAc/hexanes) affording the title compound (34.2 mg, 0.0844 mmol, 93%) as a 
faintly yellow viscous oil. TLC: Rf = 0.39 (20% EtOAc/hexanes); [α] D
22  = –23.7 (c 0.41, 
CHCl3); 1H NMR (400 MHz) δ 5.50 (d, J = 9.6 Hz, 1H), 4.51 (dd, J = 9.7, 2.8 Hz, 1H), 
4.18 (d, J = 15.7 Hz, 1H), 4.13 (d, J = 15.6 Hz, 1H), 3.68–3.61 (m, 1H), 2.87 (dd, J = 
16.4, 9.6 Hz, 1H), 2.70 (dd, J = 16.4, 3.2 Hz, 1H), 2.62–2.52 (m, 1H), 1.66 (d, J = 1.2 Hz, 
3H), 1.55–1.36 (m, 2H), 1.07 (s, 21H), 0.97 (d, J = 7.2 Hz, 3H), 0.85 (t, J = 7.2 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 202.5, 135.2, 129.3, 77.7, 73.5, 49.1, 45.5, 36.5, 27.7, 
18.5, 17.1, 13.15, 12.3, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C21H41ClO3SiNa 427.2406, found 427.2436. 
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(7S,8R,E)-1-Chloro-5,7-dimethyl-8-((triisopropylsilyl)oxy)dec-5-ene-2,4-dione (2.37). 
A flask containing alcohol 2.36 (39.0 mg, 0.0960 mmol, 1.00 equiv) dissolved in EtOAc 
(10.0 mL) was heated to reflux (77 °C) for 48 min. The reaction was removed from heat 
and allowed to cool to ambient temperature. The mixture was concentrated under reduced 
pressure. The crude product residue was purified by flash chromatography (5% 
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EtOAc/hexanes) affording the title compound (30.5 mg, 0.076 mmol, 79%) as a red-
orange viscous oil. TLC: Rf  = 0.40 (5% EtOAc/hexanes); [α] D
22  = –43.5 (c 0.43, CHCl3); 
1H NMR (400 MHz) δ 15.3 (s, 1H), 7.81 (d, J = 9.6 Hz, 1H), 6.12 (s, 1H), 4.07 (s, 2H), 
3.73–3.72 (m, 1H), 2.81–2.71 (m, 1H), 1.86 (s, 3H), 1.64–1.52 (m, 1H), 1.49–1.37 (m, 
1H), 1.11–1.06 (m, 24H), 0.86 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 188.0, 
186.1, 143.6, 131.3, 94.1, 45.0, 37.8, 28.4, 18.4, 16.8, 13.14, 13.13, 12.1, 9.8; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C21H39ClO3SiNa 425.2249, found 425.2226. 
 
O O
Me MeCl
OH
Me  
(7S,8R,E)-1-Chloro-8-hydroxy-5,7-dimethyldec-5-ene-2,4-dione (2.38). To a 
polypropylene tube containing the silyl ether 2.37 (16.4 mg, 0.0410 mmol, 1.00 equiv) 
was added MeCN (0.300 mL). The faintly yellow solution was cooled to 0 °C (ice–water 
bath) and an HF–MeCN (11:89, 48% aqueous HF–MeCN, 2.11 mL) was slowly added to 
the solution. The reaction was placed in a refrigerator (4 °C) for 32 h. The reaction was 
quenched upon slow addition of aqueous saturated NH4Cl (until pH = 7). The resulting 
mixture was allowed to warm to ambient temperature and supplemented with EtOAc 
(5.00 mL). The biphasic solution was separated and the aqueous layer was extracted with 
EtOAc (5 × 10.0 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure affording the title compound (9.80 mg, 0.0398 
mmol, 98%) as a yellow oil. TLC: Rf  = 0.11 (10% EtOAc/hexanes); [α] D
22  = –35.8 (c 
0.59, CHCl3); 1H NMR (400 MHz) δ 15.26 (br s, 1H), 6.68 (dd, J = 10.0, 1.2 Hz, 1H), 
6.09 (s, 1H), 4.08 (s, 2H), 3.52–3.46 (m, 1H), 2.72–2.62 (m, 1H), 1.88 (d, J = 1.6 Hz, 
3H), 1.59–1.50 (m, 1H), 1.46–1.38 (m, 1H), 1.07 (d, J = 6.8 Hz, 3H), 0.97 (t, J = 7.6 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ 189.3, 184.7, 142.3, 132.1, 94.5, 77.4, 45.3, 39.2, 
27.9, 16.7, 12.4, 10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C12H19ClO3Na 
269.0915, found 269.0900. 
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5-((4S,5R,E)-5-Hydroxy-4-methylhept-2-en-2-yl)furan-3(2H)-one (2.40). To a flask 
containing chloromethyl ketone 2.38 (9.80 mg, 0.0398 mmol, 1.00 equiv) in THF (5.00 
mL) was added N-acetylcysteamine (5.00 µL, 0.0438 mmol, 1.10 equiv). To the solution 
was added Cs2CO3 (13.0 mg, 0.0398 mmol, 1.00 equiv) portionwise over 10 min. The 
reaction mixture was stirred at ambient temperature for 1.5 h. The reaction was quenched 
by addition of aqueous saturated NH4Cl (5.00 mL) and the resulting biphasic mixture was 
separated. The aqueous layer was extracted with EtOAc (4 × 20 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude product was purified by flash chromatography (30% EtOAC/hexanes) yielding 
the title compound (3.80 mg, 0.0103 mmol, 26%) as a bright yellow oil. TLC: 0.45 (30% 
EtOAC/hexanes; 1H NMR (400 MHz) δ 6.59 (dd, J = 10.0, 1.2 Hz, 1H), 5.63 (s, 1H), 
4.55 (s, 2H), 3.50–3.42 (m, 1H), 2.74–2.64 (m, 1H), 1.93 (d, J = 1.2 Hz, 3H), 1.59–1.48 
(m, 1H), 1.46–1.37 (m, 1H), 1.08 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.2 Hz, 3H); HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C12H18O3Na 233.1148, found 233.1172. 
 
O
Me Me Me
OH
NO
O
iPr  
(R)-3-((4R,5R,E)-5-Hydroxy-2,4-dimethylhept-2-enoyl)-4-isopropyloxazolidin-2-one 
(2.44). This procedure is adapted from that of Hosokawa and coworkers.46 To a reaction 
vessel containing ent-2.4357 (0.720 g, 2.12 mmol, 1.50 equiv) in CH2Cl2 (42.0 mL) under 
argon atmosphere was added freshly distilled propionaldehyde56 (0.102 mL, 1.41 mmol, 
1.00 equiv). The resulting solution was cooled to -78 °C (dry ice–acetone). TiCl4 (0.621 
mL, 5.65 mmol, 4.00 equiv) was added, in one portion, to the chilled solution. The 
reaction mixture immediately developed a dark blue hue. The reaction was stirred at -78 
°C for 17 h and quenched via addition saturated aqueous NaHCO3 (10.0 mL) and 
saturated aqueous potassium sodium tartrate (10.0 mL). The biphasic solution was 
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warmed to ambient temperature, separated and the aqueous layer was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification by flash chromatography (30% 
EtOAc/hexanes) furnished the title compound (0.344 g, 1.21 mmol, 86%) as a colorless, 
clear oil. TLC: Rf = 0.26 (30% EtOAc/hexanes); [α] D
22  = –65.2 (c 1.00, CHCl3); 1H NMR 
(400 MHz) δ 5.92 (d, J = 10.8 Hz, 1H), 4.56 (dt, J = 9.6, 5.0 Hz, 1H), 4.33 (t, J = 9.0 Hz, 
1H), 4.18 (dd, J = 8.9, 5.6 Hz, 1H), 3.55 (dt, J = 8.8, 4.2 Hz, 1H), 2.76 – 2.64 (m, 1H), 
2.40 – 2.27 (m, 1H), 1.94 (d, J = 1.3 Hz, 3H), 1.63–1.51 (m, 1H), 1.45–1.31 (m, 1H), 
1.03 (d, J = 6.8 Hz, 3H), 0.98 (t, J = 7.3 Hz, 3H), 0.93 (d, 5.5 Hz, 3H), 0.91 (d, 5.7 Hz, 
3H); 13C NMR (CDCl3, 100 MHz) δ 171.9, 154.3, 142.5, 130.6, 77.4, 63.6, 58.3, 38.6, 
28.5, 26.5, 18.0, 15.3, 14.3, 13.9, 10.8; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C15H25NO4Na 306.1678, found 306.1680. 
 
(S)-3-((4S,5S,E)-5-Hydroxy-2,4-dimethylhept-2-enoyl)-4-isopropyloxazolidin-2-one 
(ent-2.44). The title compound was synthesized in an analogous matter to its enantiomer 
and was identical with respect to 1H-NMR and 13C-NMR spectra. [α] D
22  = 66.0 (c 1.00, 
CHCl3); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H25NO4Na 306.1678, found 
306.1682. 
 
O
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(R)-3-((4R,5R,E)-2,4-Dimethyl-5-((triisopropylsilyl)oxy)-hept-2-enoyl)-4-isopropyl-
oxazolidin-2-one (2.45). To a reaction flask containing aldol adduct 2.44 (0.260 g, 0.918 
mmol) in CH2Cl2 (10.0 mL) under argon atmosphere in ice-water bath (0 °C) was added 
iPr2NEt (0.192 mL, 1.10 mmol, 1.20 equiv) followed by TIPSOTf (0.296 mL, 1.10 
mmol, 1.20 equiv). The reaction was stirred at 0 °C for 19 h and quenched upon addition 
of an aqueous saturated NaHCO3 (5.00 mL). The biphasic mixture was allowed to warm 
to ambient temperature and separated. The aqueous layer was extracted with CH2Cl2 (3 × 
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20.0 mL) and the combined organic fractions were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (10% EtOAc/hexanes) affording the title compound (0.373 mg, 0.848 
mmol, 92%) as a colorless oil. TLC: Rf = 0.32 (10% EtOAc/hexanes); [α] D
22  = –42.6 (c 
1.00, CHCl3); 1H NMR (400 MHz) δ 6.04 (dd, J = 10.0, 1.4 Hz, 1H), 4.53–4.43 (m, 1H), 
4.30 (t, J = 8.8 Hz, 1H), 4.17 (dd, J = 8.9, 5.4 Hz, 1H), 3.75 (q, J = 5.2 Hz, 1H), 2.72–
2.59 (m, 1H), 2.46–2.34 (m, 1H), 1.92 (d, J = 1.4 Hz, 3H), 1.66–1.54 (m, 2H), 1.07 (s, 
21H), 1.01 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 7.2 Hz, 3H), 0.90 (d, J = 7.0 Hz, 3H), 0.88 (t, 
7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 172.2, 153.7, 142.3, 129.7, 76.2, 63.5, 58.6, 
36.7, 28.3, 28.0, 18.4, 18.1, 15.1, 14.1, 13.8, 13.1, 9.1; HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C24H45NO4SiNa 462.3010, found 462.2986. 
 
(S)-3-((4S,5S,E)-2,4-Dimethyl-5-((triisopropylsilyl)oxy)hept-2-enoyl)-4-isopropyloxa-
zolidin-2-one (ent-2.45). The title compound was synthesized in an analogous matter to 
its enantiomer and was identical with respect to 1H-NMR and 13C-NMR spectra. [α] D
22  = 
45.1 (c 1.00, CHCl3); HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H45NO4SiNa 
462.3010, found 462.3017. 
 
O
H
Me Me Me
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(4R,5R,E)-2,4-Dimethyl-5-((triisopropylsilyl)oxy)hept-2-enal (2.46). A flask 
containing acyl oxazolidinone 2.45 (0.373 g, 0.848 mmol) dissolved in CH2Cl2 (27 mL) 
under argon atmosphere was cooled to – 78 °C (dry ice–acetone). To the chilled reaction 
mixture was added DIBAL-H (1.49 M in toluene, 1.14 mL, 1.70 mmol, 2.00 equiv) 
dropwise over two min. The reaction mixture was stirred at – 78 °C for 13 min and 
quenched upon sequential addition of MeOH (10.0 mL) and saturated, aqueous potassium 
sodium tartrate solution (10.0 mL). The biphasic solution was allowed to warm to 
ambient temperature and separated. The aqueous layer was extracted with CH2Cl2 (3 × 
15.0 mL) and the combined organic fractions were dried over Na2SO4, filtered and 
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concentrated under reduced pressure. The crude product was purified by flash 
chromatography (10% EtOAc/hexanes) to provide the title compound (0.229 g, 0.733 
mmol, 86%) as a clear and colorless oil. TLC: Rf = 0.56 (10% EtOAc/hexanes); [α] D
22  = –
17.7 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 9.39 (s, 1H), 6.55 (d, J = 9.8 Hz, 1H), 3.79 
(dt, J = 8.1, 4.4 Hz, 1H), 2.93 – 2.78 (m, 1H), 1.76 (s, 3H), 1.72–1.49 (m, 2H), 1.10–1.04 
(s, 24H), 0.89 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 195.8, 158.7, 137.9, 
76.4, 37.3, 27.9, 18.4, 13.6, 13.1, 9.52, 9.46; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C18H36O2SiNa 335.2377, found 335.2396. 
 
(4S,5S,E)-2,4-Dimethyl-5-((triisopropylsilyl)oxy)hept-2-enal (ent-2.46). The title 
compound was synthesized in an analogous matter to its enantiomer and was identical 
with respect to 1H-NMR and 13C-NMR spectra. [α] D
23  = 18.5 (c 1.00, CHCl3); HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C18H36O2SiNa 335.2377, found 335.2375. 
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Me Me Me
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S
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(3S,6R,7R,E)-3-Hydroxy-1-((R)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-
7-((triisopropylsilyl)-oxy)non-4-en-1-one (2.47). 
 
Me Me Me
OTIPSO
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S
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 (2E,4E,6R,7R)-1-((R)-4-Isopropyl-2-thioxothiazolidin-3-yl)-4,6-dimethyl-7-((triiso-
propylsilyl)oxy)nona-2,4-dien-1-one (2.48). A reaction vessel containing acyl 
thiazolidinethione 2.17 (0.126 g, 0.620 mmol, 1.70 equiv) in CH2Cl2 (2.30 mL) under 
argon atmosphere was cooled to -40 °C (dry ice–MeCN). The equilibrated solution was 
supplemented by TiCl4 (72.0 µL, 0.657 mmol, 1.80 equiv) and stirred for 30 min. To the 
reaction was slowly added freshly distilled iPr2NEt56 (0.114 mL, 0.657 mmol, 1.80 
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equiv). The blood red reaction mixture was stirred for 2 h and transferred to dry ice–
acetone bath (-78 °C). A CH2Cl2 (1.30 mL) solution of aldehyde S9 (0.114 g, 0.365 
mmol, 1.00 equiv) was slowly added to the cooled solution over 12 min. After stirring for 
4 h at -78 °C the reaction was quenched via addition of saturated aqueous NH4Cl (5.00 
mL). The biphasic mixture was warmed to ambient temperature and separated. The 
aqueous layer was extracted with CH2Cl2 (3 × 10.0 mL). Combined organic layers were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting crude 
oil was purified by flash chromatography (20% EtOAc/hexanes) to give both the aldol 
adduct S10 (99.3 mg, 0.192 mmol, 53%) as a thick, bright yellow oil, and the dehydration 
product S11 (44.4 mg, 0.0893 mmol, 24%) as a viscous, yellow oil. For 2.47: TLC: Rf = 
0.25 (20% EtOAc/hexanes); [α] D
22 = –189.2 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.49 
(d, J = 9.6 Hz, 1H), 5.16 (t, J = 7.0 Hz, 1H), 4.56 (d, J = 9.3 Hz, 1H), 3.65 (dt, J = 6.6, 
4.7 Hz, 1H), 3.53 (dd, J = 7.7, 3.7 Hz, 1H), 3.51–3.47 (m, 1H), 3.40 (dd, J = 17.4, 9.6 Hz, 
1H), 3.03 (d, J = 11.5 Hz, 1H), 2.60–2.48 (m, 2H), 2.38 (app. sextet, J = 6.7 Hz, 1H), 
1.67 (s, 3H), 1.61–1.46 (m, 2H), 1.09–1.03 (m, 24H), 0.99 (d, J = 7.0 Hz, 3H), 0.96 (d, J 
= 0.68 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.1, 173.1, 
134.0, 131.4, 77.3, 73.6, 71.6, 44.2, 36.0, 31.0, 30.8, 27.8, 19.2, 18.5, 18.0, 15.2, 13.2, 
12.2, 9.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H49NO3S2SiNa 538.2815, 
found 538.2841. 
 
For 2.48: TLC: Rf = 0.70 (20% EtOAc/hexanes); [α] D
22 = –207.8 (c 0.23, CHCl3); 1H 
NMR (400 MHz) δ 7.37 (d, J = 15.2 Hz, 1H), 7.32 (d, J = 15.3 Hz, 1H), 5.97 (d, J = 9.9 
Hz, 1H), 5.07 (ddd, J = 8.2, 5.6, 2.6 Hz, 1H), 3.72 (dt, J = 6.9, 4.6 Hz, 1H), 3.50 (dd, J = 
11.4, 8.1 Hz, 1H), 3.09 (dd, J = 11.4, 2.6 Hz, 1H), 2.74–2.64 (m, 1H), 2.54–2.41 (m, 1H), 
1.82 (d, J = 1.1 Hz, 3H), 1.64–1.47 (m, 2H), 1.09–1.03 (m, 24H), 1.00 (d, J = 6.9 Hz, 
6H), 0.86 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 202.6, 167.5, 150.4, 147.3, 
132.5, 118.1, 72.4, 37.4, 30.9, 30.7, 28.0, 19.2, 18.5, 18.4, 17.4, 14.8, 13.2, 12.7, 9.3; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C26H47NO2S2SiNa 520.2710, found 
520.2713. 
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S-(2-Acetamidoethyl) (3S,6R,7R,E)-3-hydroxy-4,6-di-methyl-7-((triisopropylsilyl)-
oxy)non-4-enethioate (2.49). To a flask containing acyl thiazolidinethione 2.47 (50.5 
mg, 0.0979 mmol) under argon atmosphere was added CH2Cl2 (3.00 mL). A super-
stoichiometric amount of imidazole (20.0 mg, 0.294 mmol, 3.00 equiv) was added to the 
rapidly stirred, yellow mixture at ambient temperature. A slight excess of N-
acetylcysteamine (11.5 µL, 0.108 mmol, 1.10 equiv) was added to the reaction solution. 
After stirring at ambient temperature for 13.5 h, the mixture was concentrated under 
vacuum and purified by column chromatography (5% MeOH/CH2Cl2, 1.00 cm thick 
CuSO4-SiO2) affording the title compound (32.3 mg, 0.682 mmol, 70%) as a clear, 
colorless wax. TLC: Rf = 0.30 (5% MeOH/CH2Cl2); [α] D
23 = –2.5 (c 1.00, CHCl3); 1H 
NMR (400 MHz) δ 5.80 (br s, 1H), 5.48 (d, J = 9.6 Hz, 1H), 4.48 (dd, J = 9.4, 3.0 Hz, 
1H), 3.64 (dt, J = 6.8, 4.7 Hz, 1H), 3.46 (app. dq, J = 6.6, 1.8 Hz, 1H), 3.06 (q, J = 6.3 
Hz, 1H), 2.84 (dd, J = 15.0, 9.5 Hz, 1H), 2.70 (dd, J = 15.0, 3.2 Hz, 1H), 2.56–2.46 (m, 
1H), 1.97 (s, 3H), 1.65 (d, J = 1.2 Hz, 3H), 1.62–1.41 (m, 2H), 1.06 (s, 21H), 0.95 (d, J = 
6.8 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.2, 170.5, 133.8, 
131.7, 77.4, 74.5, 49.7, 39.6, 36.0, 29.0, 27.8, 23.4, 18.5, 15.2, 13.2, 12.0, 9.3; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C24H47NO4SSiNa 496.2887, found 496.2887. 
 
OH
Me Me Me
OHO
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S-(2-Acetamidoethyl) (3S,6R,7R,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate 
(2.41). A polypropylene tube (15.0 mL, BD FalconTM) containing silylether 2.49 (32.3 
mg, 0.682 mmol) dissolved in MeCN (3.40 mL) was placed in ice-water bath (0 °C) and 
allowed to equilibrate. To the chilled reaction vessel was added a solution of 48% HF–
MeCN (11:89, 8.90 mL). The reaction mixture was transferred to a refrigerator (4 °C) for 
48 h and quenched at 0 °C via careful neutralization by saturated aqueous NaHCO3. The 
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resulting mixture was extracted with EtOAc (4 × 25.0 mL). The combined organic layers 
were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
product residue was purified by column chromatography (10% MeOH/CH2Cl2) 
furnishing the title compound (20.2 mg, 0.0630 mmol, 93%) as a clear, colorless oil. 
TLC: Rf = 0.26 (10% MeOH/CH2Cl2); [α] 365
22 = 5.0 (c 1.47, CHCl3); 1H NMR (400 MHz) 
δ 6.23 (br s, 1H), 5.35 (d, J = 9.7 Hz, 1H), 4.45 (dd, J = 7.8, 4.8 Hz, 1H), 3.41 (app. hept, 
J = 7.5 Hz, 2H), 3.34–3.28 (m, 1H), 3.08–2.95 (m, 2H), 2.82 (dd, J = 14.8, 8.2 Hz, 1H), 
2.75 (dd, J = 14.8, 4.7 Hz, 1H), 2.47 (dq, J = 12.8, 6.4 Hz, 1H), 1.95 (s, 3H), 1.65 (s, 3H), 
1.56–1.43 (m, 1H), 1.35–1.22 (m, 1H), 0.96 (d, J = 6.8 Hz, 3H), 0.92 (t, 7.4 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 198.7, 170.8, 135.7, 129.8, 77.2, 74.1, 49.8, 39.4, 37.8, 29.0, 
27.1, 23.3, 15.7, 12.4, 10.6; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H27NO4SNa 
340.1553, found 340.1547. 
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 (3S,6S,7S,E)-3-Hydroxy-1-((R)-4-isopropyl-2-thioxo-thiazolidin-3-yl)-4,6-dimethyl-
7-((triisopropylsilyl)-oxy)non-4-en-1-one (2.50). To a reaction flask containing acyl 
thiazolidinethione 2.17 (88.8 mg, 0.437 mmol, 1.70 equiv) under argon atmosphere was 
added CH2Cl2 (2.50 mL). The yellow solution was placed in dry ice–MeCN bath (-40 °C) 
and allowed to equilibrate. To the chilled solution was added TiCl4 (50.7 µL, 0.463 
mmol, 1.80 equiv) and the resulting orange solution was stirred for 30 min. An aliquot of 
freshly distilled iPr2NEt (80.6 µL, 0.463 mmol, 1.80 equiv) was slowly added to the 
reaction mixture and the blood red solution was stirred at - 40 °C for 2 h. The reaction 
was transferred to a dry ice–acetone bath (-78 °C) and supplemented with a CH2Cl2 
(0.400 mL) solution of aldehyde ent-2.46 (80.3 mg, 0.257 mmol, 1.00 equiv) in a 
dropwise fashion. The resulting reaction mixture was stirred at -78 °C for 1 h 45 min and 
quenched upon addition of aqueous saturated NH4Cl (7.00 mL). The biphasic mixture 
was warmed to ambient temperature and separated. The aqueous layer was extracted with 
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CH2Cl2 (3 × 15 mL) and the combined organic layers were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude product residue was purified by flash 
chromatography (20% EtOAc/hexanes) affording the title compound (0.102 g, 0.198 
mmol, 77%) as a bright yellow oil. TLC: Rf = 0.38 (20% EtOAc/hexanes); [α] D
22 = –199.5 
(c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.50 (d, J = 9.6 Hz, 1H), 5.15 (d, J = 6.8 Hz, 1H), 
4.55 (dd, J = 9.4, 2.2 Hz, 1H), 3.68 (q, J = 4.8 Hz, 1H), 3.57–3.51 (m, 1H), 3.51–3.47 (m, 
1H), 3.41 (dd, J = 17.4, 9.5 Hz, 1H), 3.03 (d, J = 11.5 Hz, 1H), 2.58–2.48 (m, 1H), 2.39 
(app. sextet, J = 6.8 Hz, 1H), 1.67 (s, 3H), 1.61–1.49 (m, 2H), 1.10–1.03 (m, 24H), 0.99 
(d, J = 6.9 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 
100 MHz) δ 203.1, 173.0, 134.1, 131.1, 77.3, 73.2, 71.7, 44.3, 35.9, 31.0, 30.8, 27.9, 
19.3, 18.4, 17.9, 15.1, 13.2, 12.7, 9.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C26H49NO3S2SiNa 538.2815, found 538.2830. 
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S-(2-Acetamidoethyl) (3S,6S,7S,E)-3-hydroxy-4,6-dimethyl-7-((triisopropylsilyl)-
oxy)non-4-enethioate (2.51). To a flask containing aldol adduct 2.50 (42.0 mg, 0.0814 
mmol) dissolved in CH2Cl2 (3.00 mL) under argon atmosphere was added imidazole 
(17.0 mg, 0.250, 3.07 equiv). To the stirred reaction mixture was added N-
acetylcysteamine (9.50 µL, 0.0893 mmol, 1.10 equiv) and the resulting solution was 
stirred at ambient temperature for 7 h. The reaction mixture was quenched upon addition 
of a saturated, aqueous NH4Cl (5.00 mL) and the biphasic solution was separated. The 
aqueous layer was extracted with CH2Cl2 (4 × 15.0 mL) and the combined organic layers 
were dried over Na2SO4, filtered and concentrated under reduced pressure. Crude product 
residues were purified by flash chromatography (5% MeOH/CH2Cl2) providing the title 
compound (35.3 mg, 0.746 mmol, 92%) as a clear, colorless oil. TLC: Rf = 0.23 (5% 
MeOH/CH2Cl2); [α] D
22 = –9.4 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 5.85 (br s, 1H), 
5.48 (d, J = 9.6 Hz, 1H), 4.47 (dd, J = 9.0, 3.5 Hz, 1H), 3.76–3.60 (m, 1H), 3.45 (q, J = 
6.2 Hz, 2H), 3.05 (dt, J = 5.3, 3.0 Hz, 2H), 2.82 (dd, J = 15.0, 9.0 Hz, 1H), 2.73 (dd, J = 
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15.0, 3.7 Hz, 1H), 2.58–2.44 (m, 1H), 1.97 (s, 3H), 1.65 (s, 3H), 1.60–1.46 (m, 2H), 1.06 
(s, 21H), 0.92 (d, J = 6.8 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) 
δ 199.1, 170.5, 133.9, 131.4, 77.4, 74.3, 49.8, 39.6, 35.9, 29.0, 27.8, 23.4, 18.4, 15.1, 
13.2, 12.2, 9.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C24H47NO4SSiNa 496.2887, 
found 496.2881. 
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Me Me Me
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S-(2-Acetamidoethyl) (3S,6S,7S,E)-3,7-dihydroxy-4,6-dimethylnon-4-enethioate 
(2.42). A large conical polypropylene tube (50.0 mL, BD FalconTM) containing silylether 
2.51 (35.3 mg, 0.0746 mmol) dissolved in MeCN (3.75 mL) was placed in ice-water (0 
°C) bath and allowed to equilibrate. To the chilled reaction vessel was added a solution of 
48% HF–MeCN (11:89, 5.52 mL). The resulting clear solution was stored at 4 °C for 23 
h and neutralized via addition of an aqueous saturated NaHCO3 solution at 0 °C. The 
reaction mixture was extracted with EtOAc (4 × 15.0 mL) and the combined organic 
fractions were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude residue was purified by flash column chromatography (10% MeOH/CH2Cl2) 
yielding the title compound (18.5 mg, 0.0583 mmol, 78%) as a colorless oil. TLC: Rf = 
0.38 (10% MeOH/CH2Cl2); [α] D
23 = -25.0 (c 0.62, CHCl3); 1H NMR (400 MHz) δ 6.19 (br 
s, 1H), 5.36 (d, J = 9.7 Hz, 1H), 4.46 (dd, J = 8.2, 3.5 Hz, 1H), 3.42 (q, J = 6.1 Hz, 2H), 
3.38–3.29 (m, 1H), 3.09–2.95 (m, 2H), 2.83 (dd, J = 14.8, 8.6 Hz, 1H), 2.73 (dd, J = 14.8, 
3.8 Hz, 1H), 2.48 (dq, J = 13.3, 6.6 Hz, 1H), 1.95 (s, 3H), 1.65 (s, 3H), 1.58–1.47 (m, 
1H), 1.32 (dq, J = 15.1, 7.8 Hz, 1H), 0.94 (d, J = 6.9 Hz, 3H), 0.93 (t, J = 7.2 Hz, 3H); 
13C NMR (CDCl3, 100 MHz) δ 198.8, 170.8, 135.8, 129.7, 77.3, 74.2, 49.6, 39.4, 37.8, 
29.0, 26.9, 23.3, 15.8, 12.5, 10.7; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C15H27NO4SNa 340.1553, found 340.1556. 
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S-(2-Acetamidoethyl) (2E,4E,6R,7R)-4,6-dimethyl-7-((triisopropylsilyl)oxy)nona-2,4-
dienethioate (2.52). To a round bottom flask containing acyl thiazolidinethione 2.48 
(44.2 mg, 0.0889 mmol) under argon atmosphere was added CH2Cl2 (3.00 mL). To the 
resulting clear solution was added DMAP (32.6 mg, 0.267 mmol, 3.00 equiv) followed 
by N-acetylcysteamine (10.4 µL, 0.098 mmol, 1.10 equiv). The resulting mixture was 
stirred at ambient temperature for 10 h and concentrated under reduced pressure. 
Purification of the crude residue by column chromatography (5% MeOH/CH2Cl2) yielded 
the title compound (23.1 mg, 0.0507 mmol, 57%) as a colorless wax. TLC: Rf = 0.38 (5% 
MeOH/CH2Cl2); [α] D
23 = 7.6 (c 1.00, CHCl3); 1H NMR (400 MHz) δ 7.25 (d, J = 15.3 Hz, 
1H), 6.10 (d, J = 15.4 Hz, 1H), 6.01 (d, J = 9.8 Hz, 1H), 5.94 (br s, 1H), 3.72 (dt, J = 7.0, 
4.6 Hz, 1H), 3.48 (app. q, J = 5.9 Hz, 2H), 3.12 (t, J = 6.3 Hz, 2H), 2.76–2.65 (m, 1H), 
1.96 (s, 3H), 1.79 (s, 3H), 1.66–1.46 (m, 2H), 1.08–1.04 (m, 21H), 1.01 (d, J = 6.8 Hz, 
3H), 0.87 (t, J = 7.5 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 190.7, 170.4, 148.9, 146.9, 
131.4, 122.6, 40.2, 37.5, 28.5, 27.9, 23.4, 18.42, 18.37, 14.7, 13.1, 12.4, 9.3; HRMS 
(ESI-TOF) m/z: [M + Na]+ Calcd for C24H45NO3SSiNa 478.2781, found 478.2780. 
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S-(2-Acetamidoethyl) (2E,4E,6R,7R)-7-hydroxy-4,6-dimethylnona-2,4-dienethioate 
(2.53). A polypropylene tube (15.0 mL, BD FalconTM) containing silylether 2.52 (18.0 
mg, 0.0395) dissolved in acetonitrile (4.15 mL) was equilibrated in ice-water bath (0 °C). 
To the chilled starting material was added a solution 48% HF–MeCN (11:89, 5.00 mL). 
The resulting acidified solution was stored at 4 °C for 48 h and quenched via addition of 
NaSO4 at 0 °C. The reaction mixture was extracted with EtOAc (4 × 15.0 mL) and the 
combined organics were dried over Na2SO4. Filtration and concentration under reduced 
pressure gave the crude product residue. Purification by column chromatography (5% 
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MeOH/CH2Cl2) provided the title compound (8.1 mg, 0.0271 mmol, 69%) as a cloudy, 
colorless oil. TLC: Rf = 0.28 (5% MeOH/CH2Cl2); [α] D
23 = 37.5 (c 0.52, CHCl3); 1H NMR 
(400 MHz) δ 7.26 (d, J = 15.5 Hz, 1H), 6.12 (d, J = 15.5 Hz, 1H), 5.94 (s, 1H), 5.87 (d, J 
= 10.1 Hz, 1H), 3.47 (q, J = 6.0 Hz, 2H), 3.39 (ddd, J = 9.2, 6.5, 3.4 Hz, 1H), 3.11 (t, J = 
6.3 Hz, 2H), 2.63 (dt, J = 10.1, 6.6 Hz, 1H), 1.96 (s, 3H), 1.81 (d, J = 0.9 Hz, 3H), 1.61–
1.49 (m, 1H), 1.41–1.27 (m, 1H), 1.06 (d, J = 6.7 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 190.7, 170.4, 146.8, 146.6, 132.6, 123.1, 77.0, 40.1, 39.6, 
28.5, 27.9, 23.4, 15.8, 12.6, 10.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C15H25NO3SSiNa 332.1447, found 322.1447. Upon literature analysis we discovered that 
this compound had been synthesized through a different route by Cane, DE and co-
workers.58 Our analytical data match that of the original report in all respects. 
 
O
NACS
OH
Me  
(±)-S-(2-Acetamidoethyl) 3-hydroxypentanethioate ((±)-2.54). The details for the 
synthesis of racemic diketide substrate 26 are included in a recently published manuscript 
by Yang Li, et al.29 
 
Scheme 2.11. Chemoenzymatic synthesis of diene products. 
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S-(2-Acetamidoethyl) (2E,4E,6S,7R)-7-hydroxy-4,6-di-methylnona-2,4-dienethioate 
(2.10). To a small polypropylene conical tube (15 mL) containing sterile deionized water 
(0.630 mL) was added a concentrated Tris buffer solution (0.500 M Tris-HCl, 1.50 M 
NaCl, pH 8.0, 0.500 mL). The clear solution was vortexed to mix and β-hydroxy 
thioester 2.7 (3.17 mg, 0.0100 mmol) was added as a 50:50 DMSO-water stock solution 
(100 mM, 100 µL) and mixed by inversion. Heterologously expressed TylDH3KR3 (2.53 
mg/mL stock solution, 1.52 mL, 3.85 mg, 50.3 nmol) was added to the buffered solution. 
The reaction mixture was capped and incubated at ambient temperature with shaking 
(250 rpm) for 26 h. The aqueous solution was extracted with EtOAc (3 × 10.0 mL) 
followed by drying over Na2SO4, filtration and concentration under vacuum. The crude 
product residue was purified via flash chromatography (5% MeOH/CH2Cl2) affording the 
title compound (2.00 mg, 0.00667 mmol, 67%) as a cloudy, colorless oil. TLC: Rf = 0.32 
(5% MeOH/CH2Cl2); Due to stability issues, an optical rotation was not obtained; 1H 
NMR (400 MHz, CDCl3) δ 7.29 (d, J = 15.6 Hz, 1H), 6.12 (d, J = 15.5 Hz, 1H), 5.96 (d, 
J = 10.1 Hz, 1H), 5.91 (br s, 1H), 3.52–3.39 (m, 3H), 3.12 (t, J = 6.3 Hz, 2H), 2.72–2.60 
(m, 1H), 1.96 (s, 3H), 1.82 (s, 3H), 1.54–1.49 (m, 1H), 1.45–1.34 (m, 1H), 1.05 (d, J = 
6.8 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 190.7, 170.4, 146.6, 
146.0, 133.5, 123.1, 77.0, 40.2, 39.2, 28.5, 27.8, 23.4, 17.0, 12.7, 10.2; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C15H25NO3SNa 322.1447, found 322.1451. 
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N-(2-(((4E,6E,8S,9R)-9-Hydroxy-6,8-dimethyl-3-oxoundeca-4,6-dien-1-
yl)thio)ethyl)acetamide (2.11). β-Hydroxy ketone 2.9 (3.45 mg, 0.0100 mmol) was 
dehydrated in an analogous matter as the generation of dienoate 8 resulting in dienone 9 
(3.17 mg, 0.00969 mmol, 97%). TLC: Rf = 0.30 (5% MeOH/CH2Cl2); Due to stability 
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issues, an optical rotation was not obtained; 1H NMR (400 MHz) δ 7.17 (d, J = 16.7 Hz, 
1H), 6.05 (d, J = 15.9 Hz, 1H), 5.89 (d, J = 10.0 Hz, 1H), 3.43–3.35 (m, 3H), 2.87–2.80 
(m, 2H), 2.80–2.74 (m, 3H), 2.66–2.54 (m, 3H), 1.94 (s, 3H), 1.76 (s, 3H), 1.52–1.42 (m, 
1H), 1.40–1.28 (m, 1H), 0.99 (d, J = 6.8 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 198.8, 170.4, 148.7, 145.5, 133.9, 124.6, 77.0, 40.2, 39.2, 38.7, 
32.3, 27.8, 26.1, 23.4, 17.1, 12.7, 10.2; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C17H29NO3SNa 350.1760, found 350.1762. 
2.8 Biology experimental section 
General biology procedures. All chemical reagents were purchased from Sigma-Aldrich 
and were used directly without further purification.  E. coli BL21–AI cells were from 
Life Technologies. IPTG was acquired through Gold Biotechnology. L-(+)-Arabinose 
(≥99%) was purchased through Sigma Aldrich. His60 Ni Superflow resin was purchased 
from Clontech Laboratories, Inc. OD600 was measured on an Eppendorf BioPhotometer. 
Sonication was carried out by Branson Sonifier 450. Gel filtration purification was 
performed on HiLoad 16/600 Superdex 200 pg column (GE). Protein mass spectrometry 
was carried out using an Agilent 6250 QTOF LC/MS. Kinetic LC–MS/MS was 
conducted with AB Sciex QTRAP 5500 mass spectrometer and Shimadzu LC system. 
The TylKR3-DH3 didomain was ordered as codon-optimized synthetic DNA from Life 
Technologies. The synthetic DNA encoded the region 957-1682 from the tylactone 
synthase module 3 polypeptide. The insert was cloned into pMCSG7 using ligation 
independent cloning (LIC). TylKr3-DH3 synthetic forward primer: 5’-TACTTCCAAT-
CCAATGCCCATCCGCTGCTGAGCG-3’; TylKr3-DH3 synthetic reverse primer: 5’-
TTATCCACTTCCAATGTTAGTTGGTATCTTCCGGTGTACCAGGCG-3’ (LIC-
overhangs in bold; inserted stop codon underlined). The insert was confirmed via 
sequencing.  
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Cloning and Expression of TylDH3-KR3 Construct 
 
Initial efforts to recombinantly express the mono-domain TylKR3 were hampered by 
with poor expression levels and protein aggregation. Strategies to alleviate these issues 
included an increase of rare tRNA codons (Rosetta cell line), optimization of codon 
selection (synthetic TylKR3 gene), toxic protein-compatible expression hosts (pLysS cell 
line), appending a fusion protein (attempted with SUMO, mOCR, and GST), chaperone 
coexpression (GroEL-GroES) and truncations of both N- and C-termini. Disappointingly, 
these techniques failed to improve expression of soluble non-aggregated TylKR3 and 
forced us to abandon the expression of the mono-domain construct.  
 
The tylGII region encoding TylDH3-KR3 didomain comprising residues 957-1682 was 
cloned into a pMCSG7 vector and transformed into E. coli BL21-AI cells containing the 
pRARE plasmid. A large TB media culture (0.5 L in 2.8 L Fernbach flask) was 
inoculated with as small amount of overnight culture (5 mL) and incubated at 37 °C, 
shaking at 250 RPM until OD600 = 1.00–1.20. The culture was cooled to 20 °C and 
incubated with shaking (250 RPM) for 1 h. Cells were induced upon addition of IPTG 
(0.100 mM) and L-arabinose (1.00 g) and allowed to shake (250 RPM) at 20 °C for 19 h. 
The cell pellet was collected after centrifugation (4 °C, 5,000 x G, 30 min) and 
resuspended in lysis buffer (50 mM tricine, 50 mM (NH4)2SO4, 100 mM urea, pH 8.5, 4 
mL/g of pellet). The cells were lysed (3 x 2 min, 50% duty cycle, 40 % power, 4 °C) and 
centrifuged (4 °C, 28,600 x G, 45 min). The soluble protein was purified by sequential 
metal-immobilized affinity chromatography and size exclusion chromatography to afford 
approximately 9 mg of purified protein (18 mg / L) that was greater than 90% pure as 
judged by SDS-PAGE (Figure 2.6) and to be near the predicted calculated mass by mass 
spectrometry (Figure 2.7). 
 
	 68 
 
Figure 2.6. SDS-PAGE image of TylDH3-KR3 purification. The ladder, cell lysate, 
insoluble pellet, soluble protein and serial nickel elution fractions are shown in lanes 1-9, 
respectively. The band corresponding to TylDH3-KR3 is boxed. 
 
 
 
 
Figure 2.7. Mass spectrometry analysis of TylDH3-KR3. The convoluted (raw) spectrum 
and deconvoluted are both displayed. TylDH3-KR3 was found to have a mass of 76,264 
Da. The spectrum was obtained using 0.5 mg/mL of recombinant TylDH3-KR3 in 25% 
formic acid. (This mass was determined by Greg Dodge –University of Michigan) 
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Determination of TylDH3-KR3 Ketoreductase Activity 
A small eppendorf tube (1.5 mL, 100 µL total volume) containing substrate 2.4 or 2.5 (1 
mM), heterologously expressed TylDH3-KR3 (5 µM), NADPH (2 mM), Tris (50 mM), 
NaCl  (150 mM) at pH 8.0 was incubated at ambient temperature for 15 h. The reaction 
was quenched upon addition of MeCN–H2O (100µL) and brief centrifugation. A portion 
of the diluted  reaction solution (60 µL) was added to a HPLC vial and analyzed by LC-
MS/MS (Table S4) employing a Kinetix reverse-phase C18 column (50 mm × 2.1 mm, 2.6 
µm, Phenomenex) operated at 0.4 mL min-1 with a gradient between mobile phase A 
(H2O) and mobile phase B (MeCN). The gradient program was 0 min, 5% B; 2 min, 5% 
B; 7 min, 55% B; 8 min, 70% B; 9 min, 70% B; 10.5 min, 5% B; 12 min, 5% B.  Co-
injection of standards 2.6, 2.7, and 2.10 for substrate 2.4 confirmed the identity of 
product traces. The standards 2.8, 2.9, and 2.11 were used for the analysis of the 
incubation of substrate 2.5.  
 
Table 2.2. LC-MS/MS analysis of analytes 2.6, 2.7, 2.10, 2.8, 2.9, and 2.11. 
Analyte 
HPLC retention 
time (min) 
Transition 
2.6 5.19 340→184 
2.7 5.27 340→184 
2.10 6.17 300→181 
2.8 
2.9 
2.11 
5.24 
5.30 
6.00 
368→212 
368→212 
328→151 
 
Analysis of TylDH3-KR3 Dehydratase Activity 
 
Steady-State Analysis. 
The enzymatic reactions were carried out in a total volume of 50 µL under initial velocity 
conditions containing TylDH3-KR3 (1 µM), reaction buffer (50 mM Tris, 150 mM NaCl, 
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pH 8.0) and substrates 2.7 or 2.9 at variable concentrations (0.5, 1, 2, 3, 4, 6, 8 mM). The 
final DMSO concentration was held constant at 4%. After incubation at 25 °C for 8 min 
(the reaction found to be linear up to 10 min), 5 µL of the reaction mixture was added to 
495 µL of 1:1 MeCN–reaction buffer (100-fold dilution). The resulting solution was 
vortexed, centrifuged and analyzed by 60 µL of the diluted reaction solution was added to 
a HPLC vial with 10 µL of internal standard (320 nM) and analyzed by LC-MS/MS 
(Table S4) employing a Kinetix reverse-phase C18 column (50 mm × 2.1 mm, 2.6 µm, 
Phenomenex) operated at 0.4 mL min-1 with a gradient between mobile phase A (H2O) 
and mobile phase B (MeCN). The gradient program was 0 min, 5% B; 2 min, 5% B; 7 
min, 55% B; 8 min, 70% B; 9 min, 70% B; 10.5 min, 5% B; 12 min, 5% B. Standard 
curves of enzymatic products 2.10 and 2.11 were generated by injecting the authentic 
standard at varying concentrations with a fixed concentration of an internal standard 
(2.10 for the standard curve of 2.11 and 2.11 for the standard curve of 2.10). The amount 
of enzymatic product formation at each time point was calculated by plotting the area 
ratio (analyte/internal standard) into the standard curve. Control reactions for each 
concentration of substrate were performed without the addition of enzyme. Each reaction 
was performed in duplicate. The specificity constants (KM/kcat) were determined by fitting 
the normalized v0 vs [S] plots to linear equations (Figure S3 panels A and B).  
 
Substrates 2.41 and 2.42 were analyzed in an analogous way using synthetic 2.53 as the 
product standard (Figure 2.5 panels C and D). The LC-MS/MS trace of 2.53 is provided 
in 2.13 
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Figure 2.8. LC-MS/MS trace of dienethiolate 2.53. The synthetic compound 2.53 was 
used to confirm the identity of the dehydration products arising from thioesters 2.41 and 
2.42. A standard curve for quantitative determination of specificity constants was 
generated from the synthetic compound. 
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Chapter 3: Curacin Module K Cryptic Dehydratase 
 
3.1 Background on the natural product curacin  
 
Curacin A, a mixed polyketide-nonribosomal peptide natural product isolated from the 
cyanobacteria Moorea producens (formerly Lyngbya majuscula) is a potent 
antiproliferative agent that arrests mitosis through the inhibition of tubulin 
polymerization.59 Curacin A is biosynthesized via a nonribosomal peptide synthase-
polyketide synthase pathway incorporating three malonyl-CoA units in a unique 
cyclopropyl moiety, one L-cysteine in a thiazoline cyclization reaction, and 7 units of 
malonyl-CoA through KS-catalyzed Claisen condensations (Figure 3.1). The curacin 
(Cur) biosynthetic pathway has provided a wealth of information about non-canonical 
enzymatic processes in polyketide biosynthesis including a GCN5-related N-
acetyltransferase (GNAT)-like strategy for polyketide chain initiation, cyclopropane 
synthesis through β-branching and cryptic halogenation, and polyketide termination via 
off-loading of a terminal alkene60-62 Moreover, the Cur pathway has yielded tremendous 
structural insight into this unprecedented PKS chemistry and three dimensional structures 
of fourteen proteins in the Cur pathway have been published.12,63-69  
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Figure 3.1. The curacin A biosynthetic pathway. Displayed are the detailed module 
products for CurF to CurK modules. 
 
3.2 Chemical strategy and rationale 
 
We selected the curacin biosynthetic pathway as a platform for studying dehydratase 
activity in PKSs. The pathway uniquely produces nearly every possible olefin 
substitution pattern (Figure 3.1). Additionally, curacin B and C constitute geometric 
isomers of A and suggest a degree of pathway flexibility in regards to olefin formation 
(Figure 3.2).70 We were initially interested in the CurK dehydratase, catalyzing the last 
canonical dehydration in the pathway. The CurK ER reduces the product of dehydration, 
obscuring the olefin bond geometry of the intermediary unsaturated thioester. We wanted 
to probe the alkene to determine its identity (E or Z) as well as determine any substrate 
selectivity for the KR product. In so doing, we hoped to predict the cryptic KR 
stereochemistry in a fashion similar to the previous TylDH3 study (Chapter 2). 
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Figure 3.2. A comparison of natural curacin geometric isomers. Curacins B (3.2) and C 
(3.3) E,Z and Z,E isomers of the central diene moiety. 
 
Due to the unique structure of the late-module CurK intermediates we chose to amend 
our previous synthetic strategy utilized in the synthesis of tylosin module 3 substrates and 
products. Specifically, we rationalized that due to the preference for thioesters exhibited 
by dehydratase domains in the tylosin pathway, there was no need to synthesize thioether 
CurK substrates. The complex distal components of the native substrate 3.4 (i.e. 
thiazoline and cyclopropyl moieties) persuaded us to truncate CurK substrates to ease 
their synthesis (Figure 3.3). As a result, we designed the target CurK DH substrates 
compounds 3.5 and 3.6. We hoped to isolate the triene product 3.7 after incubation with 
the CurK DH. 
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Figure 3.3. Curacin module K DH substrate and product design. The full ACP-loaded 
substrate 3.4 is highlighted in blue on the truncated region serving as the basis for 
synthetic substrate design. Enzymatic dehydratase substrates 3.5 and 3.6 were designed to 
reduce molecular complexity. The hypothetical triene product 3.7 is shown with 
ambiguous olefin geometry, as the CurK ER in curacin biosynthesis later reduces this 
moiety. 
 
3.3 Synthesis of truncated CurK DH substrates 
 
The synthesis of D-alcohol thioester substrate 3.5 commenced with commercially 
available trans-2-pentenal (Scheme 3.1). Addition of the aldehyde to a preformed enolate 
solution of Horner-Wadsworth-Emmons (HWE) reagent 3.9 quantitatively furnished 
dienoate 3.10. The moderately volatile ester was fully reduced to the corresponding 
allylic alcohol 3.11 via action of excess DIBAL-H. MnO2 was used to oxidize the crude 
3.11 to the corresponding aldehyde 3.12 in an overall yield of 96% from trans-2-
pentenal. The aldehyde 3.12 was found to be thermally unstable leading to a complex 
mixture upon attempted distillation. In light of this, aldehyde was 3.12 dried over 4 Å 
molecular sieves for (12 h) prior to submitting to the key acetate aldol reaction. In the 
event, the reaction with D-valine-derived Nagao thiazolidinethione 3.13 with 
titanium(IV) chloride as the Lewis acid cleanly produced aldol adduct 3.14 as a single 
diastereomer.32,33 The resulting thiazolidinethione was displaced by commercially 
available N-acetylcysteamine to form the desired truncated CurK dehydratase substrate 
3.15. The corresponding enantiomer (L-alcohol, 3.6) was synthesized in a similar manner 
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from the common aldehyde 3.12 and the antipode of chiral auxiliary 3.13. 
 
Scheme 3.1. Synthetic route towards CurK DH substrate 3.5. 
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3.4 CurK DH-catalyzed production and characterization of triene intermediate 
 
Both substrates 3.5 and 3.6 (1 mM) were separately incubated overnight (12 h) with 
recombinant CurK DH (Figure 3.4). Both reaction mixtures were quenched via 
acetonitrile promoted protein precipitation and analyzed via low-resolution mass 
spectrometry. The D-alcohol substrate (3.5) was efficiently eliminated based on a new 
mass appearing at m/z = 267.4. No product formation was observed in the L-alcohol (3.6) 
mixture, indicating the reaction had occurred in a stereoselective fashion. This result 
matches the bioinformatic, amino acid sequence-based prediction that the CurK KR 
produces D-alcohols. The LC-MS/MS extracted ion chromatograms revealed that the 
CurK DH had the highest conversion of 3.5 to 3.7 (Figure 3.5, Panels A and C). Similar 
to the LRMS results, we found that substrate 3.6 showed no product formation when 
incubated with any the dehydratases in the pathway (Figure 3.5, Panel B). A time course 
study revealed that equilibrium between 3.5 and 3.7 was reached within one hour of 
incubation with CurK DH (5 µM) (Figure 3.5, Panel D). Additionally, we were able to 
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test catalytic dyad mutants (H996F and D1169N) provided to us courtesy of Gregory 
Dodge (Dr. Janet L. Smith Lab, University of Michigan- Life Sciences Institute) and 
show they were catalytically inactive (H→F) or severely inhibited (D→N, <2% 
conversion over 12 h) with 3.5.  
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Figure 3.4. Graphical display of the stereoselective action of the CurK DH. Incubation 
with D-alcohol 3.5 resulted in conversion to dehydrated product 3.7 by LRMS. 
Conversely, the same enzyme failed to turnover L-alcohol 3.5, yielding only starting 
material.  
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Figure 3.5. LC-MS/MS analysis of the incubation of 3.5 and 3.6 with the CurK DH. 
Panels A and B display the incubation of the curacin dehydratases for 12 h with 
substrates 3.5 and 3.6, respectively. Panel C shows the area ratio of 3.7:3.5 for each 
dehydratase. Panel D displays the time course incubation of substrate 3.5 with CurK and 
formation of 3.7. Extracted ion chromatograms were generated by scanning for MRM 
268→121. 
 
We were interested in investigating the triene product of the CurK DH more closely for 
its olefin bond geometry as well as obtaining a sample to serve as a standard for LC-
MS/MS. A large amount of substrate 3.5 (10.0 mg, 35.0 µmol) and CurK DH were 
incubated overnight. The crude mixture was extracted with ethyl acetate and the crude 
residue was purified by silica gel chromatography and the purified product was analyzed 
via 1H NMR to determine the critical α, β J-coupling values. The J-values were found to 
be diagnostic of a trans-olefin (15.3 Hz) (Figure 3.6). This suggests that the frequently 
proposed empirical rule that the DH catalyzed elimination of D-alcohols typically results 
in trans-alkene geometry indeed holds true in the case of the CurK module.17 
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Figure 3.6. The diagnostic α, β-protons used to assign geometry in the CurK DH product. 
Correlating peaks are highlighted with blue. The J-coupling value is 15.3 Hz, indicative 
of a trans-olefin.  
 
3.5 Quantitative Analysis of CurK DH-catalyzed dehydration 
 
Next we investigated the kinetics of the CurK DH-catalyzed triene formation to compare 
with the previous TylDH3 activity. With dehydrated product 3.7 in hand we were able to 
generate a standard curve for quantitative LC-MS/MS analysis. We chose synthetic 
dienoate 4.6 (See Chapter 4 for synthetic details) as the internal standard given its 
molecular similarity to the product. A constant amount of internal standard (320 nM) was 
added to a range of concentrations of authentic product and the resulting mixture was 
analyzed via LC-MS/MS. We determined that the enzyme activity was linear up to 10 
minutes and at a range of enzyme concentrations  (10–250 nM) allowing us to set an 
enzymatic stop point at 4 minutes and 20 nM of enzyme for determining steady state 
enzyme kinetic parameters. By varying the substrate concentration from 0.25–6 mM we 
were able to obtain the area ratios (product/internal standard) that could be converted to 
concentrations (with the standard curve) necessary for generating kinetic plots. In so 
doing we were able to determine both the kcat (4319 ± 1237 min-1) and KM (12.0 ± 4.68 
mM) for the enzymatic dehydration of 3.5 via Michaelis-Menten analysis. (Figure 3.7) 
This results in a 396–fold increase in specificity constant (360 ± 84.3 min-1 mM-1) over 
the previously characterized TylDH3 specificity constant (908 ± 30 min-1 M-1). 
Remarkably, this is determined with the severely truncated substrate 3.5, suggesting that 
	 80 
the native substrate may be processed even more efficiently.  
 
Figure 3.7. Michaelis-Menten analysis of substrate 3.5. The points are derived through 
duplicate steady state analyses of CurK DH while varying substrate concentrations (0.25–
6.0 mM). R2 = 0.974. 
 
 
 
3.6 Chemistry Experimental Section 
 
Me
Me
EtO
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Ethyl (2E,4E)-2-methylhepta-2,4-dienoate (3.10). A flask containing THF (36.0 mL) 
and triethyl 2-phosphonopropionate 3.9 (2.81 mL, 13.1 mmol, 1.10 equiv) was placed in 
ice-water cooling bath (0 °C). To the chilled mixture was added NaH (60% (w/w) in oil, 
0.595 g, 14.9 mmol, 1.25 equiv) and stirred for 2 h. The enolate solution was 
supplemented with distilled trans-2-pentenal 3.856 (1.16 mL, 11.9 mmol, 1.00 equiv) over 
20 min. After stirring at 0 °C for 5.5 h, the reaction was was quenched upon addition of 
H2O (20.0 mL). The biphasic solution was separated and the aqueous layer was extracted 
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with diethyl ether (4 × 20.0 mL). The combined organic layers were dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product residue was purified 
by flash chromatography (5% Et2O/pentane) affording the title compound (2.00 g, 11.9 
mmol, quant.) slightly yellow oil (2.00 g, 11.9 mmol, quant.).   TLC: Rf  = 0.22 (2% 
Et2O/pentane); 1H NMR (CDCl3, 400 MHz) δ 7.16 (d, J = 11.2 Hz, 1H), 6.33 (dd, J = 
14.8, 11.2 Hz, 1H), 6.11 (dt, J = 15.2, 6.4 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 2.21 (app. 
quint, J = 7.2 Hz, 2H), 1.93 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H), 1.05 (t, J = 7.6 Hz, 3H); 13C 
NMR (CDCl3, 100 MHz) δ 168.8, 144.6, 138.7, 125.3, 125.2, 60.6, 26.5, 14.5, 13.3, 12.7; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C10H16O2Na 191.1043, found 191.1039 (Δ = 
2.0 ppm). 
 
Me
Me
O
 
(2E,4E)-2-Methylhepta-2,4-dienal (3.12). To a flask containing dienoate 3.9 (486 mg, 
2.89 mmol, 1.00 equiv) was added CH2Cl2 (13.0 mL). The clear solution was cooled via 
ice-water bath (0 °C). To the chilled reaction mixture was slowly added DIBAL-H (1M 
in hexanes, 6.93 mL, 6.93 mmol, 2.40 equiv). After 42 min the reaction was quenched via 
successive addition of MeOH (3.50 mL) and aqueous saturated sodium potassium tartrate 
(10.0 mL). The resulting biphasic mixture was stirred vigorously at room temperature for 
14 h. The reaction mixture was diluted with H2O (10.0 mL) and CH2Cl2 (10.0 mL). The 
biphasic mixture was separated and the aqueous layer was extracted with CH2Cl2 (3 × 
12.0 mL). The combined organics were dried over NaSO4, filtered and concentrated 
under reduced pressure. The crude residue was carried to the next reaction without further 
purification. TLC: Rf  = 0.58 (20% EtOAc/hexanes). 
 
The crude alcohol 3.11 (2.89 mmol (assuming quantitative conversion for the preceding 
reduction)) was dissolved in CH2Cl2 (15.0 mL) and purged with argon atmosphere. To 
the reaction flask was added anhydrous MgSO4 (1.04 g, 8.67 mmol, 3.00 equiv) followed 
by MnO2 (88% activated, 1.76 g, 20.23 mmol, 7.00 equiv). The resulting gray solution 
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was vigorously stirred at ambient temperature for 24 h. The reaction mixture was filtered 
through celite pad (2.00 cm) and concentrated under reduced pressure. The crude residue 
was purified by flash choromatography (2% Et2O/pentanes) affording the title compound 
(0.345 g, 2.77 mmol, 96% over 2 steps) as a colorless oil. TLC: Rf  = 0.43 (10% 
Et2O/pentane); 1H NMR (CDCl3, 400 MHz) δ 9.42 (s, 1H), 6.83 (d, J = 11.2 Hz, 1H), 
6.52 (ddt, J = 14.8, 11.2, 1.6 Hz, 1H), 6.28 (dt, J = 14.8, 6.4 Hz, 1H), 2.32–2.23 (m, 2H), 
1.84 (t, J = 0.8 Hz, 3H), 1.10 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 195.3, 
149.5, 147.3, 136.2, 125.1, 26.7, 13.1, 9.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C8H12ONa 147.0780; found 147.0794 (Δ = 9.5 ppm). 
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(S,4E,6E)-3-Hydroxy-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)-4-methylnona-4,6-
dien-1-one (3.14). To a flask acetyl thiazolidinethione 3.13 (0.484 g, 2.38 mmol, 1.60 
equiv) was added CH2Cl2 (12.0 mL). The bright yellow solution was cooled via dry ice–
MeCN (-40 °C). To the chilled solution was added TiCl4 (0.277 mL, 2.53 mmol, 1.70 
equiv) causing a color change to orange-red. The solution was stirred for 29 min prior to 
the slow addition of distilled iPr2NEt56 (0.441 mL, 2.53 mmol, 1.70 equiv). After 2.25 h 
the blood-red solution was cooled via dry ice–acetone (-78 °C) and aldehyde 3.12 (dried 
overnight over 4 Å molecular sieves) (185.0 mg, 1.49 mmol, 1.00 equiv) was added to 
the solution over 1 min. The aldol reaction was stirred at -78 °C for 3.5 h and quenched 
by addition of saturated aqueous NH4Cl (6.00 mL). The biphasic solution was separated 
and the aqueous layer was extracted with CH2Cl2 (4 × 10.0 mL). The combined organics 
were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified via flash chromatography (30% EtOAc/hexanes)) affording the title 
compound (0.230 g, 0.703 mmol, 47%) as a bright yellow, viscous oil. TLC: Rf  = 0.41 
(30% EtOAc/hexanes)); [α] D
24 = –245.7 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 
6.24 (dd, J = 14.8, 10.8 Hz, 1H), 6.09 (d, J = 10.8 Hz, 1H), 5.76 (dt, J = 14.8, 6.8 Hz, 
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1H), 5.14 (t, J = 6.8 Hz, 1H), 4.61 (dd, J = 8.8, 0.8 Hz, 1H), 3.59–3.48 (m, 2H), 3.42 (dd, 
J = 17.2, 9.2 Hz, 1H), 3.03 (d, J = 11.6 Hz, 1H), 2.65 (br s, 1H), 2.37 (app. sext, J = 6.4 
Hz, 1H), 2.13 (app. quint, J = 7.2 Hz, 2H), 1.77 (s, 3H), 1.08–0.97 (m, 9H); 13C NMR 
(CDCl3, 100 MHz) δ 203.2, 172.9, 137.5, 135.2, 125.9, 124.9, 73.0, 71.7, 44.1, 31.0, 
30.8, 26.2, 19.2, 18.0, 13.8, 13.0; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C16H25NO2S2Na 350.1219; found 350.1207 (Δ = 3.4 ppm). 
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S-(2-Acetamidoethyl) (S,4E,6E)-3-hydroxy-4-methylnona-4,6-dienethioate (3.5). The 
aldol adduct 3.14 (109.4 mg, 0.334 mmol, 1.00 equiv) and anhydrous dichloromethane 
(10.00 mL). The bright yellow solution was supplemented with N-acetylcysteamine (39.0 
µL, 0.367 mmol, 1.10 equiv) and imidazole (14.7 mg, 0.216 mmol, 3.00 equiv). The 
reaction mixture was at ambient temperature for 21 h. The reaction mixture was 
evaporated by nitrogen stream and purified by flash chromatography (5% 
MeOH/CH2Cl2). The title compound (52.4 mg, 0.184 mmol, 55%) was isolated as a a 
clear, colorless oil. TLC: Rf  = 0.39 (5% MeOH/CH2Cl2); [α] D
24 = –20.8 (c 0.52, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 6.22 (dd, J = 15.2, 10.4 Hz, 1H), 6.07 (d, J = 10.8 Hz, 
1H), 5.83 (br s, 1H), 5.76 (dt, J = 15.2, 6.4 Hz, 1H), 4.53 (dd, J = 9.2, 3.6 Hz, 1H), 3.48–
3.40 (m, 2H), 3.05 (app. sext, J = 8.0 Hz, 2H), 2.84 (dd, J = 15.2, 8.8 Hz, 1H), 2.76 (dd, J 
= 14.8, 4.0 Hz, 1H), 2.48 (br, 1H), 2.13 (app. quint, J = 7.2 Hz, 2H), 1.96 (s, 3H), 1.75 (s, 
3H), 1.01 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 199.0, 170.6, 138.0, 134.9, 
126.3, 124.7, 74.0, 49.6, 39.5, 29.0, 26.1, 23.4, 13.8, 12.6; HRMS (ESI-TOF) m/z: [M + 
Na]+ Calcd for C14H23NO3SNa 308.1291; found 308.1275 (Δ = 5.1 ppm). 
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(R,4E,6E)-3-Hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-yl)-4-methylnona-4,6-
dien-1-one (ent-3.14).The title aldol adduct was obtained as a bright yellow oil (75%) 
following an analogous procedure as compound 3.14, utilizing the L-valine derived 
Nagao’s chiral auxiliary (ent-3.13). [α] D
24 = 233.2 (c 1.00, CHCl3). The product was 
identical in all remaining respects to its enantiomer, 3.14. 
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S-(2-acetamidoethyl) (R,4E,6E)-3-hydroxy-4-methylnona-4,6-dienethioate (3.6). The 
thioester substrate was synthesized from the precursor thiazolidinethione ent-3.13 in a 
similar manner to that of thioester 3.5. The desired product was furnished as a slightly 
yellow, clear oil (24%). [α] D
24 = 17.1 (c 1.00, CHCl3). All remaining properties were 
identical to that of the enantiomeric thioester 3.5. 
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S-(2-Acetamidoethyl) (2E,4E,6E)-4-methylnona-2,4,6-trienethioate (3.7). To a small, 
conical tube (15.0 mL) was added autoclaved, deionized water (3.82 mL) and a small 
amount of 10X TRIS buffer solution (1.50 M NaCl, 0.500M Tris-HCl, pH 8.0) (0.600 
mL). The reaction mixture was briefly vortexed. To the buffered solution was added a 
DMSO–H2O (1:1) stock solution (50 mM) of the β-hydroxy thioester substrate 3.5 (0.700 
mL, 10.0 mg, 35.0 µmol). The mixture was vortexed to mix and the CurK dehydratase 
(8.19 mg/mL, 0.684 mL, 5.60 mg, 0.160 µmol). The mixture was briefly inverted and 
covered with aluminum foil to shield it from light.  The reaction mixture was shaken 
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overnight (200 rpm) at ambient temperature in the dark. The reaction mixture was 
extracted with EtOAc (4 × 10.0 mL) and the combined extracts were dried over sodium 
sulfate, filtered and concentrated under vacuum. The crude product extract was purified 
by flash chromatography (5% MeOH/CH2Cl2)) affording the title compound (2.52 mg, 
8.82 µmol, 25%) as a slightly yellow, clear oil (2.52 mg, 8.82 µmol, 25%). Rf  = 0.35 (5% 
MeOH/CH2Cl2); 1H NMR (CDCl3, 400 MHz) δ 7.30 (d, J = 15.6 Hz, 1H), 6.46 (d, J = 
11.2 Hz, 1H), 6.40 (app. t, J = 13.6 Hz, 1H), 6.15 (d, J = 15.2 Hz, 1H), 6.05 (dt, J = 13.6, 
6.4 Hz, 1H), 5.98 (br s, 1H), 3.48 (q, J = 6.0 Hz, 2H), 3.12 (t, J = 6.4 Hz, 2H), 2.22 (app. 
quint, J = 6.8 Hz, 2H), 1.97 (s, 3H), 1.87 (s, 3H), 1.06 (t, J = 7.6 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 190.5, 170.6, 146.5, 143.6, 141.6, 131.2, 125.8, 122.8, 40.3, 28.5, 
26.6, 23.4, 13.4, 12.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C14H21NO2SNa 
290.1185; found 290.1208 (Δ = 7.9 ppm). 
 
3.7 Biology Experimental Section 
 
Generation of Standard Curve 
A stock solution of the isolated triene product 3.7 (50 mM) in DMSO–H2O (1:1), was 
serial diluted with buffered (5 mM Tris, 0.5 mM NaCl, pH 8.0) MeCN–H2O (1:1) to the 
following concentrations: 1280, 640, 320 160, 80 40 and 20 nM. A small portion of each 
dilution (60 µL) was transferred to an HPLC vial containing the internal standard 4.6 (see 
Chapter 4 for structure and synthesis) (320 nM, 10 µL). Samples were briefly mixed by 
pipetting and injected onto LC-MS/MS utilizing a Kinetix reverse-phase C18 column (50 
mm x 2.1 mm, 2.6 µm, Phenomenex®) operated at 0.4 mL min-1 with a column 
temperature of 35 °C. LC–MS/MS was conducted with AB Sciex QTRAP 5500 mass 
spectrometer and Shimadzu LC system. The mobile phase A (0.1% formic acid in H2O) 
and mobile phase B (MeCN) were run at the following gradient program: 0 min, 5% B; 2 
min, 5% B; 7 min, 55% B; 8 min, 70% B; 9 min, 70% B; 10.5 min, 5% B; 12 min, 5% B, 
STOP. The monitored transitions and retention times are displayed in Table 3.1. Peak 
areas for the product and internal standard (3.7 and 4.6) were extracted via SCIEX 
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Analyst® software (Table 3.2). Area ratios (product/internal standard) were plotted in 
Microsoft Excel (Figure 3.8) 
 
Table 3.1. CurK DH substrate, product and internal standard LC-MS/MS properties. 
Analyte HPLC retention 
time (min) 
Transition 
3.5 or 3.6 6.17 308→ 142 
3.7 7.44 268→ 121 
4.6  6.80 242→ 95 
 
Table 3.2. CurK DH standard curve data. 
Conc. 3.7 
(nM) 
Transition 
(g/mol) 
Peak Area Area Ratio (3.7/4.6) 
0 268→ 121  7362.665 0.008408595 
0 242→ 95 875611.851 
 20 268→ 121  22332.363 0.025029893 
20 242→ 95 892227.710 
 40 268→ 121  31796.445 0.037390844 
40 242→ 95 850380.513 
 80 268→ 121  59521.288 0.078705923 
80 242→ 95 756249.172 
 160 268→ 121  107466.167 0.145652283 
160 242→ 95 737826.866 
 320 268→ 121  228634.211 0.300539582 
320 242→ 95 760745.754 
 640 268→ 121  425896.088 0.569489824 
640 242→ 95 747855.484 
 1280 268→ 121  730462.476 1.025132203 
1280 242→ 95 712554.414 
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Figure 3.8. Standard curve of product 3.7.  
 
Quantification of CurK DH activity 
Substrate 3.5 (0.25–6.0 mM) was incubated with recombinant CurK DH (20 nM) and 
reaction buffer (50 mM Tris, 150 mM NaCl, pH 8.0) in a total volume of 50 µL at 
ambient temperature (24 °C). The reaction was quenched at 4 min time point via transfer 
of 5 µL of the reaction mixture into 495 µL of quench solution MeCN–H2O (1:1). The 
quenched mixture was briefly vortexed and centrifuged to crash the protein. A portion of 
the resulting centrifuged solution (60 µL) was transferred to a small HPLC vial and 
combined with the internal standard (10 µL of a 320 nM solution of diene 4.6), mixed 
and injected onto LC-MS/MS. The program was identical for that of the standard curve 
(vida supra). All experiments were performed in duplicate. Transitions and retention 
times are given in Table 3.1. The amount of enzymatic product formed at each substrate 
concentration was calculated by plotting the area ratio (analyte/internal standard) into the 
standard curve (Table 3.3). Each reaction was performed in duplicate. The calculated 
initial velocity at each substrate concentration was used to generate a Michaelis-Menten 
curve utilizing GraphPad Prism software (Figure 3.7).  
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Table 3.3 LC-MS/MS data for CurK DH substrate 3.5. 
Conc. 
3.5 
(nM) 
Transition 
(g/mol) 
Peak Area Area 
Ratio 
(3.7/4.6) 
Conc. 
3.7 
(nM) 
Velocity 
(nM/min) 
×100 
(dil.) 
Velocity 
(µM/min) 
Blank 268→121 9949.448 
     Blank 242→95 23056.428 
     Blank 268→121 27593.916 
     Blank 242→95 69868.674 
     0.25 268→121 45799.656 0.0487 37.8 9.45 945.4 0.945 
0.25 242→95 940210.259 
     0.25 268→121 51390.985 0.0558 46.6 11.7 1166.1 1.166 
0.25 242→95 920671.740 
     0.50 268→121 153218.239 0.164 181.4 45.4 4535.9 4.536 
0.50 242→95 932404.409 
     0.50 268→121 88632.4536 0.0973 98.2 24.5 2455.3 2.455 
0.50 242→95 910653.094 
     1.00 268→121 154376.557 0.171 189.9 47.5 4746.6 4.747 
1.00 242→95 902209.734 
     1.00 268→121 177808.667 0.186 208.7 52.2 5217.6 5.218 
1.00 242→95 954541.380 
     2.00 268→121 359675.683 0.397 471.0 117.7 11774.6 11.775 
2.00 242→95 905047.196 
     2.00 268→121 425682.053 0.452 539.4 134.9 13485.8 13.486 
2.00 242→95 940703.784 
     3.00 268→121 587242.104 0.610 735.1 183.8 18378.3 18.378 
3.00 242→95 962612.388 
     3.00 268→121 551492.214 0.607 732.2 183.0 18304.5 18.305 
3.00 242→95 907545.802 
     6.00 268→121 1015127.87 1.03 1252. 313.0 31299.8 31.300 
6.00 242→95 989286.137 
     6.00 268→121 900205.392 0.841 1022. 255.6 25557.8 25.558 
6.00 242→95 1070107.51 
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Chapter 4: Curacin Module I and J Vinylogous Dehydration 
 
4.1 Unusual architectural features of the curacin PKS 
 
Previous analysis of the curacin gene cluster has revealed that expected dehydratases 
were missing from the PKS in modules G and I and the presence of an unpredicted and 
extraneous DH in module F (Figure 4.1).67,71 Neighboring curacin modules could 
accommodate for the missing eliminations through a process termed ‘domain stuttering’ 
(Figure 4.2).72 Stuttering entails an abnormal shuttling of the nascent polyketide chain 
directly from one ACP to the following module’s ACP. The substrate can then be 
eliminated by that modules dehydratase and is loaded onto the ketosynthase within that 
same module. Normal chain elongation and β-processing occurs within the same module 
and the polyketide continues on to form the natural product. The expression and 
structures of all four dehydratases (F, H, J and K) have been previously reported.67 The 
active site channels are surprisingly quite comparable giving few clues on the identity of 
their native substrates.  
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Figure 4.1. The curacin A biosynthetic pathway with proposed polyketide module 
intermediates. Missing dehydratase domains are shown with dotted lines in modules G 
and I. The module F dehydratase is shown highlighted in red. 
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Figure 4.2. A depiction of stuttered dehydration. The CurI domain, lacking the 
dehydratase necessary to process its formed alcohol product, shuttles the β-
hydroxythioester to CurJ’s ACP for processing by the CurJ DH. The substrate is then sent 
back to the ketosynthase in CurJ for normal Claisen reaction followed by reduction and 
elimination to give the intermediary dienoate. 
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4.2 Chemical Strategy and Rationale 
 
The stage was set for the in-vitro characterization of the atypical domain architecture of 
the curacin PKS. At the onset of the project we decided it would be most efficient to 
investigate the potential CurJ module DH substrates first as this module has a clear 
dehydratase present. Based on empirical, bioinformatic predictions on stereochemistry in 
the native substrate (4.1) the potential substrate 4.2 was designed (Figure 4.3). We also 
planned to synthesize the remaining three diastereomers (4.3, 4.4, and 4.5) to test the 
stereoselectivity of this dehydration. The trans-trans-dienoate 4.6 was also targeted to 
provide an authentic product standard. The same, proven strategy of truncation used in 
CurK (Chapter 3) was applied to the design of all CurJ substrates. Analogous work for 
CurI could determine if a stuttering mechanism was in affect based on the results for 
CurJ. 
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Figure 4.3. The predicted full length CurJ DH substrate (4.1) and designed small 
molecule substrates. The truncated region of the full-length substrate is shown 
highlighted in coral with the cryptic stereogenic centers shown. The four possible 
stereoisomers of the truncated substrate are displayed (4.2–4.5). Additionally, the 
dehydration product 4.6 is also shown. 
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4.3 Synthesis of truncated CurJ DH substrates 
 
We decided to employ a synthetic strategy based on known thiazolidinethione chiral 
auxiliary chemistry (Scheme 4.1).73,74 This strategy would allow us to obtain all the 
desired diastereomers while relying on only two chiral auxiliaries derived from L- and D-
phenylalanine. The propionyl thiazolidinethione 3.7 was submitted to anti-Evans syn-
aldol reaction with TiCl4 and 2-pentenaldehyde. The resulting aldol adduct was converted 
to the corresponding N-acetylcysteamine thioester by facile thiazolidinethione 
displacement to yield CurJ substrate analog 4.3 (Scheme 4.1, panel A). The anti-aldol 
products were synthesized utilizing a chlorotrimethylsilane-catalyzed aldol reaction 
developed by D. A. Evans and coworkers. As previously reported, the reaction provided 
the desired aldol adduct in poor yield for aldehyde substrates with a saturated γ-proton. 
Presumably under the reaction conditions the aldehyde is able to polymerize which 
outcompetes the desired aldol reaction. We were able to obtain enough of the aldol 
adduct to carry on to form the desired thioester 4.2 (Scheme 4.1, panel B). The remaining 
two diastereomers (4.4 and 4.5) were synthesized through identical procedures utilizing 
the corresponding chiral auxiliary antipode. 
 
Scheme 4.1. Synthesis of CurJ DH substates 4.2 and 4.3. 
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The predicted CurJ DH product 4.6 was synthesized through use of thioester Horner 
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Wadsworth-Emmons (HWE) reagent 4.12 (Scheme 4.2).75,76 The unique HWE reagent 
was synthesized from triethyl 2-phosphonopropionate in two steps. Due to the 
nucleofugality of the N-acetylcysteamine thioester, we chose to conduct the olefination 
under previously developed, mild reaction conditions.76,77 In the key transformation, the 
HWE enolate was preformed through use of lithium bromide and triethylamine. To the 
enolate solution at ambient temperature was added 2-pentenaldehyde in a dropwise 
fashion. After workup and purification, the CurJ product dienoate 4.6 was obtained in 
moderate yield. 
 
Scheme 4.2. Synthetic route towards CurJ DH product 4.6. 
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4.4 Comparative analysis of curacin DHs and predicted CurJ substrates 
 
With the CurJ substrates and products in hand, we were prepared to analyze the pathway 
dehydratases for possible activity. Substrates (1 mM) were incubated overnight (12 h) 
with CurF-DH, H, J, and K DHs (5 µM). The enzymatic reactions were halted upon 
addition of quench solution MeCN–H2O(1:1), centrifuged to precipitate protein and 
injected and analyzed via LC-MS/MS. The CurJ-DH substrate with stereogenic centers 
matching the bioinformatic prediction (4.2) was only eliminated in the presence of CurF-
DH or CurK-DH (Figure 4.4, panel A). The experiment highlights the syn nature of the 
elimination elimination in CurK. This result forced us to consider if the bioinformatics 
prediction, in fact, incorrectly assigned the substrate’s absolute stereochemistry. 
Surprisingly, the curacin pathway dehydratases could not eliminate any of the remaining 
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diastereomers (4.3–4.5) (Figure 4.4, panels B–D). Disheartened by the failure of CurJ to 
process any of the synthesized substrates we sought to reevaluate the curacin pathway in 
its entirety to rationalize these data. 
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Figure 4.4. LC-MS/MS analysis of predicted CurJ DH substrate activity. The four panels 
(A, B, C and D) correspond to substrates 4.2, 4.3, 4.4 and 4.5, respectively. The transition 
242→95 was used to monitor both substrate and product. The substrate peak remaining 
after 24 h incubation is shown with retention time of about 5 min. The product 4.6 has a 
retention time of 6.8 min. 
 
4.5 Vinylogous dehydration theory of anomalous elimination 
 
The failure of CurJ to process its predicted substrate necessitated a new hypothesis for 
dehydration in the curacin pathway. More specifically, the inability to process substrate 
4.2 seemed to rule out the ‘domain stuttering’ mechanism proposed in other biosynthetic 
pathways (see Figure 4.2). We observed that the modules lacking distinct DH domains 
(CurG and CurI) always have a dehydratase present in the subsequent, downstream 
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module (CurH and CurJ). Our working hypothesis was that each module lacking a DH 
processes its substrate to the β-hydroxy-intermediate (Figure 4.5). This is chain extended 
in the next module by Claisen reaction with a malonyl-unit. The substrate is β-processed 
through reduction and elimination in the normal fashion. Finally, a DH-catalyzed 
vinylogous elimination furnishes the necessary diene in the biosynthetic pathway. In 
addition to removing the awkward stuttering steps present in past proposals, this theory 
accommodates for the inactivity towards previously synthesized CurJ substrates as these 
lack the distal hydroxyl moieties from carried over from CurI. 
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Figure 4.5. Vinylogous elimination catalyzed by the CurJ module. Normal chain 
elongation occurs with reduction of the formed Claisen condensation product. Following 
canonical elimination by CurJ DH, vinylogous elimination affords the crucial diene 
intermediate for curacin biosynthesis. 
 
4.6 Chemical strategy and rationale for vinylogous elimination substrates 
 
The new vinylogous elimination hypothesis necessitated a new series of synthetic 
substrates to examine if it actually was in effect in the curacin biosynthetic pathway. We 
chose to test our proposal by two distinct compound designs. Firstly, we required 
truncated vinylogous substrates 4.13 and 4.14 to test the CurJ module dehydratase’s 
ability to catalyze the critical elimination (Figure 4.6). This would allow us to examine 
any inherent stereoselectivity in the dehydration. We also proposed to synthesize the 
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thioether substrate 4.15. This substrate would allow us to examine both proposed 
elimination events while avoiding instabilities inherent in δ-hydroxyl-α,β-saturated 
substrates which are prone to intramolecular cyclization (Scheme 4.3). Additionally, we 
hypothesized that the pendant primary alcohol of 4.15 may mimic the hydrogen bonding 
elements missing from the previous, unsuccessful CurJ substrates (4.2-4.5). 
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Figure 4.6. Designed vinylogous elimination substrates for CurJ DH. 
 
Scheme 4.3. Intramolecular cyclization of δ-hydroxyl-thioesters. 
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4.7 Synthesis of CurJ DH vinylogous elimination substrates 
 
The synthesis of 4.13 began with deprotonation of known acyl oxazolidinone 4.16 and 
trapping of the resulting enolate with tert-butyldimethylsilyl chloride (Scheme 4.4). The 
resulting N,O-silyl ketene acetal (4.17) was submitted to vinylogous Mukaiyama aldol 
reaction with propionaldehyde.30 The vinylogous aldol adduct 4.18 was saponified and 
coupled with N-acetylcysteamine to afford the D-alcohol substrate 4.13. The enantiomeric 
compound 4.14 was synthesized in an identical manner starting with the D-valine derived 
enantiomer of 4.16 (ent-4.16). 
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Scheme 4.4. The short synthesis of vinylogous dehydration substrate 4.13. 
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The synthesis of the diol substrate 4.15 commenced with known aldehyde 4.20, itself 
derived in two steps from 1,3-propanediol (Scheme 4.5).78 Acetate aldol reaction with 
Nagao’s D-valine-derived acetyl thiazolidinethione (4.21) yielded aldol adduct 4.22 and 
its diastereomer (not shown) in a ratio of 69:31 favoring the desired 4.22.32 The major 
diastereomer was submitted to thiazolidinethione displacement with methanol giving the 
known methyl ester to confirm the alcohol stereocenter (Not shown, see Chemistry 
experimental section).79,80 Facile thiazolidinethione displacement with N,O-
dimethylhydroxylamine afforded Weinreb amide 4.23. Benzylic oxidation of the para-
methoxybenzyl ether with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) served to 
protect the β-hydroxyl group. The fully protected Weinreb amide 4.24 was converted to 
the vinyl ketone 4.25 via action of vinylmagnesium bromide.34 Michael addition of N-
acetylcysteamine served to install the pantetheine-mimicking portion of the substrate. A 
final deprotection of 4.26 with Pearlman’s catalyst under an atmosphere of hydrogen 
afforded the desired diol substrate in low yields. A substantial amount of starting material 
was recovered in this reaction (~35%). Given the markedly slow reaction rate we 
rationalized that the thioether is most likely poisoning the catalyst, thereby increasing the 
reaction time and allowing for decomposition. The desired product 4.15 was obtained in 
sufficient quantities for full characterization and was found to exist in equilibrium of both 
open chain and hemi-ketal forms. 
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Scheme 4.5. The synthesis of di-dehydration substrate 4.15. 
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4.8 Comparative analysis of vinylogous elimination in the curacin pathway 
 
Having completed the synthesis of all potential substrates for vinylogous elimination we 
were poised to test for the hypothetical dehydration using recombinant curacin 
dehydratase domains. Following a similar procedure to that utilized for prior CurJ 
substrates, all substrate-enzyme combinations were tested in parallel and analyzed via 
LC-MS/MS. Similar to trends observed for canonical elimination all enzymes were 
unable to process L-alcohol substrate 4.14, but module CurH and CurJ dehydratases were 
proficient at eliminating D-alcohol 4.13, forming diene 4.6 (Figure 4.7, panels A and B). 
Although the conversion was quite low (~3%) we were encouraged by the stereoselective 
nature of the enzyme-catalyzed reaction. Moreover, the fact that moldule CurF and CurK 
DHs were unable to catalyze the reaction fit well into the theory of vinylogous 
elimination in the curacin pathway as neither of these follows a module lacking a 
dehydratase.  
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Figure 4.7. Incubation of substrates 4.13 and 4.14 with the curacin dehydratases. Panels 
A and B display the traces resulting from incubation vinylogous substrates 4.14 and 4.13, 
respectively. The loss of activity towards substrate 4.13 resulting from dyad-mutants is 
shown in panel C. Detection of the reverse reaction from diene 4.7 to form 4.13 is 
presented in Panel D. The diene was detected from the transition 242→95. The 
vinylogous substrate was detected scanning for the transition 260→141. 
 
In a similar fashion to the CurK DH we tested several potential knockout mutants of the 
CurH and CurJ dehydratases (Figure 4.7, panel C). These mutants were created by 
single-point mutation of the recombinant curacin dehydratases by our collaborator 
Gregory Dodge (Dr. Janet L. Smith lab, University of Michigan- Life Sciences Institute). 
Knockout mutations of the catalytic dyad (His and Asp residues) completely ablated 
vinylogous elimination activity. This indicates a similar mechanism between canonical 
α,β-elimination and vinylogous dehydration. 
 
Given the poor turnover of the substrate we wanted to investigate the ability of the 
enzymes to catalyze the reverse reaction. In this case, the net reaction would be hydration 
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of the diene 4.6 in across the distal, γ,δ-olefin. We incubated each enzyme overnight with 
the diene and scanned for alcohol formation using its known transition and retention time. 
Judging by the LC/MS-MS traces we could see alcohol formation with both CurK and 
CurF DHs at levels consistent with the control without enzyme (Figure 4.7, panel D). In 
contrast, incubation with CurH and CurJ dehydratases led to a significant increase in the 
amount of alcohol 4.13, consistent with enzyme-catalyzed hydration. Not unlike the 
dehydration, we only saw fractional turnover to the hydrated substrate in the reverse 
reaction. As we are unable to reach a stable equilibrium, we proposed a slow forward, 
dehydration reaction with disfavored binding of product compared to substrate. 
 
Unfortunately, we were unable to detect any product formation (mono- or di-dehydration) 
when incubating substrate 4.15 with any of the curacin dehydratase domains. We 
hypothesized two possible reasons for this result: 1) Diol 4.15, being significantly more 
polar than the native substrate, is unable to gain access to the hydrophobic substrate 
tunnel or 2) The equilibrium between hemi-ketal and open chain forms precludes 
substrate binding of the latter in the enzyme active site. Additionally, substrate 4.15 is a 
severely truncated version of the native substrate for CurH and CurJ, which may inhibit 
binding and enzyme-catalyzed dehydration. 
 
4.9 Chemistry experimental section 
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(2S,3R,E)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-3-hydroxy-2-methylhept-4-en-1-
one (4.8). To a flask containing thiazolidinethione 4.7 (0.250 g, 0.940 mmol, 1.00 equiv) 
under argon atmosphere was added CH2Cl2 (4.00 mL). The bright yellow solution was 
placed in ice-water bath (0 °C) and supplemented with TiCl4 (0.110 mL, 0.990 mmol, 
1.05 equiv). The resulting bright orange, opaque solution was stirred for 9 min. To the 
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reaction mixture was added freshly distilled iPr2NEt56 (0.183 mL, 1.05 mmol, 1.12 
equiv). The reaction was stirred at 0 °C for 40 min. To the dark red mixture was slowly 
added freshly distilled 2-pentenaldehyde56 (0.138 mL, 1.41 mmol, 1.50 equiv) causing a 
color change to dark brown. After 2 h, the reaction was halted via addition of a saturated 
NH4Cl (5.00 mL). The biphasic mixture was warmed to room temperature and the layers 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 10.0 mL) and the combined 
organic layers were dried over Na2SO4 and filtered. The filtrate was concentrated under 
reduced pressure and purified flash chromatography (20% EtOAc/hexanes). The title 
compound (0.252 g, 0.677 mmol, 72 %) was isolated as viscous, yellow oil. TLC: Rf  = 
0.20 (20% EtOAc/hexanes); [α] D
23 = –191.6 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) 
δ 7.37–7.27 (m, 5H), 5.82 (ddt, J = 15.6, 6.4, 1.2 Hz, 1H), 5.50 (ddt, J = 15.2, 6.0, 1.2 
Hz, 1H), 5.39 (ddd, J = 10.6, 6.8, 4 Hz, 1H), 4.79 (dq, J = 6.8, 3.2 Hz, 1H), 4.59–4.54 (m, 
1H), 3.37 (dd, J = 11.6, 6.8 Hz, 1H), 3.24 (dd, J = 13.2, 4.0 Hz, 1H), 3.04 (dd, J = 13.2, 
10.4 Hz, 1H), 2.88 (d, J = 11.6 Hz, 1H), 2.74 (d, J = 2.8 Hz, 1H), 2.08 (app. quint, J = 
7.2, 2H), 1.19 (d, J = 6.8 Hz, 3H), 1.01 (t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) 
δ 201.8, 177.8, 136.6, 135.0, 129.6, 129.1, 127.9, 127.4, 72.5, 69.1, 43.5, 37.1, 31.9, 25.5, 
13.6, 11.6; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C18H23NO2S2Na 372.1062, found 
372.1087 (Δ = 6.7 ppm). 
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S-(2-Acetamidoethyl) (2S,3R,E)-3-hydroxy-2-methylhept-4-enethioate (4.3). To a 
flask was added the aldol adduct 4.8 (25.2 mg, 0.0721 mmol, 1.00 equiv) and CH2Cl2 
(5.00 mL). The bright yellow solution was supplemented with N-acetylcysteamine (8.43 
µL, 0.0793 mmol, 1.10 equiv) and imidazole (14.7 mg, 0.216 mmol, 3.00 equiv). The 
reaction mixture was at ambient temperature for 21 h. The reaction mixture was 
evaporated by nitrogen stream and purified by flash chromatography (5% 
MeOH/CH2Cl2)). The title compound (16.9 mg, 0.0652 mmol, 90%) was isolated as a 
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colorless, viscous oil. TLC: Rf  = 0.20 (5% MeOH/CH2Cl2); [α] D
24  = 27.6 (c 0.87, CHCl3); 
1H NMR (CDCl3, 400 MHz) 5.79 (br s, 1H), 5.77 (ddt, J = 15.2, 6.4, 1.2 Hz, 1H), 5.44 
(ddt, J = 15.2, 6.8, 1.6 Hz, 1H), 4.37 (br s, 1H), 3.52–3.34 (m, 2H), 3.10–2.96 (m, 2H), 
2.84–2.75 (m, 1H), 2.06 (app. quint, J = 6.8 Hz, 2H), 1.96 (s, 3H), 1.22 (d, J = 6.4 Hz, 
3H), 0.99 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.6, 170.5, 135.7, 128.0, 
73.6, 54.0, 39.6, 28.7, 25.4, 23.4, 13.5, 12.0; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C12H21NO3SNa 282.1134, found 282.1136 (Δ = 0.7 ppm). 
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(2R,3R,E)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-3-hydroxy-2-methylhept-4-en-1-
one (4.9).To a flask was added MgBr2•OEt2 (14.6 mg, 0.0566 mmol, 0.100 equiv). The 
flask was charged with acyl thiazolidinethione 4.7 (0.150 g, 0.566 mmol, 1.00 equiv), 
EtOAc (1.4 mL) and freshly distilled 2-pentenaldehyde56 (60.9 µL, 0.623 mmol, 1.10 
equiv). The yellow solution was supplemented with distilled Et3N (0.158 mmol, 1.13 
mmol, 2.00 equiv) and TMSCl56 (0.108 mL, 0.849 mmol, 1.50 equiv). The reaction 
mixture was stirred under inert atmosphere at room temperature for 26 h. The reaction 
was filtered through a silica gel plug (2.00 cm), washed with Et2O (20.0 mL) and 
concentrated under reduced pressure. The crude residue was dissolved in a biphasic 
mixture of THF (10.0 mL) and aqueous HCl (1.00 N, 2.00 mL) and vigorously stirred at 
ambient temperature for 2 h. The reaction was halted via addition of aqueous NaHCO3 
(10.0 mL) and the biphasic solution was separated. The aqueous layer was extracted with 
EtOAc (3x 15.0 mL) and the combined organic fractions were dried over Na2SO4 and 
filtered. The crude residue obtained from concentration under reduced pressure was 
purified by flash chromatography (20% EtOAc/hexanes) furnishing the title compound 
(35.8 mg, 0.0962 mmol, 17% yield) as a viscous, yellow oil. TLC: Rf  = 0.28 (20% 
EtOAc/hexanes); [α] D
24 = –297.1 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.37–
7.27 (m, 5H), 5.79 (dt, J = 15.2, 5.6 Hz, 1H), 5.42 (ddt, J = 15.2, 7.2, 1.6 Hz, 1H), 5.25 
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(ddd, J = 10.8, 6.8, 3.6 Hz, 1H), 4.34 (dq, J = 7.6, 6.8 Hz, 1H), 4.26 (t, J = 7.6 Hz, 1H), 
3.39 (dd, J = 11.2, 6.8 Hz, 1H), 3.26 (dd, J = 13.2, 3.6 Hz, 1H), 3.06 (dd, J = 12.8, 10.8 
Hz, 1H), 2.90 (d, J = 11.6 Hz, 1H), 2.16 (br s, 1H), 2.06 (app. quint, J = 6.4, 2H), 1.22 (d, 
J = 6.8 Hz, 3H), 1.00 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 201.5, 178.2, 
136.7, 136.3, 129.6, 129.3, 129.0, 127.3, 76.7, 69.2, 45.2, 36.8, 32.8, 25.4, 14.9, 13.5; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C18H23NO2S2Na 372.1062, found 372.1049 
(Δ = 3.4 ppm).  
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S-(2-acetamidoethyl) (2R,3R,E)-3-hydroxy-2-methylhept-4-enethioate (4.2). To a 
flask was added the acyl thiazolidine 4.9 (31.1 mg, 0.0890 mmol, 1.00 equiv) in CH2Cl2 
(4.00 mL). The resulting bright yellow solution was supplemented with imidazole (18.2 
mg, 0.267 mmol, 3.00 equiv) and N-acetylcysteamine (10.4 µL, 0.0980 mmol, 1.10 
equiv). The reaction mixture was vigorously stirred under argon at ambient temperature 
for 21 h. The crude reaction mixture was concentrated under reduced pressure and 
purified by flash chromatography (5% MeOH/CH2Cl2). The title compound (16.8 mg, 
0.0596 mmol, 67%) was furnished as a slightly yellow, viscous oil. TLC: Rf  = 0.30 (5% 
MeOH/CH2Cl2); [α] D
24  = –34.5 (c 0.29, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 6.00 (br s, 
1H), 5.76 (dt, J = 15.6, 6.0 Hz, 1H), 5.40 (ddt, J = 15.6, 6.4, 1.2 Hz, 1H), 4.19 (t, J = 7.6 
Hz, 1H), 3.55–3.37 (m, 2H), 3.13–2.98 (m, 2H), 2.76 (app. quint, J = 7.2 Hz, 1H), 2.42 
(br s, 1H), 2.06 (app. quint, J = 7.6 Hz, 2H), 1.94 (s, 3H), 1.11 (d, J = 6.8 Hz, 3H), 1.00 
(t, J = 7.6 Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 203.6, 170.6, 136.6, 128.8, 75.5, 54.5, 
39.5, 28.7, 25.4, 23.3, 15.1, 13.5; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for 
C12H21NO3SNa 282.1134, found 282.1153 (Δ = 6.7 ppm). 
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(2S,3S,E)-1-((S)-4-Benzyl-2-thioxothiazolidin-3-yl)-3-hydroxy-2-methylhept-4-en-1-
one (ent-4.9). The desired aldol product was obtained an analogous method as the 
enantiomer, 4.9, affording the title compound (10%) as a viscous yellow oil. [α] D
24  = 
302.6 (c 1.00, CHCl3). The title compound was identical to its enantiomer, 4.9, in all 
remaining aspects.  
 
NACS
O
Me
Me
OH
 
S-(2-Acetamidoethyl) (2S,3S,E)-3-hydroxy-2-methylhept-4-enethioate (4.4). The 
thioester 4.4 was synthesized in an analogous manner to that of the prior thioester 4.2 
furnishing the title compound as a colorless oil (42%). [α] D
24  = 37.3 (c 0.35, CHCl3). 4.4  
was found to be identical to its enantiomer (4.2) in all remaining aspects. 
 
N
O
S
S
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(2R,3S,E)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3-hydroxy-2-methylhept-4-en-1-
one (ent-4.8). The desired aldol product was obtained an analogous method as the 
enantiomer, 4.8. The alcohol was a viscous, yellow oil (78%). [α] D
23  = 199.3 (c 1.00, 
CHCl3). The compound matched its enantiomer, 4.8, in all remaining aspects. 
 
The total yield was 86% from the 91:6:3 mixture of diastereomers. 
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S-(2-Acetamidoethyl) (2R,3S,E)-3-hydroxy-2-methylhept-4-enethioate (4.5). The 
thioester 4.5 was synthesized in an analogous manner to that of the thioester 4.3 yielding 
a colorless oil (63%). [α] = –24.1 (c 0.58, CHCl3). The compound matched its 
enantiomer (4.3) in all other aspects. 
 
O
P
O
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S-(2-Acetamidoethyl) 2-(diethoxyphosphoryl)propanethioate (4.12). A flask 
containing triethyl 2-phosphonopropionate 4.10 (1.00 mL, 4.66 mmol, 1.00 equiv) in 
H2O (2.00 mL) was cooled via ice water bath (0 °C). To the chilled mixture was slowly 
added a cooled (4 °C), aqueous NaOH solution (10.0 N, 0.490 ml, 4.90 mmol, 1.05 
equiv). The reaction mixture was allowed to slowly warm to room temperature and 
stirred for 20 h. The reaction was quenched upon addition of aqueous HCl (1.00 M) until 
the pH was 1.00. The resulting solution was saturated with NaCl and extracted with 
CH2Cl2 (4 × 10.0 mL). The combined organic layers were dried over Na2SO4, filtered and 
the solvent removed under reduced pressure. The crude residue was dissolved in CH2Cl2 
(40.0 mL) and cooled by placing in an ice water bath (0 °C). To the chilled solution was 
added DMAP (57.0 mg, 0.467 mmol, 0.100 equiv) and DCC (1.01 g, 4.89 mmol, 1.05 
equiv) and the solution was stirred for 2 min. N-acetylcysteamine (0.644 mL, 6.06 mmol, 
1.30 equiv) was added to the reaction mixture. The resulting solution was allowed to 
warm to ambient temperature and stirred 22 h. The reaction mixture was supplemented 
with Et2O (40.0 mL) and filtered to remove the urea precipitate. The filtrate was 
concentrated under reduced pressure and the resulting crude residue was purified by flash 
chromatography (100% EtOAc) affording the title compound (1.36 g, 4.37 mmol, 94%) 
as a clear colorless oil. TLC: Rf  = 0.15 (100% EtOAc); 1H NMR (CDCl3, 400 MHz) δ 
6.30 (br s, 1H), 4.21–4.09 (m, 4H), 3.54–3.37 (m, 2H), 3.29 (dq, J = 22.4, 7.2 Hz, 1H), 
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3.20–3.12 (m, 1H), 3.04–2.95 (m, 1H), 1.96 (s, 3H), 1.45 (dd, J = 18.0, 7.2 Hz, 3H), 1.34 
(t, J = 7.2 Hz, 6H); 13C NMR (CDCl3, 100 MHz) δ 196.1, 196.0, 170.6, 63.34, 63.27, 
63.0, 62.9, 49.2, 47.9, 39.2, 29.4, 23.2, 16.54, 16.48, 12.51, 12.45; HRMS (ESI-TOF) 
m/z: [M + Na]+ Calcd for C11H22NO5PSNa 334.0849, found 334.0847 (Δ = 0.6 ppm). 
 
O
NACS
Me
Me
 
S-(2-Acetamidoethyl) (2E,4E)-2-methylhepta-2,4-dienethioate (4.6). To a flask 
containing LiBr (0.132 g, 1.52 mmol, 3.16 equiv) was added THF (6.00 mL). To the 
resulting solution was added the phosphono-thioester 4.12 (0.150 g, 0.482 mmol, 1.00 
equiv). The solution was stirred vigorously at ambient temperature for 10 min. To the 
reaction mixture was Et3N (0.212 mL, 1.52 mmol, 3.16 equiv) resulting in the formation 
of a cloudy, colorless solution that was stirred at ambient temperature for 15 min. To the 
reaction vessel was added freshly distilled 2-pentenaldehyde56 (99.0 µL, 1.02 mmol, 2.11 
equiv) in a dropwise fashion. After stirring for 24 h, the reaction mixture was quenched 
upon addition of H2O (30.0 mL). The biphasic solution was separated and the aqueous 
layer was repeatedly extracted with EtOAc (4 × 10.0 mL). The combined organic 
fractions were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
crude product residue was purified by flash chromatography (50% EtOAc/hexanes) 
yielding the title compound (49.5 mg, 0.205 mmol, 43%) as a cloudy oil. TLC: Rf  = 0.30 
(5% MeOH/CH2Cl2); 1H NMR (CDCl3, 400 MHz) δ 7.17 (d, J = 10.8 Hz, 1H), 6.35 (dd, 
J = 14.8, 11.2 Hz, 1H), 6.22 (dt, J = 5.6, 15.2 Hz, 1H), 6.01 (br s, 1H), 3.52–340 (m, 2H), 
3.15–3.03 (m, 2H), 2.30–2.16 (m, 2H), 1.97 (s, 6H), 1.07 (t, J = 6.8 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz) δ 193.9, 170.8, 146.9, 138.5, 132.6, 124.8, 40.2, 28.5, 26.7, 23.4, 
13.2, 12.7; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C12H19NO2SNa 264.1029; Found 
264.1043 (Δ = 5.3 ppm). 
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(S)-3-((R,E)-5-Hydroxy-2-methylhept-2-enoyl)-4-isopropyloxazolidin-2-one (4.18). A 
flask containing CH2Cl2 (15.0 mL) was supplemented with freshly distilled 
propionaldehyde56 (0.443 mL, 6.14 mmol, 2.00 equiv) and cooled by dry ice–acetone 
bath (-78 °C). To the reaction mixture was added TiCl4 (0.338 mL, 3.07 mmol, 1.00 
equiv). To the resulting yellow reaction mixture was slowly added the N,O-silyl ketene 
acetal 4.1781 (1.00 g, 3.07 mmol, 1.00 equiv) as a solution in CH2Cl2 (14.6 mL). The 
reaction mixture was transferred to a dry ice–MeCN bath (-40 °C) and stirred for 7 h. The 
reaction was halted via sequential addition of a saturated aqueous potassium sodium 
tartrate (10.0 mL) and a saturated, aqueous NaHCO3 (10.0 mL). The resulting cloudy 
mixture was vigorously stirred at room temperature for 1 h. The biphasic solution was 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 20.0 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. 
The crude product residue was purified by flash chromatography (30% EtOAc/hexanes) 
affording the title compound (0.673 g, 2.49 mmol, 81%) as an white amorphous solid.  
TLC: Rf  = 0.20 (30% EtOAc/hexanes); [α] D
24 = 46.0 (c 1.00, CHCl3); 1H NMR (CDCl3, 
400 MHz) δ 6.03 (t, J = 7.6 Hz, 1H), 4.56 (dt, J = 8.8, 4.8 Hz, 1H), 4.33 (t, J = 8.8 Hz, 
1H), 4.9 (dd, J = 8.8, 5.2 Hz, 1H), 3.70–3.60 (m, 1H), 2.53 (br s, 1H), 2.43–2.26 (m, 3H), 
1.94 (s, 3H), 1.65–1.47 (m, 2H), 0.98 (t, J = 7.6 Hz, 3H), 0.92 (t, J = 6.8 Hz, 6H); 13C 
NMR (CDCl3, 100 MHz) δ 171.7, 154.4, 135.4, 133.2, 72.2, 63.6, 58.3, 36.5, 29.9, 28.5, 
18.0, 15.3, 13.9, 10.4, 7.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C14H23NO4Na 
292.1519, found 292.1529 (Δ = 3.4 ppm). 
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S-(2-Acetamidoethyl) (R,E)-5-hydroxy-2-methylhept-2-enethioate (4.13). To a flask 
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was added the imide 4.18 (0.190 g, 0.707 mmol, 1.00 equiv). The solid was dissolved in a 
THF–H2O (2:1, 6.43 mL) solution and vigorously stirred in ice–water bath (0 °C). To the 
chilled reaction mixture was added H2O2 (30% in water, 0.219 mL, 1.93 mmol, 3.00 
equiv) followed by LiOH•1H2O (80.9 mg, 1.93 mmol, 3.00 equiv). The reaction mixture 
was vigorously stirred overnight, slowly warming to ambient temperature. After 24 h, an 
additional aliquot of H2O2 (80.0 µL, 0.707 mmol, 1.00 equiv) and LiOH•1H2O (29.7 mg, 
0.707 mmol, 1.00 equiv) were added to the reaction mixture at 0 °C. The reaction mixture 
was allowed to warm to ambient temperature over 36 h. The crude solution was 
concentrated under reduced pressure, removing all ethereal solvents. The resulting 
aqueous solution was supplemented with aqueous saturated NaHCO3 (1.00 mL) and 
washed with Et2O (2 × 10.0 mL). The aqueous fraction was acidified with aqueous HCl 
(2 M) to pH 2 and extracted with Et2O (4 × 10.0 mL). The combined organics were 
concentrated to dryness under reduced pressure and the crude colorless oil (0.112 g) was 
submitted directly to the next reaction.  
 
To a flask containing a portion of the crude acid 4.19 (82.2 mg, 0.520 mmol, 1.00 equiv) 
was added anhydrous DMF (2.73 mL). The reaction flask was cooled via ice–water bath 
(0 °C) and allowed to dissolve with stirring. To the chilled solution was sequentially 
added DPPA (0.168 mL, 0.780 mmol, 1.50 equiv) and Et3N (145 µL, 1.04 mmol, 2.00 
equiv). The reaction mixture was stirred at 0°C for 2 h. An aliquot of N-acetylcysteamine 
(55.3 µL, 0.520 mmol, 1.00 equiv) was added to the reaction mixture at 0°C. The slightly 
yellow solution was allowed to gradually warm to ambient temperature and stirred 5 h 30 
min. The reaction mixture was quenched upon addition of H2O (3.00 mL) and EtOAc 
(10.0 mL) and the biphasic solution was separated. The aqueous layer was extracted with 
EtOAc (4 × 10.0 mL). The combined organic fractions were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude product residue was purified via 
flash chromatography (5–10% MeOH/CH2Cl2) yielding the title compound (92.6 mg, 
0.357 mmol, 69% over 2 steps) as a clear, colorless oil. TLC: Rf  = 0.20 (5% 
MeOH/CH2Cl2); [α] D
24 = –15.3 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 6.86 (t, J 
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= 7.2 Hz, 1H), 5.87 (br s, 1H), 3.78–3.69 (m, 1H), 3.45 (q, J = 6.0 Hz, 2H), 3.07 (t, J = 
6.4 Hz, 2H), 2.47–2.32 (m, 2H), 1.97 (s, 3H), 1.91 (s, 3H), 1.60–1.46 (m, 2H), 0.98 (t, J = 
7.2, 3H); 13C NMR (CDCl3, 100 MHz) δ 194.0, 170.4, 138.0, 137.8, 72,5, 39.9, 36.4, 
30.3, 28.7, 23.4, 12.9, 10.0; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C12H21NO3SNa 
282.1134, found 282.1136 (Δ = 0.7 ppm). 
 
The above compound matches that synthesized by another alternative and previously 
reported route in all respects.82 
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(R)-3-((S,E)-5-Hydroxy-2-methylhept-2-enoyl)-4-isopropyloxazolidin-2-one (ent-
4.18). The target alcohol was synthesized from N, O-vinyl ketene acetal ent-4.17 via an 
analogous route to that of the enantiomer, 4.18. The tile compound was produced as a 
clear, colorless oil (88%). [α] D
24 = –44.5 (c 1.00, CHCl3). Additional properties matched 
those of the enantiomer 4.18. 
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S-(2-Acetamidoethyl) (S,E)-5-hydroxy-2-methylhept-2-enethioate (4.14). The 
thioenoate substrate 4.14 was synthesized in an analogous route to that of the enantiomer 
4.13 starting from acyl oxazolidinone ent-4.18. The title compound was afforded as a 
clear, colorless oil (69% over 2 steps). [α] D
24 = 14.0 (c 1.00, CHCl3). All other properties 
matched those of the enantiomer, compound 4.14. 
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(R)-3-Hydroxy-1-((R)-4-isopropyl-2-thioxothiazolidin-3-yl)-5-((4-methoxybenzyl)-
oxy)pentan-1-one (4.22). To a flask (50 mL) containing thiazolinethione 4.21 (0.504 g, 
2.48 mmol, 1.50 equiv) was added CH2Cl2 (12.4 mL). The resulting bright yellow 
solution was placed in a dry ice–MeCN bath (-40 °C). To the chilled solution was slowly 
added TiCl4 (0.289 mL, 2.64 mmol, 1.60 equiv).  The resulting red-orange solution was 
stirred at -40 °C for 27 min. To the reaction mixture was added iPr2NEt (0.460 mL, 2.64 
mmol, 1.60 equiv), resulting in a sudden color change to blood red. The reaction mixture 
was stirred for 1 h 20 min then cooled via dry ice–acetone bath (-78 °C). To the chilled 
solution was added the aldehyde 4.2078 (0.320 g, 1.65 mmol, 1.00 equiv) in CH2Cl2 (2.10 
mL) slowly over 5 min. The reaction mixture was stirred for 4 h 40 min at -78 °C prior to 
quenching with a saturated aqueous NH4Cl solution (8.00 mL). The biphasic solution was 
warmed to ambient temperature and the layers were separated. The aqueous was 
extracted with CH2Cl2 (3 × 15.0 mL). The combined organics were dried over Na2SO4 
and concentrated under reduced pressure. The crude product residue was purified by 
silica gel flash chromatography (30% EtOAc/hexanes) furnishing the title compound 
(0.353 g, 0.889 mmol, 54%) as a yellow oil. TLC: Rf  = 0.19 (30% EtOAc/hexanes); 
[α] D
24 = –253.0 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.25 (d, J = 8.8 Hz, 2H), 
6.87 (d, J = 8.8 Hz, 2H), 5.15 (t, J = 7.2 Hz, 1H), 4.45 (s, 2H), 4.40–4.31 (m, 1H), 3.80 
(s, 3H), 3.70–3.69 (m, 2H), 3.54 (dd, J = 13.6, 2.8 Hz, 1H), 3.51–3.47 (m, 1H), 3.28 (dd, 
J = 17.6, 8.8 Hz, 1H), 3.01 (d, J = 10.8 Hz, 1H), 2.36 (app. sext, J = 6.8 Hz, 1H), 1.88–
1.80 (m, 2H), 1.06 (d, J = 6.8 Hz, 3H), 0.97 (d, J = 7.2, 3H); 13C NMR (CDCl3, 100 
MHz) δ 203.1, 172.8, 159.4, 130.3, 129.5, 114.0, 73.1, 71.6, 67.8, 67.0, 55.4, 45.6, 36.1, 
31.0, 30.8, 19.2, 18.0; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C19H27NO4S2Na 
420.1274, found 420.1253 (Δ = 5.0 ppm). 
 
The diastereomer was also recovered as a bright yellow oil (0.156 g, 0.365 mmol, 22%). 
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Methyl (R)-3-hydroxy-5-((4-methoxybenzyl)oxy)pentanoate (4.27). To a small glass 
containing the aldol product 4.22 (45.7 mg, 0.115 mmol, 1.00 equiv) at 0 °C (ice–water 
bath) was added MeOH (2.00 mL). To the resulting, bright yellow solution was added 
K2CO3 (5.00 mg, 0.0362 mmol, 0.315 equiv) in one portion. The resulting mixture was 
allowed to warm to ambient temperature with vigorous stirring for 21 h. The reaction 
mixture was supplemented with H2O (10.0 mL) and Et2O (10.0 mL). The resulting 
biphasic solution was separated and the aqueous layer was extracted with Et2O (3 × 10.0 
mL). The combined organic fractions were dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude oil was purified by flash column chromatography 
(40% EtOAc/hexanes) and the title compound (30.8 mg, 0.115 mmol, quant.) was 
isolated as a clear, colorless oil (30.8 mg, 0.115 mmol, quant.). TLC: Rf  = 0.25 (40% 
EtOAc/hexanes); [α] D
24 = –12.8 (c 1.00, CHCl3) (literature = [α] D
24 = –20.9 (c 3.10, 
CHCl3))80; 1H NMR (CDCl3, 400 MHz) δ 7.24 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 
2H), 4.44 (s, 2H), 4.23 (app. quin, J = 6.4 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.68–3.58 
(m, 2H), 2.49 (d, J = 6.4 Hz, 2H), 1.84–1.72 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 
172.9, 159.4, 130.2, 129.4, 114.0, 73.0, 67.8, 67.3, 55.4, 51.8, 41.5, 36.1; HRMS (ESI-
TOF) m/z: [M + Na]+ Calcd for C14H20O20Na 291.1203, found 291.1200 (Δ = 1.0 ppm). 
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(R)-3-Hydroxy-N-methoxy-5-((4-methoxybenzyl)oxy)-N-methylpentanamide (4.24). 
To a flask containing acyl thiazolidinethione (0.255 g, 0.641 mmol, 1.00 equiv) under 
argon atmosphere was added CH2Cl2 (4.00 mL). The resulting bright yellow solution was 
supplemented with HN(OMe)Me•HCl (0.188 mg, 1.92 mmol, 3.00 equiv) and imidazole 
(0.231 g, 0.385 mmol, 6.00 equiv). The reaction mixture was stirred at ambient 
temperature for 42 h. The reaction was halted upon addition of saturated aqueous NH4Cl 
(2.00 mL). The biphasic solution was separated and the aqueous layer was extracted with 
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EtOAc (3 × 15.0 mL). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude reaction residue was purified via 
silica flash column (100% EtOAc) yielding the title compound (0.178 g, 0.601 mmol, 
94%) as a colorless, clear. TLC: Rf  = 0.17 (50% EtOAc/hexanes); [α] D
24 = –22.5 (c 1.00, 
CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.25 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 Hz, 2H), 
4.44 (s, 2H), 4.27–4.18 (m, 1H), 3.79 (s, 3H), 3.70–3.58 (m, 5H), 3.18 (s, 3H) 2.69–2.50 
(m, 2H), 1.88–1.74 (m, 2H); 13C NMR (CDCl3, 100 MHz) δ 173.6, 159.3, 130.5, 129.4, 
113.9, 73.0, 67.6, 66.6, 61.4, 55.4, 38.6, 36.5, 32.0; HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C15H23NO5Na 320.1468, found 320.1481 (Δ = 4.1 ppm). 
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N-Methoxy-2-((4R)-2-(4-methoxyphenyl)-1,3-dioxan-4-yl)-N-methylacetamide 
(4.24). To a flask containing the weinreb amide 4.23 (0.131 g, 0.440 mmol, 1.00 equiv) 
in CH2Cl2 (4.00 mL) at -10 °C (NaCl–ice bath) was added activated molecular sieves (4 
Å, ~0.100 g). The reaction was stirred for 30 min. To the chilled solution was added 
DDQ (0.120 g, 0.529 mmol, 1.20 equiv) in one portion. The resulting dark green solution 
was allowed to warm to 4 °C (cold room) and stirred for 2h 10 min. The reaction was 
quenched via filtration through a short pad of celite (2.00 cm). The pad was rinsed with 
CH2Cl2 (25.0 mL). The filtrate was washed sequentially with saturated NaHCO3 (2 × 
15.0 mL) and brine (20.0 mL). The resulting organic solution was dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude residue was purified by flash 
chromatography (50–100% EtOAc/hexanes) affording the title compound (0.101 g, 0.342 
mmol, 78% (85% BRSM)) as a colorless oil. TLC: Rf  = 0.23 (50% EtOAc/hexanes); 
[α] D
24 = 5.9 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.38 (dd, J = 8.4, 2.0 Hz, 2H), 
6.85 (dd, J = 8.4, 2.0 Hz, 2H), 5.50 (s, 1H), 4.43–4.33 (m, 1H), 4.27–4.19 (m, 1H), 3.98 
(tt, J = 12.0, 2.0 Hz, 1H), 3.77 (s, 3H), 3.66 (s, 3H), 3.18 (s, 3H), 3.03–2.88 (m, 1H), 2.54 
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(dd, J = 16.0, 6.0 Hz, 1H), 1.83 (dq, J = 12.4, 4.8 Hz, 1H), 1.73–1.65 (m, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 171.5, 159.9, 131.3, 127.4, 113.6, 101.3, 73.9, 66.9, 61.5, 55.3, 
38.4, 32.1, 31.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H21NO5Na 318.1312, 
found 318.1308 (Δ = 1.3 ppm). 
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1-((4R)-2-(4-Methoxyphenyl)-1,3-dioxan-4-yl)but-3-en-2-one (4.25). To a flask 
containing the weinreb amide 4.24 (50.0 mg, 0.169 mmol, 1.00 equiv) was added THF 
(10.0 mL). After allowing the solution to dissolve, the clear mixture was cooled to 0 °C 
(ice–water bath). To the chilled solution was slowly added a THF solution (1.0 M) of 
vinylmagnesium bromide (0.508 mL, 0.508 mmol, 3.00 equiv). The reaction mixture was 
stirred for 4.5 h at 0 °C. An additional amount of vinylmagnesium bromide (84.7 µL, 
0.0847 mmol, 0.500 equiv) was added to the reaction. After stirring for an additional 40 
min, the reaction was quenched upon addition of a saturated aqueous NH4Cl (10.0 mL). 
The biphasic solution was allowed to warm to ambient temperature and the layers were 
separated. The aqueous layer was extracted with EtOAc (4 × 20.0 mL) and the combined 
organics were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
resulting crude residue was purified by silica column chromatography (30% 
EtOAc/hexanes) yielding the title compound (34.6 mg, 0.132 mmol, 78%) as a clear, 
colorless oil. TLC: Rf  = 0.36 (30% EtOAc/hexanes); [α] D
24 = –16.0 (c 1.00, CHCl3); 1H 
NMR (CDCl3, 400 MHz) δ 7.38 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 6.38 (dd, J 
= 18.0, 10.8 Hz, 1H), 6.25 (d, J = 17.6 Hz, 1H), 5.88 (d, J = 10.4 Hz, 1H), 5.50 (s, 1H), 
4.44–4.35 (m, 1H), 4.25 (dd, J = 11.6, 4.8 Hz, 1H), 3.99 (dt, J = 12.0, 2.4 Hz, 1H), 3.79 
(s, 3H), 3.09 (dd, J = 16.4, 6.4 Hz, 1H), 2.73 (dd, J = 16.4, 6.4 Hz, 1H), 1.81 (ddd, J = 
25.2, 12.8, 4.8 Hz, 1H), 1.66 (dq, J = 12.8, 2 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 
198.3, 160.0, 137.1, 131.2, 129.1, 127.4, 113.7, 101.3, 73.4, 66.9, 55.4, 45.6, 31.4; 
HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C15H18O4Na 285.1097, found 285.1095 (Δ = 
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0.7 ppm). 
 
O OO
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N-(2-((4-((4R)-2-(4-Methoxyphenyl)-1,3-dioxan-4-yl)-3-oxobutyl)thio)ethyl)acet-
amide (4.26). To a flask (100 mL) containing the vinyl ketone 4.25 (65.7 mg, 0.251 
mmol, 1.00 equiv) was added THF (20.0 mL). To the clear solution was added cesium 
Cs2CO3 (~ 5 mg, catalytic) and N-acetylcysteamine (32.0 µL, 0.301 mmol, 1.20 equiv). 
The resulting solution was stirred at ambient temperature for 2 h 35 min. The reaction 
was halted upon addition of saturated, aqueous NH4Cl solution (15.0 mL). The biphasic 
mixture was separated and the aqueous layer was extracted with EtOAc (4 × 15.0 mL). 
The combined organics were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude thioether was purified by flash chromatography (5% MeOH/CH2Cl2) 
affording the title compound (70.0 mg, 0.184 mmol, 73%) as a clear, viscous oil. TLC: Rf  
= 0.31 (5% MeOH/CH2Cl2); [α] D
24 = –15.4 (c 1.00, CHCl3); 1H NMR (CDCl3, 400 MHz) 
δ 7.37 (dd, J = 6.4, 2.0 Hz, 2H), 6.87 (dd, J = 6.8, 2.0 Hz, 2H), 5.96 (br s, 1H), 5.48 (s, 
1H), 4.38–4.30 (m, 1H), 4.24 (dd, J = 11.6, 4.4 Hz, 1H), 3.97 (dt, J = 12.0, 2.8 Hz, 1H), 
3.79 (s, 3H), 3.39 (q, J = 6.4 Hz, 2H), 2.85 (dd, J = 16.0, 7.6 Hz, 1H), 2.80–2.71 (m, 4H), 
2.61 (t, J = 6.4 Hz, 2H), 2.56 (dd, J = 15.6, 4.8 Hz, 1H), 1.97 (s, 3H), 1.81 (ddd, J = 24.2, 
12.8, 5.2 Hz, 1H), 1.59 (d, J =14.0 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 206.9, 170.3, 
160.1, 131.0, 127.4, 113.7, 101.3, 73.5, 66.9, 55.4, 49.1, 44.0, 38.5, 32.3, 31.2, 25.2, 
23.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C19H27NO5SNa 404.1502, found 
404.1491 (Δ = 2.7 ppm). 
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(R)-N-(2-((5,7-Dihydroxy-3-oxoheptyl)thio)ethyl)acetamide (4.15). To a flask 
containing the acetal 4.25 (17.5 mg, 0.0459 mmol, 1.00 equiv) and iPrOH (6.00 mL) was 
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added Pd(OH)2 (20% w/w, wet) (19.0 mg). The black solution was purged with hydrogen 
atmosphere and stirred for 26 h at ambient temperature. The reaction was filtered through 
a pad of Celite® (2.00 cm). The filtrate was concentrated under reduced pressure. The 
crude residue was purified by flash chromatography (5–10% MeOH/CH2Cl2) furnishing 
the title compound (4.10 mg, 0.0156 mmol, 34%, 52% BRSM) as a clear oil. TLC: Rf  = 
0.26 (10% MeOH/CH2Cl2); [α] D
24 = -11.0 (c 0.27, CHCl3); (the compound exists in linear 
and cyclic forms. Peaks listed are for the major isomer only) 1H NMR (CDCl3, 400 MHz) 
δ 5.97 (br s, 1H), 4.39–4.30 (m, 1H), 4.25 (t, J = 12.4 Hz, 1H), 3.87–3.81 (m, 1H), 3.44 
(q, J = 6.8 H, 2H), 2.79 (s, 2H), 2.73–2.63 (m, 4H), 2.00 (s, 3H), 1.94–1.82 (m, 2H), 
1.76–1.58 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 209.7, 170.5, 67.8, 61.2, 49.9, 43.4, 
38.7, 38.0, 32.1, 25.2, 23.4; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C11H21NO4SNa 
286.1083, found 289.1105 (Δ = 7.7 ppm). 
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4.10 Biology Experimental Section 
 
Recombinant protein was expressed and purified as previously reported for the curacin 
dehydratases.67 The dehydratases (5 µM) were incubated with substrate (1 mM) in a 100 
µL of Tris buffer (50 mM Tris, 150 mM NaCl, pH 8.0) at ambient temperature for 12 h. 
A small aliquot of the reaction mixture (5 µL) was added to a MeCN–H2O (1:1, 495 µL) 
quench solution and briefly vortexed to mix. The solution was centrifuged and a small 
portion (60 µL) was added to an HPLC vial. The solution was injected and analyzed by 
LC-MS/MS as discussed in Chapter 3. The monitored transitions and retention times are 
given in Table 4.1. The LC-MS/MS traces were extracted with SCIEX Analyst® software 
and were input into GraphPad Prism software to generate Figures 4.4 and 4.7 
 
 
Table 4.1. LC-MS/MS data for 4.2–4.6, 4.13 and 4.14. 
Analyte HPLC retention 
time (min) 
Transition 
4.6 6.80 242→95 
4.2 or 4.5 5.52 242→95 
4.3 or 4.4 5.24 242→95 
4.13 or 4.14 5.11 260→141 
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Chapter 5: Curacin Module G dehydratase substrates 
 
5.1 Formation of the cis-alkene within curacin biosynthetic pathway 
 
The cis olefin-generation in curacin biosynthesis remains the last unexplained 
transformation in the biosynthetic pathway. Undoubtedly there is a polyketide chain 
elongation event in module G following the CurF NRPS module. This results in a β-
ketothioester intermediate, which is the substrate for the CurG ketoreductase (Figure 
5.1). Bioinformatic prediction categorizes this ketoreductase as A-type, capable of 
forming an L-alcohol. This is a tentative assignment of stereochemistry as the absolute 
configuration is rendered cryptic by dehydration. However, this prediction matches well 
with the hypothesis that only substrates of L-orientation seem to form cis-double bonds, 
while D-alcohols form trans-alkenes in polyketides.17 Although this mnemonic seems to 
hold true for many PKSs, it remains empirical, as cis-olefin generation by a dehydratase 
has never been observed in-vitro. Further complicating matters is the absence of a 
dehydratase in the CurG module. It has been proposed that either CurF or CurH, the 
abutting modules in the biosynthetic pathway, house the dehydratase that catalyzes this 
elimination, forming the α,β-unsaturated intermediate. Presumably this occurs via a 
‘domain stuttering’ mechanism as put forth for similar cases in other pathways (See 
Chapter 4). 
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Figure 5.1. The actions of the CurF-CurG di-module from the curacin pathway. The key 
biosynthetic chain intermediates are shown attached to their respective ACP domains. 
The product of the ketoreductase is predicted to be an L-alcohol, but it is rendered cryptic 
by elimination in the pathway. The DH domain predicted for CurG was found to be 
nonexistent and is shown as a colorless circle with a dotted line. An unknown 
dehydratase, postulated to be in either CurF or CurH modules, generates the cis-olefin 
present in the ultimate CurG module product. 
 
5.2 Chemical strategy and rationale 
 
We wanted to interrogate the pathway for the identity of the CurG dehydratase. This 
would allow us to conduct the first in-vitro characterization of a cis-olefin-generating 
dehydratase. Our strategy in this regard was to synthesize analogs of the native CurG 
dehydratase substrate (5.1) for incubation with the CurF, H, J and K DHs (Figure 5.2). 
The products would be detected based on their parent mass and fragmented to verify their 
molecular identity. Further verification of the gross structure and olefin geometry could 
be determined through synthesis of the products after initial detection of enzymatic 
dehydration. The substrates 5.2 and 5.2 represent molecularly simplified substrates in two 
aspects. Firstly, we adopted N-acetylcysteamine thioesters as surrogates for the 
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phosphopantetheine-ACP thioester in the natural product. This was analogous to previous 
studies (i.e. Chapters 2, 3, and 4) giving us a reasonable degree of confidence that these 
small molecules could serve as substrates. The second simplification was the deletion of 
the pendant methyl substituent. This subtle change would eliminate two stereogenic 
centers in the substrates and, in so doing, greatly abridge their synthesis. We anticipated 
that the enzyme would tolerate this alteration, as no hydrogen bonds would be modified 
in the process. Moreover, our established LC-MS/MS detection method would allow us 
to perceive even small amounts of substrate production in the event of poor enzyme 
catalysis. 
ACP 
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Figure 5.2. Design of synthetic CurG dehydratase product and substrate. The native 
substrate for CurG dehydration (5.1) is shown with green highlighting the basis for small 
molecule substrates. Substrates 5.2 and 5.3 were designed by simplifying the 
phosphopantethine arm as well as eliminating the pendant methyl group. The product 5.4 
would be synthesized in the event of positive LC-MS/MS results to corroborate product 
formation. 
 
5.3 Synthesis and activity of the putative CurG dehydratase substrate 
 
The retrosynthesis of the proposed CurG DH substrates is shown in Scheme 5.1. A late-
stage aldol reaction between either a simple ester or acylated chiral auxiliary enolate and 
key aldehyde 5.5 would efficiently create a key carbon-carbon bond and install one of the 
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two stereogenic centers in the substrate. The resulting aldol product could undergo 
straightforward hydrolysis and thioester bond formation to give the desired product. We 
envisioned aldehyde 5.5 The thiazoline can be obtained from the commercially available 
L-cysteine methyl ester hydrochloride and the known amide 5.783. This step relies on 
cyclization chemistry developed by Charette and coworkers. 84 The resulting ester could 
be reduced to the aldehyde 5.5. 
 
Scheme 5.1. Retrosynthetic analysis of CurG DH substrates 5.2/5.3. 		
 
In the forward sense, the cyclopropane carboxylic acid was converted to cyclopropyl 
amide 5.7 through a two-step, one-pot procedure involving exposure to thionyl chloride 
and reaction of the acid chloride with excess benzylamine (Scheme 5.2). Conveniently, 
the cyclopropyl carboxamide could be readily recrystallized from a mixture of ethyl 
acetate–hexane, avoiding the need for column chromatography. Tf2O-promoted 
thiazoline cyclization afforded the desired heterocycle 5.10 in modest yield, similar to 
that previously reported.84 With ester 5.10 in hand we wanted to investigate partial 
reduction to key aldehyde 5.5. Unfortunately, reductions with both LiAlH4 and DIBAL-H 
resulted in complex product mixtures that seemed to lack the thiazoline unsaturation. 
Presumably, the thiazoline has a comparable reduction potential to that of the methyl 
ester. In line with a similar, previous report, complete reduction with zinc borohydride 
produced the alcohol 5.11.85 Attempted Swern or DMP oxidations of 5.11 failed to 
produce the desired aldehyde. The complex product mixtures exhibited higher UV 
absorbance on TLC and extraneous aromatic peaks in 1H-NMR, indicative of over 
oxidation to the thiazoline. Aldehydes similar to 5.5 have been a targeted intermediate by 
several labs but still remain unobtainable by all reports in the literature.85-87 
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Scheme 5.2. Failed synthesis of key aldehyde 5.5. 
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Disappointed by failed attempts to obtain the crucial aldehyde 5.5, we sought an 
alternative strategy to avoid this intermediate entirely. Due to the nature of polyketide 
ketosynthase domains, we rationalized that ester 5.10 (or a similar, activated compound) 
might be a willing partner in a Claisen condensation (Scheme 5.3). The β-ketoester 
resulting could be reduced under mild conditions to afford the β-hydroxyester 
intermediate, itself just two standard transformations away from the desired DH substrate 
5.2 or 5.3. Concerned by potential instability of the thiazoline to harsh enolate-forming 
conditions, we elected to utilize Masamune’s mild decarboxylative Claisen reaction.88 
The methyl ester 5.10 was saponified with lithium hydroxide. Surprisingly, we were 
unable to isolate the desired acid after aqueous hydrochloric acid workup. We 
hypothesized that the thiazoline is susceptible to hydrolysis under conditions necessary 
for carboxylic acid protonation. We were able to isolate the lithium carboxylate (5.12) in 
modest yields after quenching the reaction mixture with acetone and collection of the 
white precipitate via filtration. The necessary acyl imidazole species  (5.13) was obtained 
in-situ through reaction with CDI and the imidazole hydrochloride. Unfortunately, 
addition of the magnesium salt of methylmalonate half ester failed to produce the desired 
β-ketoester. A small amount of the oxidized carboxylate and β-ketoester thiazoles were 
obtained as judged by mass spectroscopy of the crude mixture. We reasoned that 
prolonged reaction conditions necessary for the Masamune claisen reaction allowed 
oxidation of the substrate to occur. Rationalizing that hard enolization conditions would 
provide shorter reaction conditions, we submitted the methyl ester 5.10 to reaction with 
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the lithium enolate of tert-BuOAc. To our delight, the reaction afforded the desired 
product 5.16 in modest yields. (Scheme 5.4) 
 
Scheme 5.3. Failed decarboxylative Claisen reaction. 
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Scheme 5.4. Successful Claisen condensation to form 5.16. 	
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With the key ketone 5.16 in hand, we investigated conditions for its reduction and 
completion of the CurG dehydratase substrates 5.2 and 5.3 (Scheme 5.5). During the 
course of our initial studies we noticed a large amount of thiazole formation during 
reduction with sodium borohydride, yielding an aromatic alcohol. We later traced this 
back to an inherent instability of β-ketoester 5.16 when stored above -78 C and under 
argon atmosphere for more than 2 days. Due to its oxidative susceptibility, the purified 
Claisen product was immediately carried on to the reduction reaction, reducing undesired 
thiazole product formation. The diastereomer ratio of reduction products obtained with 
sodium borohydride was found to be strongly dependent on temperature (Table 5.1). The 
mixture of diastereomers (2:1, obtained at 0 °C) was carried forward in the synthesis. We 
wanted to test both 5.2 and 5.3 because the CurG stereochemistry is cryptic and the 
mixture would allow us to synthesize and test both in unison. The tert-butyl ester was 
removed via addition of anhydrous TFA. The labile thiazoline is remarkably stable to 
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these conditions, affording the acid as the TFA salt 5.19/5.20. The crude salt was coupled 
with N-acetylcysteamine to afford the putative dehydratase substrates 5.2 and 5.3 as a 
diastereomeric mixture (2:1). 
 
Scheme 5.5. Completion of CurG DH substrates 5.2/5.3. 
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Table 5.1. Temperature-dependent diastereomeric ratio of ketone reduction. 
Temperature (°C) Diastereomer Ratio 
0 2:1 
-20 4:1 
-40 8:1 
 
 
We were interested in testing the postulated CurG DH substrates with all of the 
dehydratases from the curacin biosynthetic pathway. The purified mixture of 5.2 and 5.3 
was incubated overnight with CurF, CurH, CurJ and CurK DHs. Crude mass detection of 
all four reactions failed to indicate any product formation (i.e. loss of water, [M-18]+). 
We rationalized that, although synthetic 5.2/5.3 differs from the native substrate by 
lacking the full phosphopantetheine arm as well as the pendant methyl group, we might 
gain more insight by reassessing the early dehydration processes of the curacin pathway. 
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5.4 A holistic hypothesis for curacin biosynthesis 
 
Given the precedence for both canonical (CurK DH) and non-canonical (CurJ DH) 
dehydration in the curacin A pathway we were extremely skeptical of the proposed CurG 
substrate. The truncated dehydratase substrate 5.2/5.3 was similar to failed CurJ DH 
substrates 4.2-4.5 (Chapter 4) in the sense that they assume canonical elimination. 
Moreover, all the dehydratases (from CurF, CurH, CurJ and CurK modules) were unable 
to dehydrate synthesized these truncated substrates. These striking similarities led us to 
deduce that the CurG module intermediate, similar to the CurI KR product, is not directly 
dehydrated by any module. The β-hydroxythioester product of the CurG module 
ketoreductase is directly loaded onto the CurH ketosynthase domain and undergoes 
extension through a decarboxylative Claisen condensation (Figure 5.3). The δ-hydroxy-
β-ketothioester intermediate is reduced to the diol and shuttled to the dehydratase domain 
(CurH DH). A standard, α, β-elimination occurs followed by a non-canonical γ, δ- 
elimination furnishing a diene intermediate. An enoyl reductase (ER) domain in CurH 
reduces α, β-olefin. This product, still containing the distal olefin, is loaded onto the KS 
domain in module I for another round of extension. The CurI module produces a β-
hydroxythioester which, as put forth in chapter 3, is loaded onto CurJ for extension, 
normal processing and vinylogous elimination. Module K faithfully carries out a normal 
series of polyketide reactions with proven, cryptic D-alcohol and E-olefin configurations 
(Chapter 2). Finally, CurL and CurM modules carry out the final two extensions, 
complete with processing events and decarboxylative cleavage of the mature 
intermediate, forming curacin A. We propose that the DH domain in module F is vestigial 
and possibly originates from a gene duplication event in Moorea producens’ evolutionary 
history. The overall process with module terminating intermediates is displayed in Figure 
5.4. 
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Figure 5.3. Proposed vinylogous elimination between modules CurG and CurH. All 
extension and processing steps between CurG ketoreductase action and CurH ER 
reduction are displayed. 
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Figure 5.4. Proposed pathway incorporating vinylogous eliminations for curacin A 
biosynthesis. The DH domain in CurF and highlighted in red is predicted to serve no 
catalytic function in the pathway. The missing dehydratases not present in curacin A 
biosynthesis are denoted as while circles with hashed lines. The β-hydroxythioester 
products of modules G and I are extended and processed by modules H and J, 
respectively. 
 
5.5 Vinylogous dehydration-Unknowns and future directions 
 
Several mechanistic questions still remain unanswered about the novel vinylogous 
elimination. Firstly, it is unknown if the reaction utilizes a syn-elimination mechanism, 
similar to that seen in the FabA isomerization of fatty acids.89 This could be elucidated by 
dehydration experiments utilizing selectively γ-deuterated vinylogous substrates. 
Secondly, does the catalytic dyad’s function differ between canonical and non-canonical 
eliminations? Although the key histidine and aspartate residues for α, β-elimination were 
shown to be necessary for γ, δ- elimination, we have yet to discover the exact orientation, 
and role played by these residues and the substrate. Continued efforts by our 
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collaborators, Dr. Janet Smith and Gregory Dodge at the University of Michigan, seek to 
illuminate these questions through a co-crystal structure between substrates and His or 
Asp knockout mutants. Third, what is the mechanism dictating cis vs. trans olefin 
formation in vinylogous elimination? Although our work suggests the cis olefin in 
curacin A is put into place by vinylogous elimination, we observed trans olefin bond 
formation by the CurH DH on the vinylogous CurJ substrate. Additionally, the 
stereoselectivity observed in CurH for the CurJ DH substrate opposes the predicted L-
alcohol furnished from the CurG KR. We predict that this discrepancy is actually a clue 
as to the mechanism of olefin bond preference. Specifically, a clear difference between 
the CurJ and CurH vinylogous DH substrates is the presence of a trisubstituted olefin in 
the case of CurJ. This α-methyl group imposes a restraint on the conformational freedom 
of rotation along the β-γ bond via 1,3-allylic (A1,3) strain (Figure 5.5). This impacts the 
orientation of the two prochiral γ-protons and, in so doing, the accessibility for 
deprotonation by the catalytic base. In contrast, the putative vinylogous substrate of the 
CurH DH lacks the α-methyl, affording greater flexibility and choice in which proton the 
enzyme may abstract for elimination. In this system, A1,2 strain is the predominant factor 
in determining preferred conformations. By abstraction of the pro-S proton, a syn-
elimination of the D-alcohol occurs with a transition state favoring the cis olefin (Figure 
5.6). The enhanced flexibility may also be propagated to the δ-center, allowing for 
tolerance of the predicted L-alcohol substrate. In this case, the pro-R proton would be 
deprotonated setting up a transition state resulting in cis olefin formation. Obviously an 
anti-elimination mechanism could also be considered but, as the enzyme apparently uses 
the same enzymes and displays a strict stereochemical bias, we are operating under the 
assumption that a syn-dehydration is still at play. This mechanism could be elucidated 
through synthesis of truncated CurH vinylogous dehydration substrates and deuterium 
labeling experiments. 
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Figure 5.5. Depiction of allylic strain in vinylogous dehydration substrates. The 
trisubstituted (top) and disubstituted (bottom) conformations differ in terms of A1,3 strain. 
In disubstituted substrates, A1,2 strain is predicted to be an important factor in the relative 
distribution of conformers. 
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Figure 5.6. The proposed mechanistic basis for cis alkene formation through vinylogous 
elimination. Deprotonation of the pro-R or pro-S proton from the D-alcohol substrate and 
syn-elimination yields a trans or cis olefin, respectively. A cis olefin is obtained through 
syn-elimination of an L-alcohol only if the dehydratase deprotonates the pro-S proton. 
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5.6 Chemistry experimental section 
O
BnHN 	
N-Benzylcyclopropanecarboxamide (5.9). To a flask equipped with reflux condenser 
containing toluene (5.00 mL) under argon atmosphere was added SO2Cl2 (0.932 mL, 12.8 
mmol, 1.10 equiv) and the mixture was heated to 40 °C (oil bath). To the warm mixture 
was slowly added cyclopropanecarboxylic acid (0.925 mL, 11.6 mmol, 1.00 equiv) 
dropwise over 2 min. The reaction mixture was heated to 80–85°C for 2h 15 min. The 
slightly yellow solution was cooled to –10°C (ice–NH4Cl). To the chilled solution was 
added BnNH2 (4.40 mL, 40.6 mmol, 3.50 equiv) in one portion. The yellow slurry was 
allowed to warm to ambient temperature over 2 h. The resulting mixture was quenched 
upon addition of saturated aqueous NH4Cl (5.00 mL) and extracted with EtOAc (4 × 10.0 
mL). The organic fractions were dried under reduced pressure, yielding a bright yellow 
amorphous solid. The solid was recrystallized from EtoAc–hexanes providing the title 
compound (1.51 g, 8.60 mmol, 75%) as tan crystal needles. TLC: Rf = 0.14 (30% 
EtOAc/hexanes); 1H NMR (CDCl3, 400 MHz) δ 7.37–7.28 (m, 5H), 5.85 (br s, 1H), 4.47 
(d, J = 5.6 Hz, 2H), 1.39–1.31 (m, 1H), 1.02 (dt, J = 6.8, 4.0 Hz, 2H), 0.76 (dq, J = 8, 3.6 
Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 173.5, 138.6, 128.8, 128.0, 127.6, 44.0, 14.9, 
7.4. Data collected matches the known compound.83 
 
H S
N
MeO
O
 
Methyl (R)-2-cyclopropyl-4,5-dihydrothiazole-4-carboxylate (5.10). To a flask 
containing containing cyclopropylcarboxamide 5.9 (0.790 g, 4.51 mmol, 1.00 equiv) 
under argon atmosphere was added CH2Cl2 (45.1 mL). The clear solution was cooled by 
a dry ice–MeCN bath (-40 °C). A solution of freshly distilled pyridine (1.09 mL, 13.5 
mmol, 3.00 equiv) was added to the reaction mixture. An aliquot of Tf2O (0.986 mL, 5.86 
mmol, 1.30 equiv) was added dropwise over 10 min. The reaction mixture was allowed to 
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slowly warm to 0°C over 2 h. After 4 h at 0 °C, the reaction was cooled to –30 °C. To the 
red-orange solution was quickly added crushed L-cysteine methyl ester–HCl (1.16 g, 6.77 
mmol, 1.50 equiv) followed by another aliquot of pyridine (1.09 mL, 13.5 mmol, 3.00 
equiv). The solution slowly developed a golden hue. After 6 h, the reaction was vacuum 
filtered through silica gel plug (2.00 cm). The plug was washed with EtoAc–hexanes 
(1:1, 40 mL). The resulting organic solution was concentrated under reduced pressure and 
the product residue was purified by flash chromatography (30–50% EtOAc/hexanes) 
affording the title compound (0.595 g, 3.21 mmol, 71%) as a light yellow oil. TLC: Rf = 
0.27 (30% EtOAc/hexanes); 1H NMR (CDCl3, 400 MHz) δ 5.02 (t, J = 8.8 Hz, 2H), 3.80 
(s, 3H), 3.50 (dq, J = 11.2, 8.8 Hz, 2H), 1.98 (app. quin, J = 7.2 Hz, 1H), 1.67–1.59 (br s, 
1H), 1.05–0.94 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 177.1, 171.5, 77.7, 52.6,35.0, 
15.3, 9.3; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C8H11NO2SNa 208.0403; found 
208.0409 (Δ = 2.9 ppm). 
 
H S
N
HO
 
(R)-(2-Cyclopropyl-4,5-dihydrothiazol-4-yl)methanol (5.11). To a flask containing the 
thiazoline 5.10 (63.0 mg, 0.340 mmol, 1.00 equiv) was added Et2O (10.0 mL). To the 
faintly yellow solution was added Zn(BH4)2 in Et2O (0.147 M, 4.60 mL, 0.68 mmol, 2.00 
equiv) over 3 min. The reaction mixture developed a cloudy, white appearance. After 
2.75 h, another aliquot of Zn(BH4)2 in Et2O (1.50 mL, 0.22 mmol) was added. After 1 h, 
the reaction was quenched via saturated aqueous NH4Cl (10.0 mL). The biphasic mixture 
was separated and the aqueous extracted with Et2O (6 × 20 mL). The organic layers were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue 
was purified by flash chromatography (5% MeOH/CH2Cl2) yielding the title compound 
(37.0 mg, 0.236 mmol, 70%) as a clear, colorless oil. TLC: Rf = 0.29 (5% 
MeOH/CH2Cl2); 1H NMR (CDCl3, 400 MHz) (contaminated with MeOH) δ 4.53–4.42 
(m, 1H), 3.68 (dd, J = 11.2, 4.8 Hz, 1H), 3.63–3.54 (m, 1H), 3.36 (dd, J = 11.2, 8.8 Hz, 
1H) 3.24 (dd, J = 11.2 8.8 Hz, 1H), 1.96–1.87 (m, 1H), 1.18 (t, J = 7.2 Hz, 1H), 1.02–
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0.86 (m, 4H). 
 
H S
N
LiO
O
 
Lithium (R)-2-cyclopropyl-4,5-dihydrothiazole-4-carboxylate  (5.12). To a flask 
containing the methyl ester 5.11 (127.5 mg, 0.690 mmol, 1.00 equiv) in MeOH (3.45 mL) 
in an ice–water bath (0 °C) was added an aqueous solution of LiOH (1N, 0.69 mmol, 
1.00 equiv) dropwise over 2 min. The mixture was allowed to warm to room temperature 
for 1.5 h. The reaction was quenched by the addition of acetone (13.8 mL). The white 
precipitate was vacuum filtered and dried under reduced pressure affording the title 
compound (74.6 mg, 0.421 mmol, 61%) as a white, flakey solid. 1H NMR ((CD3)2SO, 
400 MHz) δ 4.52 (t, J = Hz, 1H), 3.40–3.25 (m, 2H), 1.85–1.76 (m, 1H), 0.92–0.75 (m, 
4H). 
 
H S
N
OO
tBuO
 
tert-Butyl (R)-3-(2-cyclopropyl-4,5-dihydrothiazol-4-yl)-3-oxopropanoate (5.16). A 
flask containing iPr2NH (0.361 mL, 2.58 mmol, 2.20 equiv) in THF (10.0 mL) was 
equilibrated in dry ice–MeCN bath (–78 °C). To the cooled solution was slowly added n-
BuLi (2.39M, 1.08 mL, 2.58 mmol, 2.20 equiv) and the reaction mixture was stirred for 
1.5 h. An aliquot of t-BuOAc (0.346 mL, 2.58 mmol, 2.20 equiv) was added slowly over 
5 min. A THF solution (2.00 mL) of methyl ester 5.10 (0.217 g, 1.17 mmol, 1.00 equiv) 
was added over 3 min. After 1h 40 min, the reaction was quenched by addition of 
aqueous saturated NH4Cl (5.00 mL). The quenched reaction was warmed to ambient 
temperature and the layers were separated. The aqueous layer was extracted with EtOAc 
(4 × 15.0 mL). The organic fractions were concentrated under reduced pressure. The 
crude residue was purified by flash chromatography (15% EtOAc/hexanes) affording the 
title compound (0.174 g, 0.642 mmol, 55%) as a colorless cloudy oil. TLC: Rf = 0.39 
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(30% EtOAc/hexanes); 1H NMR (CDCl3, 400 MHz) δ 5.08 (dd, J = 9.6, 7.6 Hz, 1H), 
3.72–3.53 (m, 3H), 3.42 (t, J = 10.0 Hz, 1H), 1.98–1.90 (m, 1H), 1.47 (s, 9 H), 1.15–0.96 
(m, 4H); 13C NMR (CDCl3, 100 MHz) δ 202.2, 176.5, 166.5, 84.5, 82.1, 48.7, 33.5, 28.1, 
15.1, 9.71, 9.65; HRMS (ESI-TOF) m/z: [M + Na]+ Calcd for C13H19NO3SNa 292.0978; 
found 292.0990 (Δ = 4.1 ppm). (In practice this compound was reduced immediately 
after isolation to combat undesired thiazoline oxidation to the corresponding thiazole). 
 
H S
N
OHO
tBuO
 
tert-Butyl 3-((R)-2-cyclopropyl-4,5-dihydrothiazol-4-yl)-3-hydroxypropanoate 
(5.17/5.18). To a flask containing β-ketoester 5.16 (87.7 mg, 0.326 mmol, 1.00 equiv) 
was added MeOH (10.0 mL). The resulting clear, colorless solution was cooled to 0 °C 
(ice–water). To the chilled solution was added NaBH4 (37.0 mg, 0.978 mmol, 3.00 equiv) 
in one portion. The reaction was stirred for 35 min and quenched upon addition of 
saturated aqueous NH4Cl (5.00 mL). The biphasic solution was warmed to ambient 
temperature and extracted with EtOAc (4 × 10.0 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude residue 
was purified by flash chromatography (30–40% EtOAc/hexanes) affording a 2:1 mixture 
of title compounds (74.0 mg, 0.273 mmol, 84%) as a slightly yellow oil. TLC: Rf = 0.35 
and 0.34 (30% EtOAc/hexanes); 1H NMR (CDCl3, 400 MHz) δ 4.50–4.41 (m, 0.33H), 
4.38–4.28 (m, 0.66H), 4.18–4.10 (m, 0.33 H), 4.07–4.00 (m, 0.66H), 3.34–3.29 (m, 1H), 
3.28–3.16 (m, 1H), 2.73 (ddd, J = 16.4, 4.4, 3.2 Hz, 0.66H), 2.61–2.42 (m, 1.33H), 1.95–
1.84 (m, 1H), 1.48 (s, 2 H), 1.47 (s, 4H), 1.06–0.90 (m, 4H); HRMS (ESI-TOF) m/z: [M 
+ Na]+ Calcd for C13H21NO3SNa 294.1134; found 294.1126 (Δ = 2.7 ppm). 
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H S
H
N
OHO
HO
+ O
-O CF3  
(4R)-4-(2-Carboxy-1-hydroxyethyl)-2-cyclopropyl-4,5-dihydrothiazol-3-ium 
trifluoroacetate (5.19/5.20). A flask containing tert-butyl ester 5.17/5.18 (2:1 
diastereomer mixture, 45.9 mg, 0.169 mmol, 1.00 equiv) in CH2Cl2 (4.50 mL) was cooled 
to 0 °C (ice–water). TFA (0.500 mL, 6.53 mmol, 38.6 equiv) was added dropwise and the 
reaction mixture was stirred at ambient temperature for 18 h. The reaction was quenched 
upon addition of MeOH (1.00 mL) and concentrated under reduced pressure affording the 
crude mixture (2:1) of title compounds (56.0 mg, 101%) as an off-white amorphous solid. 
TLC: Rf  = 0.0 (10% MeOH/CH2Cl2); 1H NMR (CD3OD, 400 MHz) δ 4.75 (dt, J = 8.4, 
3.6 Hz, 1H), 4.34 (app. quin, J = 4.8 Hz, 0.66H), 4.17 (dt, J = 8.0, 4.8 Hz, 0.33H), 3.80 
(dd, J = 11.6, 10.0 Hz, 0.33H), 3.71–3.64 (m, 1.66 H), 3.57 (dd, J = 12, 7.2 Hz, 0.33 Hz), 
2.68–2.52 (m, 1.33H), 2.46 (dd, J = 16.0, 8.4 Hz, 0.66H), 2.42–2.27 (m, 1H), 1.56–1.44 
(m, 2H), 1.33–1.20 (m, 2H). 
 
H S
N
OHO
S
H
NMe
O  
S-(2-Acetamidoethyl) 3-((R)-2-cyclopropyl-4,5-dihydrothiazol-4-yl)-3-
hydroxypropanethioate (5.2/5.3). To a flask containing the crude acid 5.19/5.20 (0.169 
mmol, based on quant. yield for the prior deprotection) was added CH2Cl2 (20.0 mL) at 0 
°C (ice–water). The resulting white opaque solution was supplemented with N-
acetylcysteamine (35.9 µL, 0.338 mmol, 2.00 equiv). DMAP (22.7 mg, 0.186 mmol, 1.10 
equiv) was slowly added to the mixture resulting in a colorless, clear solution. To the 
reaction mixture was added EDCI•HCl (38.6 mg, 0.202 mmol, 1.19 equiv) and the 
solution was slowly warmed to ambient temperature over 1 h 10 min. The reaction was 
quenched upon addition of saturated aqueous NH4Cl (5.00 mL) and the biphasic solution 
was separated. The aqueous layer was extracted with EtOAc (4 × 10 mL) and the 
combined organic layers were dried over Na2SO4, filtered and concentrated under 
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reduced pressure. The crude residue was purified by flash chromatography (5–10% 
MeOH/CH2Cl2) affording a 2:1 mixture of the title compounds (21.7 mg, 0.0686 mmol, 
41%) as a cloudy colorless oil. TLC: Rf = 0.34 (10% MeOH/CH2Cl2); 1H NMR (CDCl3, 
400 MHz) δ 6.48 (br s, 0.33H), 6.19 (br s, 0.66H), 4.53 (app. quin, J = 5.2 Hz, 0.66H), 
4.38 (d, J = 5.6, 0.33H), 4.30 (dd, J = 8.4, 2.8 Hz, 0.33H), (dt, J = 8.0, 6.0 Hz, 0.66H), 
3.75–3.60 (m, 1H), 3.55 (q, J = 6.4, 0.66H), 3.41 (q, J = 6.0 Hz, 0.66H), 3.32–3.17 (m, 
1H), 3.12–2.78 (m, 4H), 2.69–2.63 (m, 0.66H), 2.63–2.54 (m, 1H), 2.53–2.46 (m, 0.66H), 
2.01 (s, 1H), 2.00 (s, 2H), 1.14–1.08 (m 0.66H), 1.00–0.95 (m, 0.66H), 0.72–0.63 (m, 
1.2H), 0.63–0.56 (m, 0.66H), 0.51–0.44 (m, 0.66H); HRMS (ESI-TOF) m/z: [M + Na]+ 
Calcd for C13H20N2O3S2Na 339.0808; found 339.0795, (Δ = 3.8 ppm). 
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Appendix 
1H NMR and 13C NMR data for synthetic compounds are provided following the order of 
their synthetic route in the text. 
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f1 (ppm)
3.
26
6.
03
24
.0
7
2.
42
2.
81
1.
00
0.
96
1.
00
1.
00
1.
00
0.
99
0.
94
1.
92
0.
84
0.
86
0.
88
0.
99
1.
01
1.
04
1.
06
1.
54
1.
56
1.
58
1.
59
1.
82
1.
82
2.
45
2.
47
2.
47
2.
49
2.
49
3.
10
3.
11
3.
48
3.
50
3.
51
3.
53
3.
70
3.
71
3.
72
3.
72
3.
73
5.
05
5.
05
5.
06
5.
07
5.
07
5.
08
5.
09
5.
96
5.
99
7.
26
7.
30
7.
34
7.
35
7.
39
	
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
9.
26
12
.7
3
13
.1
6
14
.7
9
17
.3
9
18
.4
0
18
.4
5
19
.2
3
27
.9
7
30
.6
5
30
.8
9
37
.3
7
72
.3
5
77
.1
6
11
8.
09
13
2.
54
14
7.
31
15
0.
42
16
7.
46
20
2.
61
	
Me Me Me
OTIPS
2.48
O
NS
S
iPr
	 175 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
12
3.
00
21
.0
1
2.
22
3.
00
3.
00
1.
07
1.
13
1.
13
2.
09
2.
11
1.
07
1.
06
1.
06
1.
00
0.
83
0.
85
0.
87
0.
94
0.
96
1.
06
1.
54
1.
56
1.
65
1.
65
1.
97
2.
69
2.
72
2.
73
2.
81
2.
83
3.
03
3.
05
3.
06
3.
08
3.
45
3.
45
3.
47
3.
47
3.
63
3.
65
4.
47
4.
47
4.
49
4.
50
5.
47
5.
50
5.
80
7.
26
	
0102030405060708090100110120130140150160170180190200210
f1 (ppm)
9.
28
11
.9
5
13
.1
7
15
.2
0
18
.4
7
23
.3
8
27
.7
8
29
.0
0
35
.9
7
39
.5
7
49
.6
9
74
.5
0
77
.1
6
77
.3
6
13
1.
74
13
3.
84
17
0.
49
19
9.
17
	
OH
Me Me Me
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NACS
2.49
	 176 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
05
3.
26
1.
45
1.
27
3.
36
3.
37
1.
31
1.
20
1.
31
2.
35
1.
13
2.
14
1.
07
1.
06
1.
00
0.
90
0.
92
0.
95
0.
96
1.
23
1.
25
1.
27
1.
29
1.
30
1.
32
1.
34
1.
45
1.
47
1.
48
1.
49
1.
50
1.
51
1.
53
1.
65
1.
95
2.
46
2.
48
2.
76
2.
77
2.
79
2.
81
2.
99
3.
01
3.
02
3.
04
3.
30
3.
31
3.
32
3.
39
3.
40
3.
42
4.
44
4.
45
4.
46
4.
47
5.
33
5.
36
6.
23
7.
26
	
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
10
.6
0
12
.4
0
15
.6
7
23
.2
7
27
.1
1
29
.0
0
37
.8
1
39
.3
6
49
.7
9
74
.1
2
77
.1
6
77
.2
1
12
9.
82
13
5.
70
17
0.
78
19
8.
72
		
OH
Me Me Me
OHO
NACS
2.41
	 177 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
25
3.
03
3.
27
22
.9
2
2.
67
3.
00
1.
35
1.
28
1.
20
1.
26
0.
96
1.
09
1.
08
1.
06
1.
12
1.
09
0.
84
0.
86
0.
88
0.
93
0.
95
0.
98
1.
00
1.
07
1.
08
1.
52
1.
54
1.
55
1.
57
1.
67
2.
38
2.
39
2.
52
2.
52
2.
53
2.
54
3.
02
3.
05
3.
41
3.
44
3.
49
3.
50
3.
52
3.
53
3.
67
3.
68
4.
54
4.
54
4.
56
4.
57
5.
13
5.
15
5.
17
5.
49
5.
52
7.
26
	
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
9.
35
12
.6
6
13
.1
7
15
.1
2
17
.9
3
18
.4
3
19
.2
5
27
.8
6
30
.7
7
31
.0
1
35
.8
7
44
.2
7
71
.6
8
73
.2
3
77
.1
6
77
.2
8
13
1.
14
13
4.
08
17
3.
00
20
3.
07
	
OH
Me Me Me
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S
iPr 2.50
	 178 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
32
3.
10
21
.2
8
2.
21
3.
07
3.
02
1.
16
1.
16
1.
02
2.
11
2.
13
1.
07
1.
02
1.
00
0.
88
0.
83
0.
85
0.
87
0.
91
0.
93
1.
06
1.
53
1.
54
1.
56
1.
65
1.
97
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75
2.
76
2.
79
2.
81
3.
04
3.
05
3.
05
3.
06
3.
07
3.
43
3.
44
3.
46
3.
47
3.
65
3.
67
3.
68
4.
45
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46
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4.
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47
5.
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5.
85
7.
26
	
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
9.
30
12
.1
9
13
.1
6
15
.1
4
18
.4
2
23
.3
7
27
.7
9
28
.9
9
35
.9
1
39
.5
5
49
.7
6
74
.2
8
77
.1
6
77
.3
6
13
1.
41
13
3.
86
17
0.
50
19
9.
09
	
OH
Me Me Me
OTIPSO
NACS
2.51
	 179 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
5.
68
1.
32
1.
30
2.
86
2.
81
1.
23
1.
23
1.
32
2.
11
1.
08
1.
96
0.
99
1.
00
1.
19
0.
91
0.
93
0.
95
1.
29
1.
31
1.
33
1.
52
1.
65
1.
95
2.
71
2.
72
2.
75
2.
76
2.
80
2.
82
3.
00
3.
02
3.
03
3.
05
3.
33
3.
34
3.
39
3.
41
3.
42
3.
44
4.
44
4.
45
4.
46
4.
47
5.
35
5.
37
6.
19
7.
26
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
10
.6
6
12
.4
7
15
.7
8
23
.2
7
26
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3
29
.0
4
37
.8
3
39
.3
8
49
.6
1
74
.2
0
77
.1
6
77
.3
1
12
9.
69
13
5.
75
17
0.
81
19
8.
81
OH
Me Me Me
OHO
NACS
2.42
	 180 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
47
3.
30
21
.0
3
2.
29
3.
02
3.
09
1.
00
2.
04
2.
05
1.
03
0.
93
0.
98
1.
00
1.
72
0.
85
0.
86
0.
88
1.
00
1.
01
1.
06
1.
07
1.
52
1.
54
1.
56
1.
58
1.
60
1.
79
1.
96
2.
69
2.
70
2.
70
2.
71
3.
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3.
13
3.
45
3.
47
3.
49
3.
50
3.
70
3.
71
3.
72
3.
72
3.
73
3.
74
5.
93
6.
00
6.
03
6.
08
6.
12
7.
23
7.
26
7.
27
	
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
9.
34
12
.4
3
13
.1
3
14
.6
6
18
.3
7
18
.4
2
23
.4
0
27
.8
9
28
.5
1
37
.4
8
40
.1
6
77
.1
6
12
2.
61
13
1.
37
14
6.
93
14
8.
87
17
0.
41
19
0.
68
	
Me Me Me
OTIPSO
NACS
2.52
	 181 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
15
3.
12
1.
34
1.
98
3.
02
3.
07
1.
01
2.
01
1.
03
2.
04
0.
99
0.
93
1.
00
1.
69
0.
94
0.
95
0.
97
1.
05
1.
07
1.
31
1.
33
1.
33
1.
34
1.
35
1.
36
1.
36
1.
38
1.
52
1.
53
1.
54
1.
55
1.
56
1.
57
1.
58
1.
59
1.
81
1.
81
1.
96
2.
62
2.
63
2.
64
2.
65
3.
10
3.
11
3.
13
3.
37
3.
38
3.
38
3.
39
3.
40
3.
40
3.
41
3.
45
3.
46
3.
48
3.
49
5.
86
5.
88
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94
6.
10
6.
14
7.
24
7.
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7.
28
	
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
10
.4
0
12
.6
5
15
.8
0
23
.4
0
27
.9
4
28
.5
0
39
.6
3
40
.1
2
77
.0
0
77
.1
6
12
3.
10
13
2.
57
14
6.
59
14
6.
83
17
0.
43
19
0.
65
		
Me Me Me
OHO
NACS
2.53
	 182 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
00
2.
87
1.
20
0.
91
2.
87
2.
85
1.
02
1.
94
2.
95
0.
84
1.
06
1.
06
1.
02
0.
94
0.
96
0.
98
1.
04
1.
06
1.
39
1.
40
1.
42
1.
52
1.
54
1.
57
1.
82
1.
96
2.
64
2.
65
2.
66
2.
67
3.
12
3.
13
3.
45
3.
47
3.
48
3.
50
5.
91
5.
95
5.
97
6.
10
6.
14
7.
26
7.
27
7.
31
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
10
.1
8
12
.6
9
16
.9
8
23
.4
0
27
.7
9
28
.5
4
39
.2
4
40
.1
5
76
.9
8
77
.1
6
12
3.
14
13
3.
54
14
6.
03
14
6.
57
17
0.
41
19
0.
68
Me Me Me
OHO
NACS
2.10
	 183 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
08
2.
99
1.
18
1.
31
3.
00
2.
97
3.
05
2.
07
1.
83
2.
95
1.
00
1.
81
2.
46
0.
88
0.
90
0.
92
0.
98
0.
99
1.
34
1.
36
1.
38
1.
45
1.
46
1.
47
1.
76
1.
94
2.
61
2.
62
2.
64
2.
77
2.
78
2.
81
3.
36
3.
37
3.
38
3.
39
3.
41
3.
42
5.
87
5.
90
6.
03
6.
07
7.
15
7.
20
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
10
.1
9
12
.7
3
17
.0
7
23
.4
4
26
.0
7
27
.8
1
32
.3
2
38
.6
7
39
.1
7
40
.2
3
77
.0
3
77
.1
6
12
4.
57
13
3.
89
14
5.
46
14
8.
68
17
0.
38
19
8.
78
	
O
Me
OH
Me Me
NACS
2.11
	 184 
-1.5-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
23
3.
50
3.
19
2.
14
2.
14
1.
01
1.
03
1.
00
0.
88
1.
03
1.
05
1.
07
1.
25
1.
28
1.
30
1.
31
1.
60
1.
92
1.
93
1.
94
2.
17
2.
19
2.
19
2.
21
2.
23
2.
24
4.
17
4.
19
4.
21
4.
22
6.
08
6.
09
6.
11
6.
13
6.
15
6.
30
6.
33
6.
34
6.
37
7.
15
7.
18
7.
26
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
12
.6
8
13
.3
3
14
.4
8
26
.4
8
60
.5
7
77
.1
6
12
5.
17
12
5.
25
13
8.
71
14
4.
59
16
8.
81
 
Me
Me
EtO
O
3.10
	 185 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
3.
08
2.
94
1.
99
1.
04
1.
05
1.
00
1.
01
1.
08
1.
10
1.
12
1.
83
1.
84
1.
84
2.
24
2.
24
2.
25
2.
26
2.
26
2.
27
2.
27
2.
28
2.
29
2.
29
2.
29
2.
31
2.
31
6.
26
6.
28
6.
28
6.
30
6.
32
6.
48
6.
49
6.
49
6.
51
6.
52
6.
52
6.
52
6.
53
6.
55
6.
56
6.
81
6.
84
7.
26
9.
42
-100102030405060708090100110120130140150160170180190200210220230
f1 (ppm)
-20
0
20
40
60
80
100
120
140
160
180
200
220
240
260
280
300
320
340
360
380
0.
14
9.
53
13
.1
1
26
.6
6
77
.1
6
12
5.
10
13
6.
19
14
7.
30
14
9.
48
19
5.
25
 
Me
Me
O
3.12
	 186 
-1.5-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
9.
41
3.
02
2.
01
1.
25
0.
95
1.
34
1.
14
2.
33
0.
97
1.
10
1.
06
0.
94
1.
00
0.
97
0.
99
1.
01
1.
03
1.
06
1.
07
1.
77
2.
11
2.
13
2.
15
2.
35
2.
36
2.
38
3.
01
3.
04
3.
45
3.
49
3.
51
3.
52
3.
53
3.
54
4.
59
4.
60
4.
62
4.
62
5.
12
5.
14
5.
15
5.
72
5.
74
5.
76
5.
77
5.
79
6.
08
6.
11
6.
21
6.
24
6.
25
6.
27
7.
26
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
13
.0
2
13
.8
0
17
.9
6
19
.2
4
26
.1
5
30
.8
3
30
.9
9
44
.1
0
71
.7
2
72
.9
8
77
.1
6
12
4.
92
12
5.
86
13
5.
23
13
7.
48
17
2.
93
20
3.
15
Me
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OH
N
O
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S
iPr 3.14
	 187 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
45
3.
21
3.
32
2.
03
0.
95
1.
09
1.
11
2.
31
2.
22
1.
10
1.
23
0.
85
1.
00
1.
00
0.
99
1.
01
1.
03
1.
65
1.
75
1.
96
2.
09
2.
11
2.
13
2.
15
2.
77
2.
78
2.
81
2.
84
3.
04
3.
06
3.
42
3.
43
3.
44
3.
44
3.
45
3.
46
4.
51
4.
52
4.
53
4.
54
5.
73
5.
75
5.
76
5.
78
5.
80
5.
83
6.
06
6.
08
6.
19
6.
21
6.
22
6.
25
7.
26
 
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
12
.5
6
13
.7
6
23
.3
7
26
.1
4
29
.0
4
39
.4
9
49
.6
0
74
.0
4
77
.1
6
12
4.
71
12
6.
33
13
4.
88
13
8.
00
17
0.
55
19
8.
98
 
Me
Me
OH
NACS
O
3.5
	 188 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
03
2.
97
3.
33
2.
09
2.
32
2.
44
0.
89
1.
12
1.
00
0.
93
0.
95
1.
04
1.
06
1.
08
1.
87
1.
97
2.
18
2.
20
2.
22
2.
23
2.
25
3.
10
3.
12
3.
14
3.
46
3.
47
3.
49
3.
50
5.
98
6.
02
6.
03
6.
05
6.
07
6.
08
6.
13
6.
17
6.
37
6.
40
6.
44
6.
45
6.
47
7.
26
7.
28
7.
32
-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
12
.4
8
13
.4
0
23
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8
26
.5
8
28
.4
9
40
.2
5
77
.1
6
12
2.
82
12
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1.
17
14
1.
60
14
3.
62
14
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47
17
0.
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19
0.
46
 
Me
Me
NACS
O
3.7
	 189 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
06
3.
06
2.
34
1.
08
1.
08
1.
08
1.
09
0.
99
1.
09
1.
01
1.
10
1.
15
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00
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98
0.
99
1.
01
1.
21
1.
23
2.
03
2.
04
2.
05
2.
06
2.
06
2.
07
2.
08
2.
08
2.
09
2.
10
2.
88
2.
91
3.
03
3.
05
3.
06
3.
09
3.
24
3.
25
3.
27
3.
28
3.
37
3.
37
3.
38
3.
39
3.
39
3.
40
3.
41
3.
41
4.
24
4.
26
4.
28
4.
33
4.
34
4.
35
4.
36
5.
23
5.
24
5.
25
5.
26
5.
26
5.
27
5.
39
5.
41
5.
42
5.
43
5.
44
5.
45
5.
77
5.
77
5.
78
5.
81
5.
81
7.
25
7.
26
7.
27
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27
7.
29
7.
29
7.
32
7.
33
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34
7.
34
7.
34
7.
36
7.
36
-100102030405060708090100110120130140150160170180190200210220
f1 (ppm)
13
.5
2
14
.9
0
25
.4
0
32
.8
5
36
.8
5
45
.1
8
69
.1
7
76
.7
3
77
.1
6
12
7.
34
12
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03
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28
12
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13
6.
34
13
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68
17
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17
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N
O
S
S
Bn
Me
Me
OH
4.9
	 190 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
3.
17
3.
06
2.
05
0.
94
1.
01
1.
06
1.
01
1.
02
0.
95
0.
98
0.
99
1.
02
1.
00
5.
00
0.
99
1.
01
1.
03
1.
18
1.
20
1.
57
2.
04
2.
05
2.
06
2.
08
2.
08
2.
10
2.
74
2.
74
2.
87
2.
90
3.
01
3.
04
3.
04
3.
07
3.
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N
O
S
S
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Me
Me
OH
4.8
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Me
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OH
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OH
4.3
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O
P
O
OEt
OEtNACS
Me
4.12
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O
NACS
Me
Me
4.6
	 195 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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NO
O
iPr
O
Me
OH
Me
4.18
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-100102030405060708090100110120130140150160170180190200210220230
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O
Me
OH
Me
NACS
4.13
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f1 (ppm)
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O
BnHN
5.9
	 198 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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H S
N
MeO
O
5.10
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H S
N
HO
5.11
	 200 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
4.
00
1.
26
1.
15
1.
49
1.
10
0.
77
9
0.
78
3
0.
79
1
0.
79
5
0.
80
3
0.
80
8
0.
80
9
0.
81
4
0.
82
7
0.
84
8
0.
86
5
0.
87
1
0.
88
4
0.
88
5
0.
89
2
0.
89
4
1.
78
9
1.
79
7
1.
80
2
1.
80
9
1.
81
8
1.
82
1
1.
83
0
2.
50
0
3.
25
3
3.
27
6
3.
28
0
3.
30
3
3.
32
1
3.
34
6
3.
37
1
3.
39
7
4.
49
1
4.
51
5
4.
53
8
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H S
N
LiO
O
5.12
	 201 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
f1 (ppm)
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H S
N
O
5.16
O
tBuO
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H S
H
N
OH
5.19/5.20
O
HO
+ O
-O CF3
	 204 
-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
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H S
H
N
OH
5.2/5.3
O
NACS
